











Of science and the human heart
There is no limit
There is no failure here sweetheart
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ABSTRACT
Routine use of beta adrenoreceptor antagonists has been the most significant advance in
the management of chronic heart failure (CHF) in the past decade. This thesis compares
two adrenoreceptor antagonists with proven benefit in CHF but with very different
pharmacological properties.
An open label, parallel group study was designed to comprehensively compare and
contrast the actions of carvedilol (17 patients) and metoprolol (12 patients) in NYHA
class II and III chronic heart failure. Haemodynamic actions (during rest and adrenergic
stimulation), neurohumoral effects, forearm blood flow effects, effects on cardiac
electrical stability, antioxidant status, beta adrenoreceptor density, and effects on
cytokines were assessed.
Mean resting heart rate reduction after 20 weeks of metoprolol (14.5 beats per minute)
was greater than with carvedilol (10.1 beats per minute) but did not reach statistical
significance (p=0.12). Metoprolol also reduced the heart rate response to dobutamine
(p=0.009) and salbutamol (p=0.007) after 20 weeks of treatment, compared to baseline,
an effect not seen with carvedilol.
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Metoprolol reduced plasma renin concentration. Neither beta-blocker affected plasma
angiotensin II concentration. Carvedilol significantly decreased plasma aldosterone
concentration, and increased plasma atrial natriuretic peptide concentration, after both
10 weeks and 20 weeks. Both drugs increased plasma B-type natriuretic peptide
concentrations. Neither agent significantly affected plasma endothelin concentration.
Carvedilol alone significantly increased plasma norepinephrine concentration at both
time points (+30.9%, p=0.026 and +30.7%, p=0.046).
Forearm blood flow (FBF) response to local high-dose dobutamine infusion was
reduced by carvedilol alone (p=0.007). When FBF was enhanced by local high-dose
salbutamol, 20 weeks treatment with metoprolol alone significantly reduced
vasodilatation (p=0.028). Neither agent affected the reduction in FBF in response to
local high dose phenylephrine nor altered the increase with local high dose
acetylcholine.
QT dispersion parameters and signal averaged ECG late potentials did not alter
significantly with either agent.
There was a general non-significant trend for carvedilol to increase LDL oxidation lag
time, total plasma antioxidant activity and vitamin E concentration. Carvedilol also
increased plasma malondialdehyde concentration (p=0.033) over 10 weeks, but not at
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20 weeks. Metoprolol's only significant effect was reducing vitamin E concentration
reaching significance after 20 weeks of treatment (p=0.004).
After 20 weeks of treatment, carvedilol (increasing) and metoprolol (decreasing) had
divergent but non- significant effects on lymphocyte beta-receptor density. No
significant effect of either agent on plasma concentrations of the cytokines TNF-a and
sTNFR-I was detected in this study.
Metoprolol produced a higher degree of heart rate reduction at the doses used, while
carvedilol opposed the peripheral effects of dobutamine infusion more completely.
Neurohumoral differences also existed between the two agents. Carvedilol had a non¬
significant tendency to reduce oxidative state. These interesting differences between the
agents may translate into important clinical effects.
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1.1. HISTORY OF ADRENERGIC RESEARCH
In 1893 George Oliver, a spa physician working in Harrogate, produced extracts from
adrenal glands in the belief that they might raise blood pressure and be of use in patients
with hypotension. Oliver's work was probably inspired by Brown-Sequard, who had
demonstrated that removal of the adrenals from experimental animals reduced their
blood pressure and was invariably fatal. As a means of testing his hypothesis, Oliver
took the remarkable step of giving some of the extract to his own son. Using a device of
his own invention (an 'arteriometer') he showed that his son's brachial artery narrowed
under the influence of the injection.(Henderson 2005)
Oliver had no means to measure blood pressure directly, so he took some of his extract
to Edward Schafer, Professor of Physiology at University College, London. Henry Dale
described the meeting: 'Oliver went to tell Professor Schafer what he thought he had
observed, and found him engaged in an experiment in which the blood pressure of a dog
was being recorded: found him, not unnaturally, incredulous about Oliver's story and
very impatient at the interruption. But Oliver was in no hurry, and urged only that a
dose of his adrenal extract, which he produced from his pocket, should be injected into
a vein when Schafer's own experiment was finished. And so, just to convince Oliver
that it was all nonsense, Schafer gave the injection, and then stood amazed to see the
mercury mounting in the manometer 'til the recording float was lifted almost out of the
distal limb . . .'(Dale 1948) Incidentally, the same Henry Dale is responsible for
insisting on the naming of the extract "adrenaline", resulting in the British objection to
the name "epinephrine" until recent European legislation was introduced.(Aronson
2000)
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In 1894 Oliver and Schafer published their findings that an extract of the adrenal gland
exerted a profound effect on the heart and blood vessels in a variety of animals,
producing tachycardia and vasoconstriction.(01iver and Schafer 1894)
By the early 1960s, agents that could antagonise the effects of'"adrenaline" had been
developed by Sir James Black's group(Black and Stephenson 1962) After long term
toxicity of some of the early agents was noted, propranolol was eventually developed
and became the first commercially available beta-adrenergic antagonist in
1964.(Prichard 1976) Since then, many other beta-adrenergic agents have been
developed, and have been used in the treatment of hypertension, control of tachycardia,
and reduction of angina.
1.2. HISTORICAL ASPECTS OF THE USE OF BETA BLOCKERS IN
HEART FAILURE
For many years, these beta-adrenergic antagonists (beta-blockers) were believed to be
detrimental in heart failure,(Stephen 1968) as it was thought that the spontaneous
enhanced sympathetic activity that occurred in heart failure was necessary to maintain
cardiac output.
In January 1973 in Gothenburg, Sweden, Finn Waagstein decided to treat a 59-year-old
female patient with idiopathic dilated cardiomyopathy and decompensated heart failure
with intravenous practolol.(Waagstein, Fljalmarson et al. 1975) He had noted that she
was very tachycardic, and was not responding to diuretic therapy. Waagstein's rationale
was that her poor cardiac function was at least partially caused by the high-energy
33
demand from her tachycardia.(Waagstein 1974) This daring treatment flew in the face
of conventional medical thinking at the time, but was nonetheless very
successful.(Waagstein, Hjalmarson et al. 1975) The patient improved dramatically, and
lived to the age of 84 being treated with beta-blockers throughout the intervening years.
This Gothenburg group developed the concept of heart failure treatment with beta-
blockers for more than two decades before widespread acceptance occurred.
1.3. DEFINING CHRONIC HEART FAILURE
Industrialisation of societies had resulted in a world wide epidemic of chronic heart
failure due to changes in life span and life style. The condition becomes increasingly
prevalent with increasing age, whilst affluent lifestyles and declining activity levels
have increased the prevalence of ischaemic heart disease and hypertension, the two
most common precursors of the condition.
Chronic heart failure (CHF) occurs when myocardial function is impaired. A
universally accepted definition of the condition has proven elusive,(Denolin, Kuhn et al.
1983) as heart failure is not a single diagnosis but is rather a recognisable collection of
symptoms and signs resulting from cardiac dysfunction. Typical symptoms of CHF are
breathlessness, orthopnoea, paroxysmal nocturnal dyspnoea, ankle swelling and fatigue.
Typical clinical signs of CHF include tachycardia, a raised venous pressure, pulmonary
crepitations and ankle oedema. Thus CHF may be regarded as a "syndrome" of
recognisable symptoms and signs. This syndrome is usually progressive, resulting in
serious morbidity and a poor prognosis for the sufferer.
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In pathophysiological terms, heart failure is a "state in which an abnormality of cardiac
function is responsible for failure of the heart to pump blood at a rate commensurate
with the requirements of the metabolising tissues or to do so only from an elevated
filling pressure". Current European Society of Cardiology guidelines for the diagnosis
of heart failure state that there should be appropriate symptoms present in a patient with
objective evidence of appropriate underlying heart disease.(The Task Force on Heart
Failure of the European Society of Cardiology 1995) "Objective evidence" generally
means confirmation of cardiac dysfunction by an imaging modality such as
echocardiography, fluoroscopy, or radionuclide methods.
Chronic heart failure is the final common pathway for a range of pathophysiological
states but is most commonly due to ischaemic, hypertensive, or valvular heart disease.
When heart failure is clinically evident (i.e. the symptoms and signs mentioned above
are present) the underlying heart condition is already at an advanced stage: by this point
further progression is usually inevitable. Until recent times no therapy existed which
even retarded this progression, and despite advances in the understanding and
management of chronic heart failure, this condition is still a major cause of morbidity
and mortality in our society.
1.3.1. THE SCALE OF THE CHRONIC HEART FAILURE EPIDEMIC
In Western society, heart failure is a common and malignant condition. Epidemiological
surveys estimate prevalence of CHF in North American and European populations at
between 3 and 20 individuals per 1000.(Cowie, Mosterd et al. 1997) The wide variation
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in prevalence estimates is probably due more to differences in methodology rather than
due to large differences between populations. The prevalence in the elderly is
consistently higher at 30 to 130 individuals per 1000 in those aged over 65
years.(Cowie, Mosterd et al. 1997)
Thus, ageing of our population is one of the factors causing a global growth in
hospitalisation for heart failure. Better survival rates from myocardial infarction (due to
the use of coronary care units, thrombolytics and revascularisation procedures) are also
contributing to the overall burden of heart failure: in the past, many patients died who
would now survive and will later develop heart failure. Treatments aimed at saving lives
seem actually to be increasing the potential numbers of people suffering with this
condition. Numbers are also increasing due to changes in classification and improved
accuracy of diagnosis. This increase in heart failure admissions is occurring at a time
when other cardiovascular conditions such as stroke and myocardial infarction are on
the decrease. In the USA, heart failure continues to be the most common cause of
hospitalisation in people over 65 years of age.(Haldeman, Croft et al. 1999)
Whether heart failure incidence is still increasing has been called into question by some
recent studies. An assessment of long term trends in incidence from the Framingham
Heart Study suggests that the incidence of heart failure has actually declined in women,
though not in men.(Levy, Kenchaiah et al. 2002) This study also suggests some
improvement in survival rates, though again the overall survival rate of someone
diagnosed as having heart failure, even in the 1990s, was less than 50% at five years.
Scottish data also supports an impact of modern treatment on the prognosis of patients
suffering with heart failure.(Maclntyre, Capewell et al. 2000)
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In addition to the reduced life expectancy of individuals suffering from CHF,
considerable disability and morbidity are caused. This is costly because of the need for
complex pharmacological therapy, community care, and especially due to frequent
hospital admissions. A recent estimate suggests that 1.9% of total National Health
Service expenditure in the United Kingdom is currently on CHF, of which 69% is due
to hospitalisations.(Stewart, Jenkins et al. 2002)
In health care systems, hospital admissions account for a disproportionately large
component of total health care expenditure. By their nature, hospital admissions due to
heart failure are prolonged, and readmissions are common. Scottish figures reveal that
in the early 1990s, 0.2% of the population were hospitalised for heart failure per annum
accounting for more than 5% of adult general medicine and geriatric hospital
admissions.(McMurray, McDonagh et al. 1993)
1.3.2. PROGNOSIS OF CHRONIC HEART FAILURE
Irrespective of its underlying cause, CHF is a serious condition indicating a poor
prognosis.(Ho, Anderson et al. 1993) As might be expected, mortality in CHF is related
to disease severity, and prognosis is determined largely by stage of heart failure.
However, even in mild to moderate CHF, as in the "Study of Men Born in 1913",
comparative 5-year mortality was 26% in the symptomatic group compared to 8% in
non-CHF men.(Eriksson, Wilhelmsen et al. 1991) In the treatment arm of the Studies of
Left Ventricular Dysfunction (SOLVD) trial, 35% of the relatively young patients
(mean age 61 years) with "mild to moderate" heart failure who were treated with
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enalapril died within three and a half years of follow-up.(The SOLVD Investigators
1992)
Much of the current thrust of research in heart failure has been to improve early
diagnosis of the condition. By initiating therapy before symptoms arise (during so-
called asymptomatic left ventricular dysfunction) it is hoped that progression to the end
stage of the disease is delayed or prevented. The validity of this approach depends upon
the availability of therapies that are known to make a difference to prognosis, even
when the condition is at an early stage; both angiotensin converting enzyme (ACE)
inhibitors and more recently beta-blockers would fall into this category. ACE inhibitors
have radically altered the treatment of heart failure due to left ventricular systolic
dysfunction, but few patients are rendered asymptomatic by treatment with these agents
or are able to lead a normal life. For this reason, more complete means of producing
neurohumoral inhibition have been sought.
1.4. NEUROENDOCRINE ACTIVATION
Neuroendocrine activation is a cardinal feature of chronic heart failure and is now
generally believed to promote progression of this syndrome. Much of this understanding
has evolved from implementation of ACE inhibitors as therapy for CHF.(The
CONSENSUS Trial Study Group 1987; Francis, Cohn et al. 1993) For the last twenty
years, ACEIs have been used to modulate neuroendocrine activation in CHF by
inhibiting the renin-angiotensin system. This neuroendocrine effect is crucial for the
known advantages of ACEIs over simple vasodilators.(Cohn, Johnson et al. 1991)
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It is proposed that additional benefit might be produced by modulation of other
components of neuroendocrine activation. Sympathetic nervous system (SNS)
overactivity is a particularly attractive target, with circulating plasma concentration of
noradrenaline shown to be a powerful predictor of prognosis. As a means of achieving
SNS inhibition, beta adrenoreceptor antagonists (beta-blockers) have now been
established as an additional therapy in CHF.
A number of recent clinical trials have shown major improvements in mortality using
the beta-blockers carvedilol, metoprolol and bisoprolol. These three agents (whilst all
termed beta-blockers) have diverse pharmacological actions. It is not yet understood
which particular properties of beta-blockers are responsible for their beneficial effects.
Carvedilol, for example, exhibits ai antagonism in addition to being a non-selective
beta receptor antagonist, and is also a powerful antioxidant: the relevance of these
known in vitro actions in the clinical setting of CHF is unclear. It is postulated that
some of the benefit of this particular agent is more related to these properties than to
pure beta-receptor antagonism. For instance, ai antagonism causes peripheral
vasodilatation, which may offset the negative inotropism of beta-receptor antagonism;
CHF has been shown to be associated with a detectable increase in the oxidant status of
patients, and antioxidant activity might be a beneficial drug property. Clinically
important differences between different beta blocking agents would obviously have
major implications for the use of these agents in general in CHF.
By using a systematic approach to the known mechanisms of action of carvedilol, this
study sets out to differentiate the pharmacological properties of this medication from
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those of metoprolol. In this way we might elucidate the mechanism by which these
promising agents are of assistance in the management of this important condition.
1.4.1. THE ROLE OF THE SYMPATHETIC NERVOUS SYSTEM IN CHF
Increased activity of the sympathetic nervous system (SNS) is an essential physiological
reaction to environmental changes: even postural change would not be possible without
a rapid SNS response.
Damage to the myocardium attacks the organism in a more permanent manner. Any
significant myocardial damage results in a reduction in cardiac output, which is
recognised by the systems that maintain cardiovascular homeostasis, and these systems
attempt to correct the situation. This forlorn attempt to regain cardiovascular stability
activates the SNS, the renin angiotensin system, and various other neurohumoral
responses.
Unlike other situations such as hypovolaemia, where cardiac output may be temporarily
reduced, ventricular damage is not normally reversible and neurohumoral stimulation
persists. In the CHF patient, a scenario is produced in many ways similar to a normal
person undertaking exercise: in the case of the heart failure patient, however, there is no
period of rest for the cardiovascular system. Tachycardia, increased peripheral
resistance, and salt and water retention occur and further increase cardiac workload. The
counter-regulatory vasodilator, natriuretic and diuretic responses (such as increased
plasma concentrations of natriuretic peptides and perhaps adrenomedullin) cannot
adequately oppose the neurohumoral imbalance during permanent ventricular
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dysfunction. Chronic imbalance of neurohumoral activation results in a progressive
decline in circulatory performance and the clinical features of CHF. Over the last three
decades it has become clear that sustained and inappropriate sympathetic nervous
system activation accompanies(Chidsey, Braunwald et al. 1965; Thomas and Marks
1978; Francis, Satoh et al. 1982; Levine, Francis et al. 1982) and contributes to(Packer
1989; Kaye, Lefkovits et al. 1995) progression of the clinical syndrome of CHF.
1.4.2. EVIDENCE SUPPORTING THE NEUROHORMONAL HYPOTHESIS
OF HEART FAILURE
The "neurohormonal hypothesis" of heart failure attributes clinical manifestations and
progression of CHF to abnormal modulation of neurohumoral systems.(Francis,
Goldsmith et al. 1984) Increased plasma concentrations of renin, angiotensin,
endothelin and catecholamines are believed to not just accompany the condition, but are
thought to perpetrate it.
Severe heart failure has been recognised as being associated with increased urinary
noradrenaline excretion for many years.(Chidsey, Braunwald et al. 1965) Subsequently,
elevated plasma noradrenaline concentration was reported.(Thomas and Marks 1978) It
remained unclear whether these findings were simply a marker of heart failure or
whether SNS activation worsened the situation.
Technical developments have subsequently enabled more "direct" methods of SNS
assessment such as microneurography(Leimbach, Wallin et al. 1986) (direct intraneural
recordings of e.g. peroneal sympathetic nerve traffic). Microneurography has confirmed
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that SNS activity correlates with cardiac index, stroke volume index, and systemic and
pulmonary vascular resistances, though is not related to ejection fraction.(Ferguson,
Berg et al. 1990) Modern indirect methods of SNS assessment such as measurement of
heart rate variability (Kienkle, Ferguson et al. 1992) and plasma "spill over" of
noradrenaline (Esler, Jennings et al. 1988) collectively confirm that SNS activity is
progressively increased, and parasympathetic activity blunted,(Eckberg, Drabinsky et
al. 1971; Binkley, Nunziata et al. 1991) as left ventricular dysfunction develops into
clinical CHF and this syndrome increases in severity. Despite these impressive technical
achievements, an irrefutable demonstration that increased SNS output directly causes or
contributes to the decline in cardiac performance and disease progression remains
elusive.
Data from the Studies of Left Ventricular Dysfunction (SOLVD) registry have shown
that elevated plasma concentration of noradrenaline, renin, arginine-vasopressin, and
atrial natriuretic peptide are associated with a poor prognosis.(Benedict, Shelton et al.
1996) The Second Veterans Administration Co-operative Vasodilator Heart Failure
Trial (VHeFT-II) has shown that elevated plasma concentrations of noradrenaline and
renin are independently related to mortality and that the most beneficial response to
ACE inhibition occurred in those patients with the highest pre-treatment concentrations
i.e. the most neurohumoral activation.(The V-Heft VA Cooperative Studies Group
1993) This emphasises the importance of the relationship between neurohumoral
activation and mortality. It also suggests that further neurohumoral blockade might
produce further benefit.
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The hypothesis has been bolstered by the results of several beta-blocker trials, which are
discussed in further detail below. More recently, the RALES trial using spironolactone
at a dose chosen to block aldosterone receptors has also proven significant mortality
benefits in CHF.(Pitt, Zannad et al. 1999)
A more mature comprehension of the actions of the ACEIs is that they alter the
unbalanced neurohumoral milieu from vasoconstricted, positively inotropic and fluid
retaining to a more beneficial vasodilated, less inotropic and more diuretic state. In this
way, cardiac workload is reduced and further decline in cardiac function is attenuated.
1.4.3. EVIDENCE THAT SYMPATHOMIMETIC AGENTS WORSEN
PROGNOSIS IN CHF
It was long believed that cardiac stimulation by inotropes would support circulatory
function when chronically impaired ventricular performance was present. Adrenergic
activation of the failing human heart helps maintain cardiac performance over the short
term by increasing contractility and heart rate. An apparently logical approach was the
use of therapeutic agents to enhance endogenous adrenergic activity.
In the failing heart, p-adrenergic signal transduction (catecholamine responsiveness) is
reduced secondary to desensitisation changes in Pi and P2 receptors, the inhibitory G
protein (GO, and by reduction in an enzyme responsible for modulating receptor activity
by phosphorylation (PARK).(Bristow 2000) There is also reduction in the expression of
adenylate cyclase and specific down regulation in the numbers of Pi receptors. In end-
stage heart failure, 50%-60% of the total signal-transducing potential is lost, but
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substantial signalling capacity remains.(Bristow 2000) We now speculate that these
changes are in fact adaptive, as the heart tries to reduce the harmful effects of
adrenergic over activity.
Trials involving several sympathomimetic positive inotropes such as dobutamine (Pi
agonist),(O'Connor, Gattis et al. 1999) dopamine agonists such as levodopa,(Shah,
Amin et al. 1985) xamoterol (partial Pi- agonist)(The Xamoterol in Severe Heart
Failure Study Group 1990) and phosphodiesterase inhibitors (acting via SNS second
messenger systems)(Maskin, Forman et al. 1982; Bairn, McDowell et al. 1983; Shah,
Amin et al. 1985; Petein, Levine et al. 1986) worsened mortality in CHF (see Table
1-1). Whilst such drugs could often improve symptoms and measures of cardiac
function in the short term,(Liang, Sherman et al. 1984) they contributed to progressive
decline in the long term.(Packer and Leier 1987; O'Connor, Gattis et al. 1999) In fact,
no positive inotrope has so far been shown to favourably influence mortality in CHF in
a significant clinical trial.
Gradually it has become clear that this approach to the treatment of CHF was
fundamentally flawed. To produce long-term improvements in mortality, strategies are
required which actually reduce cardiac workload, by reducing heart rate, reducing
inotropic drive, reducing vasoconstriction, and permitting diuresis. Clearly, these
outcomes might be expected from agents that withdraw sympathetic influences from the
circulation. It is tempting to speculate that the attenuated ability of myocardium to
respond to continuously high levels of endogenous or exogenous catecholamines is a
natural counter-regulatory attempt to withdraw from unhelpful influences.
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Table 1-1: Summary of failed sympathomimetic positive inotrope trials in
chronic heart failure
DRUG MODE OF ACTION INOTROPISM
Xamoterol
(The Xamoterol in Severe Heart
Failure Study Group 1990)
P receptor agonist ++
Dobutamine
(O'Connor, Gattis et al. 1999)
Dopamine, a, p agonist +++
Ibopamine
(Hampton, Van et al. 1997)
Dopamine, a, p agonist +
Amrinone
(Maskin, Forman et al. 1982)
Phosphodiesterase inhibitor +++
Enoximone
(Cowley and Skene 1994)
Phosphodiesterase inhibitor +++
Flosequinan
(Cowley, McEntegart et al.
1994)
Attenuates inositol triphosphate +
Milrinone
(Bairn, McDowell et al. 1983)
Phosphodiesterase inhibitor +++
Piroximone
(Petein, Levine et al. 1986)
Phosphodiesterase inhibitor ++
Fenoximone
(Shah, Amin et al. 1985)
Phosphodiesterase inhibitor ++
Levodopa
(Shah, Amin et al. 1985)
Dopamine agonist ++
Vesnarinone
(Cohn, Goldstein et al. 1998)
Phosphodiesterase inhibitor ++
1.5. OTHER POSSIBLE MECHANISMS OF CHF PROGRESSION
The effects of oxidative stress, (believed to increase in CHF) elevated concentrations of
cytokines (mediators of inflammation known to be increased in advanced CHF) and
increased apoptosis may also contribute to disease progression. As the influence of
oxidative stress, cytokines and apoptosis may in part explain the adverse consequences
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of excess neurohumoral activity, these areas are considered here. More detailed
discussion of the influence of oxidative stress and cytokines is undertaken later in the
relevant chapters.
1.5.1. THE OXIDATIVE STRESS HYPOTHESIS OF CONGESTIVE HEART
FAILURE
Many disease states ranging from aging to cancer and coronary heart disease have been
associated with excess free-radical activity, and antioxidants have received attention as
a potential therapy for these conditions.
Oxidative stress, which may result in oxidative tissue damage, occurs when there is an
imbalance between reactive oxygen species (ROS) production and antioxidant defenses
such that either ROS production is increased and/or defense mechanisms are impaired.
Recently, the role of oxidative stress in CHF has been explored as a mechanism of
disease progression. In the setting of CHF, excess free-radical generation may arise
from many sources, including vascular nicotinamide adenine dinucleotide oxidases,
xanthine oxidases, autooxidation of catecholamines, nitric oxide synthase activation, or
mitochondrial leakage.(Mak and Newton 2001) Besides excess ROS generation, animal
models of CHF have suggested that myocardial antioxidant defenses are also
impaired.(Dhalla, Hill et al. 1996; Hill and Singal 1997) These observations have
prompted the formulation of an oxidative stress hypothesis of CHF. This hypothesis
states that CHF is characterized by generalized and cardiac-specific oxidative stress,
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and that chronic oxidant injury contributes to impairment of myocardial function and
ultimately clinical progression of CHF.
In vitro experiments have demonstrated that excess free-radical generation or impaired
antioxidant function adversely affects several myocyte functions,(Rowe, Manson et al.
1983; Kim and Akera 1987; Goldhaber, Ji et al. 1989; Kaneko, Beamish et al. 1989)
depresses myocardial contractility,(Blaustein, Schine et al. 1986; Schrier and Hess
1988) causes myocardial tissue injury,(Burton, McCord et al. 1984) and may also
induce myocyte apoptosis.(Gottlieb, Burleson et al. 1994) In vivo animal models have
also demonstrated the significance of oxidative injury to cardiac function; the best-
studied example is that of myocardial stunning and injury due to reperfusion after a
period of ischaemia.(Bolli, Zhu et al. 1987; Bolli, Zughaib et al. 1995)
Several animal models of chronic CHF have also confirmed a role for oxidative stress.
Anthracycline-mediated cardiomyopathy in animals has been shown to result primarily
from oxidative injury and antioxidant therapy attenuated myocardial injury in this
model.(Doroshow 1983) The administration of an antioxidant acutely improved cardiac
function in a dog model of tachycardia-induced cardiomyopathy providing evidence
that, besides oxidant injury, oxidative stress may also reversibly depress cardiac
function in this setting.(Ukai, Cheng et al. 2001 )However, as will be expanded upon in
section 7.2 , there is as yet no conclusive proof that oxidative stress is important in
human CHF, nor that use of antioxidant medication can help.
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1.5.2. THE IMMUNE SYSTEM AND CYTOKINES IN CHF
It is becoming increasingly apparent that inflammatory mediators play a role in the
progression of CHF, to the extent that several strategies to counterbalance different
aspects of the inflammatory response have recently been explored in clinical
trials.(Damas, Gullestad et al. 2001) Cytokines are a family of relatively low molecular
weight, pharmacologically active proteins secreted by different cell types for the
purpose of altering either their own function (autocrine) or that of adjacent cells
(paracrine). Cytokines implicated in the progression of CHF are tumour necrosis factor
a (TNF-a), interleukin (IL) 1, and IL-6. These cytokines share some of their major
characteristics, and all are proinflammatory.
TNF-a is the cytokine that has been studied in greatest detail. Amongst other actions,
TNF-a has been implicated in the development of left ventricular dysfunction,(Torre-
Amione, Kapadia et al. 1995) left ventricular remodelling,(Suffredini, Fromm et al.
1989) increased cardiac myocyte apoptosis,(Krown, Page et al. 1996) the development
of anorexia and cachexia, reduced skeletal muscle blood flow and endothelial
dysfunction,(Anker, Volterrani et al. 1998) and beta receptor uncoupling from adenylate
cyclase.(Loppnow, Werdan et al. 2002)
Several hypotheses have been suggested to describe the origin of immune activation in
CHF. Of note is the fact that treatment aimed at improving CHF, use of ACE inhibitors,
has the effect of reducing cytokine levels.(Gullestad, Aukrust et al. 1999) Some
evidence suggests that catecholamines augment this myocardial cytokine
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production,(Hasko, Nemeth et al. 1998) which would obviously have great relevance
with regard to this thesis.
1.5.3. APOPTOSIS AND CHF
Apoptosis and "programmed cell death" are terms used interchangeably. Apoptosis is
an active, precisely regulated, energy-requiring process which appears to be
orchestrated by a genetic programme.(Kerr, Wyllie et al. 1972) Apoptosis plays a
crucial role in the regulation of proliferating cell populations in adult tissues and in
normal tissue development.(Steller 1995) Even though cardiac myocytes are terminally
differentiated, the cells still contain the genes and signal transduction apparatus for
programmed cell death and thus retain the ability to die by apoptosis.(Barr and Tomei
1994) In recent years a working hypothesis has evolved that progressive left ventricular
dysfunction in CHF may result in part from ongoing loss of functional cardiac
units.(Sabbah 2000) Apoptosis may be the "final common pathway" of cardiac
deterioration caused by various destructive influences, and thus promotes CHF
progression.
This theory was based on the presence of ultrastructural degenerative changes of
cardiomyocytes in failing human and animal hearts. Changes noted include myofibrillar
disruption and disarray,(Sharov, Sabbah et al. 1994) disrupted internal and external
membranes of mitochondria,(Sabbah, Sharov et al. 1992) hyperplasia of organelles, and
abnormalities of the cardiac interstitium caused by accumulation of collagen.(Sabbah,
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Sharov et al. 1995) These observations provided indirect support to the concept that
ongoing myocyte degeneration and loss may occur in the failing heart.
Previous dogma stated that the heart is a terminally differentiated organ without
regenerative capacity.(MacLellan and Schneider 2000) This static view of the
myocardium implied that both myocyte death and myocyte replication played no
meaningful role in cardiac homeostasis. In the absence of myocyte renewal, cell death
by apoptosis or necrosis had to be extremely low to explain the preservation of the
cardiac mass throughout the life span of the individual, as even very low rates of
myocyte death would result in the complete disappearance of the myocardium. Thus, it
is not surprising that the existence of myocyte apoptosis remained controversial during
the past decade.(Kang and Izumo 2000) Studies in tissues obtained from explanted
hearts of patients with end stage heart failure have since confirmed the presence of
cardiomyocyte apoptosis.(Narula, Haider et al. 1996; Olivetti, Abbi et al. 1997)
Recent findings indicating the presence in the adult myocardium of a cell population
with the behavior and potential of cardiac stem cells has challenged the status quo. One
particularly intriguing report has even shown migration of cells from the recipient to the
donor heart in transplant recipients.(Quaini, Urbanek et al. 2002)These findings have
provided an explanation for the existence of a sub-population of immature cycling
myocytes and embraced myocyte death and myocyte renewal as two aspects of cardiac
homeostasis.(Nadal-Ginard, Kajstura et al. 2003) This myocyte renewal depends on the
differentiation of primitive cells into immature myocytes that might divide two to four
times before becoming terminally differentiated and permanently withdrawn from the
cell cycle. Although there is no evidence that already mature cardiomyocytes can de-
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differentiate, reenter the cell cycle, and proliferate, the heart has regenerative potential
and it is not a terminally differentiated organ. In this new light, the presence, regulation,
and physiological consequences of myocyte apoptosis have gained new significance.
Two recent papers highlight the effect of this type of myocyte death in cardiac
performance and provide new insights on the role of myocyte death and renewal in
cardiovascular physiology.(Wencker, Chandra et al. 2003; Yamamoto, Yang et al.
2003) Although it is well accepted that myocyte death is a determining factor of
ventricular dysfunction and end-stage failure, whether diffuse myocyte apoptosis can,
by itself, cause cardiac failure has remained controversial. These transgenic animal
models of myocyte apoptosis provide conclusive proof that myocyte dropout by itself
can cause cardiac failure.(Wencker, Chandra et al. 2003; Yamamoto, Yang et al. 2003)
In these studies, appearance of dilated cardiomyopathy was mediated by diffuse
myocyte apoptosis across the ventricular wall. Prevention of apoptosis prevented
development of heart failure.
With regard to this thesis, the importance of apoptosis is in relation to the factors that
can trigger this process. These factors include formation of oxygen free
radicals,(Gottlieb, Burleson et al. 1994) excess levels of angiotensin-II,(Kajstura, Cigola
et al. 1997) excess levels of norepinephrine (and particularly its action via Pi
adrenoreceptors)(Communal, Singh et al. 1998; Zaugg, Xu et al. 2000) and increased
levels of specific cytokines such as TNF-a.(Bozkurt, Shan et al. 1996; Krown, Page et
al. 1996) The underlying theme of this thesis may be to decide which of the diverse
actions of the two beta-blockers under study are important to reduce the level of
apoptosis in the failing heart. '
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1.6. STRATEGIES FOR MODULATION OF THE SNS IN CHF.
Angiotensin converting enzyme inhibitors have produced impressive benefits in heart
failure prognosis, at least in part by their modulation of the renin-angiotensin-
aldosterone system. Now interest has turned to methods of adjusting other
neurohumoral systems and foremost potential target for pharmacological intervention is
the SNS. Of note is that ACEIs themselves reduce SNS activity as measured by several
means, but several other more specific methods of achieving this goal exist.
Inhibition of sympathetic traffic to the heart and peripheral vasculature may be
accomplished by various means:
1. Blocking post-synaptic a and (3 receptors (as illustrated in Figurel .1).
2. Activating central inhibitory centres using drugs such as clonidine or
moxonidine.
3. Ganglion blocking drugs which interrupt transmission in the sympathetic
ganglia by blockade of nicotinic cholinergic receptors e.g. hexamethonium,
pentapyrrolidinium. Unfortunately, drugs in this class block almost all autonomic
outflow at both sympathetic and parasympathetic ganglia, and thus produce such a wide
range of side effects as to make routine use impossible. Short reports indicated a
worsening in heart failure with pentapyrrolidinium.(Ronnov-Jensen 1955)
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4. Depletion or inactivation of noradrenaline stores in the peripheral postganglionic
sympathetic neurones using, for example, guanethidine or reserpine. These drugs also
worsened heart failure in small studies.(Perera 1955; Marley and Pare 1956)
5. Inhibition of tyrosine hydroxylase to reduce production of catecholamines: one
small study of the use of metyrosine for this purpose exists.(Franciosa and Schwartz
1989) Whilst a decrease in plasma noradrenaline concentration was observed, no
haemodynamic effect was found and the study was taken by the authors to show no
influence in CHF.
Of these options, only the first two are practical at the present time in the sense that
drugs are available which are well tolerated during long term use. A diagram of the
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1.6.1. ALPHA BLOCKERS IN HEART FAILURE
When strategies for treating heart failure were dominated by the haemodynamic
hypothesis of heart failure, various different approaches to producing vasodilatation
were attempted. Alpha-adrenergic receptor antagonists were employed in the hope of
producing sustained vasodilatation by blocking the vasoconstriction caused by SNS
overactivity.
Phentolamine and phenoxybenzamine are non-selective alpha-blockers, with action on
both pre- and post-synaptic alpha receptors. Oral administration of phentolamine
(Screiber, Maier et al. 1976) and phenoxybenzamine (Kovick, Tillisch et al. 1976)
produced acute haemodynamic improvement in early observational reports. However,
phentolamine causes reflex stimulation of the sympathetic neurones resulting in greater
overall neurotransmitter release and heightened stimulation of beta-receptors,
consequently accelerating heart rate. Phenoxybenzamine also produces tachycardia, by
reducing presynaptic reuptake of noradrenaline (see Figure 1-1).
Short-term haemodynamic benefits were reported after administration of prazosin
(Miller, Awan et al. 1977) and trimazosin,(Awan, Hermanovich et al. 1979) both
selective al blockers. Enthusiasm for the use of alpha-blockers faltered when it was
found that tolerance to the acute haemodynamic effects developed, and there was no
clinical benefit after longer-term usage.(Markham, Corbett et al. 1983) In particular,
prazosin was found to produce no sustained haemodynamic or mortality benefit in
CHF,(Packer, Meller et al. 1979; Packer, Medina et al. 1986) and was found to actually
increase the circulating concentration of noradrenaline and to result in salt and water
55
retention.(Colucci, Williams et al. 1980; Stein, Henry et al. 1981) More recently, the al
blocker, urapidil, was tried in a small study of 36 patients with severe (NYHA III and
IV) heart failure.(Dorszewski, Gohmann et al. 1997) Apart from its peripheral al
blockade, urapidil also has some central action due to stimulation of serotonergic
5HT1A receptors in the medulla. This agent caused an almost 5 times increased
mortality rate in the urapidil arm of the study.(Dorszewski, Gohmann et al. 1997)
Doxazosin has a more prolonged duration of action than earlier members of the class,
which raised the expectation that it might be more useful in CHF. However, the
ALLHAT (Antihypertensive and Lipid -lowering treatment to Prevent Heart Attack
Trial) study(ALLHAT Collaborative Research Group 2000) had its doxazosin-treatment
arm discontinued owing to a significant increase in the numbers of patients developing
congestive heart failure. It seems unlikely that further trials of a-blockers in chronic
heart failure will be attempted.
1.6.2. BETA BLOCKERS IN HEART FAILURE
Since their development in the sixties, the conventional view of the use of beta-blockers
has been that these drugs depress cardiac performance due to negative inotropy and
negative chronotropy, and would thus worsen the situation in CHF. Swedish work more
than twenty years ago contradicted this view,(Waagstein, Hjalmarson et al. 1975) but
was not widely accepted. A number of small-scale clinical trials in the seventies and
eighties were inconclusive: inotrope development was in vogue, and progress appeared
to lie in this direction instead.
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The enormous success of ACE inhibitors in large-scale clinical trials helped evolve the
neurohormonal hypothesis of CHF and improve our understanding of this condition.
This finally led to a number of clinical trials of several different beta-blocking agents in
the nineties. The emphasis in these trials was not necessarily to detect an improvement
in patient symptoms, at least in the short term, but was rather to detect an improvement
in morbidity and mortality, which might suggest a delay in disease progression.
Most early beta-blocker trials were uncontrolled, usually assessed what might arguably
be called less important parameters, or were simply under-powered to detect mortality
improvements during beta-blocker therapy. The first Swedish trials were
observational,(Waagstein, Hjalmarson et al. 1975) whilst during the eighties surrogate
outcome parameters were employed such as exercise tolerance and change in ejection
fraction. Results using different agents seemed variable, doing little to bolster the case
for the use of beta-blockers in general in CHF.
Experience with ACE inhibitor trials showed that larger scale trials were required, and
after the worsening mortality seen in the inotrope trials, the consensus developed that
the primary end-point of trials should be influence on mortality rate. Huge numbers of
patients are required for such studies, so that enough end points occur to reveal genuine
differences between groups. The first of the large scale placebo-controlled beta blocker
trials occurred during the early nineties, but the first which have been sufficiently
powered to look at all-cause mortality have only been completed over the past few
years.
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1.6.3. CENTRAL INHIBITION OF SNS ACTIVITY
Centrally acting anti-adrenergic agents offer the opportunity of reducing systemic
vascular resistance to offset the potential negative inotropism of withdrawing cardiac
adrenergic drive. This reduced drive might be detectable by, for example, a lowered
plasma noradrenaline concentration.
Centrally mediated modulation of the sympathetic nervous system has been available
for many years in the form of clonidine,(Hermiller, Magorien et al. 1983; Giles, Thomas
et al. 1985; Magorien, Hermiller et al. 1985; Good, Unverferth et al. 1988; Manolis,
Olympios et al. 1995; Manolis, Olympios et al. 1997) a-methyldopa,(Kirlin, Das et al.
1986) guanabenz(01ivari, Levine et al. 1986) and guanfacine.(Collart, Staroukine et al.
1985) However, the concept of using these medications in the treatment of CHF has
surprisingly never been subjected to significant placebo-controlled trials, despite
encouraging preliminary data in these small studies.
Treatment of hypertension with centrally acting drugs originated with the use of a-
methyldopa in the 1960s. This pro-drug was quickly recognised as having its
predominant effect within the central nervous system. Clonidine became the main drug
of this class to be used in hypertension due to its better degree of tolerability. However
clonidine itself has side effects, which often make routine use unacceptable to patients:
sedation (due to the central 0C2 effect), dry mouth, fatigue and impotence (due to the
peripheral 0C2 effect) are common.
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A decade ago a number of small-scale studies of clonidine in CHF were conducted, at a
time when other vasodilators were becoming established. Despite some encouraging
early results, there was no impetus to conduct essential larger scale trials: the
"haemodynamic hypothesis" of heart failure was in vogue at the time, and seemed to
explain why vasodilator medication improved the condition. The "neurohormonal
hypothesis" of CHF progression was still in evolution and this, coupled with trials
showing a mortality reduction with nitrates and hydralazine and thereafter with ACE
inhibitors, led to a loss of interest in the results of these early clonidine trials.
The success of beta-blockers in heart failure therapy has prompted a further look at
clonidine as a possible alternative means of reducing the deleterious effects of
sympathetic overactivity. Moxonidine, a recently developed central SNS inhibitor,
seems to avoid most of the tolerability problems associated with other centrally-acting
agents, and has thus been under intense scrutiny.
An attractive feature of centrally acting anti-adrenergic drugs is that circulatory reflexes
are left largely intact despite the depression of peripheral sympathetic activity. Both
clonidine and moxonidine cause a fall in blood pressure, and act to reset the sensitivity
of the baroreceptor reflex (which is normally reduced in CHF). This action may explain
the improvement in heart rate variability (an important predictive factor for mortality in
CHF) seen with both drugs.(JuulMoller, Swedberg et al. 1997) Haemodynamic studies
confirm clonidine as a potential adjunctive therapy to ACE inhibitors,(Manolis,
Olympios et al. 1997; Girgis, Chakko et al. 1998) and it is safe in acute
dosing.(Mitrovic, Strasser et al. 1996; Dickstein, Manhenke et al. 1999)
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The first large scale trial of moxonidine, the MOXCON (Sustained Release Moxonidine
for Congestive Heart Failure) study was terminated early, in controversial
circumstances, due to increased mortality rates in the treatment group.(Coats 1999;
Cohn, Pfeffer et al. 2003) The Data and Safety Monitoring Board discontinued the study
when only 2000 of the planned 4540 patients had been enrolled, due to the deaths of 53
patients in the treatment group compared to 29 in the placebo group, most deaths being
sudden. There were also a greater number of hospitalisations for worsening heart
failure, acute MI and other adverse events.(Cohn, Pfeffer et al. 2003) It is not yet clear
why these effects have been seen, but it was noted during the study that plasma
noradrenaline concentration fell to sub-physiological levels in some patients. The drug
had a greater-than-expected effect on noradrenaline levels, a feature which had been
noted in the preliminary MOXSE study.(Swedberg, Bergh et al. 2000) Some
investigators believe that the failure of moxonidine in MOXCON has been due to the
choice of an inappropriately high dose.
Given the apparent results from MOXCON the use of centrally acting agents, and
particularly sustained-release moxonidine, in CHF is not currently recommended.
1.7. LARGE PLACEBO-CONTROLLED STUDIES OF BETA-BLOCKERS
IN CHRONIC HEART FAILURE.
For a summary of the large placebo-controlled beta-blocker trials, see Table 1.3
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1.7.1. MDC (metoprolol)
The Metoprolol in Dilated Cardiomyopathy (MDC) study (Waagstein, Bristow et al.
1993) randomised 383 patients on standard treatment to either metoprolol or placebo,
and follow up was for 12-18 months. Even with this size of study, there was no
significant effect on total mortality, but there was an effect which almost reached
statistical significance on the combined endpoint of mortality or progression to cardiac
transplantation. There was a non-significant excess of deaths seen in the metoprolol-
treated group.
1.7.2. CIBIS-I (bisoprolol)
The Cardiac Insufficiency Bisoprolol Study randomised 641 patients with heart failure
of various aetiologies to bisoprolol or placebo for a mean follow up period of 1.9 years:
again, there was no significant difference between groups in mortality, but fewer
bisoprolol-treated patients required hospitalisation, and more showed improvement in
function class.(CIBIS investigators 1994) Subgroup analysis suggested that benefit from
beta- blockade therapy was greater for those with non-ischaemic cardiomyopathy,
which at the time of publication appeared to add support to the view that idiopathic
cardiomyopathy patients had more to gain from beta-blocker therapy.
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1.7.3. US carvedilol trials
This key publication persuaded large sections of the cardiology community of the value
of beta blockade in heart failure.(Packer, Bristow et al. 1996) The publication was
actually the amalgamated result from four smaller studies (see Table 1-2),(Bristow,
Gilbert et al.; Colucci, Packer et al. 1996; Packer, Colucci et al. 1996; Cohn, Fowler et
al. 1997). A total of 1094 patients were enrolled for 6.5 months, and showed a 65%
relative risk reduction in mortality with carvedilol (p=0.001) regardless ofheartfailure
aetiology. A common data and safety monitoring board monitored the collective
mortality in these 4 separate trials (with separate efficacy end points) and the decision
was taken to terminate the trials early due to the marked reduction in mortality seen in
the treated group.
In addition to effects on mortality, carvedilol reduced the proportion of patients
requiring hospitalisation for a cardiovascular cause (risk reduction 27% with 95%
confidence intervals of 3-45%). The proportions admitted for any cause and for
worsening chronic heart failure were also significantly reduced. Tolerability of
carvedilol seems broadly similar to that of other beta-blockers in chronic heart failure,
although dizziness is perhaps more common. This study was, however, an amalgam of
four smaller studies, none of which had been powered to look at mortality. Follow-up
was short and the number of clinical events was very small.
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Table 1-2: Components of the US carvedilol programme
Number of
patients




(Colucci, Packer et al.
1996)
366 2:1 Progression of CHF
MOCHA
(Bristow, Gilbert et al.
1996)
345 3:1 Exercise tolerance
PRECISE
(Packer, Colucci et al.
1996)
278 1:1 Exercise tolerance
Severe CHF
(Cohn, Fowler et al.
1997)
105 2:1 Quality of life
1.7.4. ANZ (carvedilol)
This study enrolled 415 patients with mild CHF and randomised to placebo or
carvedilol. There was a non-significant reduction in mortality at 18 months: lack of
significance has been attributed to the relatively good prognosis for patients with mild
CHF.(Australia-New Zealand Heart Failure Research Collaborative Group 1995)
1.7.5. CIBIS-II (bisoprolol)
This study was the first randomised, double-blind, placebo-controlled trial of a beta
blocker in heart failure with sufficient power to address all-cause mortality as a primary
end-point.(CIBIS-II investigators and committees 1999) The large number of patients
and the large number of deaths in the study (384 in CIBIS-II compared to 54 in the US
carvedilol studies) make the data much more robust than the carvedilol studies. Due to
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its robust methodology, CIBIS-II was actually the first study to provide conclusive
evidence in favour of beta-blockers in heart failure. A total of 2647 ambulatory, mostly
male, patients said to have NYHA grade III or IV heart failure of ischaemic or non-
ischaemic aetiology and left ventricular ejection fraction <35% were recruited. The
study was halted early, with average follow-up of 1.3 years, due to a highly significant
mortality reduction in favour of bisoprolol. A fall of 34% in all cause mortality
(p<0.0001) was seen, and of particular note was the 45% reduction in sudden death.
Bisoprolol also achieved a significant effect on cardiovascular morbidity, with fewer
bisoprolol-treated patients (33%) requiring hospital admission as compared with
placebo (39%). Hospital admission for worsening heart failure was also reduced to 12%
form 18% in the placebo group. Tolerability of the medication was the same (15%
discontinued) in both the placebo and the treatment groups.
1.7.6. MERIT-HF (metoproiol CR/XL)
The Metoproiol CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF) is the largest trial so far of beta-blockers in heart failure, and has been
particularly encouraging as its results are highly consistent with those of CIBIS-II and
with meta-analyses of previous beta-blocker trials.(MERIT-HF investigators and
committees 1999) The 3991 patients included were in NYHA functional class II-IV, had
left ventricular ejection fractions less than 40% and all were on standard heart failure
therapy. Use of a long-acting form of metoprolol produced a 34% reduction in mortality
after a mean follow-up time of 1 year. Again, an independent safety committee
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recommended early completion of the study due to the magnitude of benefit seen in the
treated group. Both sudden deaths and deaths due to heart failure were reduced. Like
CIBIS-II, the large study size and large number of events (362 deaths) would suggest
that the data are robust. Tolerability of the drug was very similar to that of placebo
(15.3% in the placebo group discontinued because of side effects, compared to 13.9% of
the metoprolol group).
1.7.7. BEST (Bucindolol)
Bucindolol is another beta-blocker with vasodilating properties, which has already been
extensively evaluated in heart failure patients. Results from the BEST (Beta-Blocker
Evaluation of Survival Trial) study suggest no statistically significant benefit of
treatment on all-cause mortality.(BEST Trial Investigators 2001) This was an
unexpected result, with only a non-significant trend toward benefit in patients with
moderate to severe heart failure: mortality was reduced by 10% on bucindolol as
compared with placebo (P=0.109). This magnitude of benefit is obviously considerably
less than that seen in CIBIS-II and MERIT-HF. A higher proportion of patients had
severe heart failure (recruitment was open to patients with NYHA class III-IV) in this
study than in CIBIS II or MERIT-HF, and the ethnicity of the patients was different
(whilst CIBIS II and MERIT-HF had predominantly Caucasian subjects, BEST had a
23% African-American complement). Subgroup analysis showed that in patients with
NYHA III heart failure or left ventricular ejection fraction >20%, improved survival
occurred, but there was no benefit in those with LVEF <20% or in NYHA IV. Of
particular note was a non-statistically significant excess mortality in the African-
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American subgroup. Commentators have suggested that future studies should pay more
attention to the ethnicity of the study population, as there may in fact be differences
between racial groups in their response to therapy.
Bucindolol cannot therefore be recommended as a treatment option in CHF. This opens
up the question as to whether the mortality benefit of beta-blockers in CHF is a "class
effect", whether there are specific properties of some beta-blockers, which are more
desirable, or whether bucindolol has some peculiar adverse property. Bucindolol has
intrinsic sympathomimetic activity, and comparison might be made with xamoterol, a
beta-blocker with marked sympathomimetic properties which also had adverse effects
on mortality when used in CHF. (The Xamoterol in Severe Heart Failure Study Group
1990)
1.7.8. COPERNICUS (carvedilol)
Despite the large numbers of patients enrolled in the above studies, concern still existed
about the administration of beta-blockers to those patients with more severe heart
failure. Earlier large-scale studies with carvedilol, metoprolol and bisoprolol had
enrolled patients with mainly NYHA grade II-III heart failure. The COPERNICUS
study attempted to address this issue.(Packer, Coats et al. 2001)
Patients were enrolled who had dyspnoea or fatigue at rest or on minimal exertion, and
with a left ventricular ejection fraction of 25% or less. Patients were excluded if they
were not clinically euvolaemic, and thus the most severely affected patients were still
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excluded (those with pulmonary rales, ascites, significant peripheral oedema, those
requiring intensive cardiac care, and those with a serum creatinine >248|umol/litre).
In a double blind manner, 1133 patients were assigned to placebo and 1156 to treatment
with carvedilol. Over a period of 10.4 months, there were 190 deaths in the placebo
group and 130 deaths in the carvedilol group, reflecting a 35% decrease in the risk of
death during treatment with carvedilol. The combined endpoint of death or
hospitalisation was also reduced by 24%. An additional finding was that treatment with
carvedilol was very well tolerated, with fewer patients in the active treatment arm (as
opposed to the placebo arm) requiring permanent treatment withdrawal because of
adverse events. Despite exclusion of the most severely affected patients, the true
severity of the heart failure in the patients enrolled has been verified by an annual
mortality rate of 19.7% per patient year of follow-up in the placebo arm. This compares
to rates of 11.0%-16.6% in the other trials above. Indeed, when subgroup analysis was
performed to look at particularly high-risk patients (for example, those with recent or
recurrent cardiac decompensation), even this group benefited greatly by treatment with
carvedilol. Whilst not permitting the benefits of beta-blocker therapy to be extended to
all CHF patients, the COPERNICUS study certainly gave more confidence in applying
treatment to much less healthy patients.
67





























































































































































































































































































































1.8. EFFECTS OF BETA BLOCKERS ON MORBIDITY AND QUALITY OF
LIFE
Although beta-blockers prolong life, effects on quality of life and morbidity are of
course very important. In the mid nineties a debate occurred after studies employing
positive inotropes were found to reduce survival in chronic heart failure, but improve
quality of life.(Cowley and Skene 1994; Rector, Tschumperlin et al. 1995)One side of
the argument is that patients should be permitted to choose between quantity and
quality of life. (Lewis, Johnson et al. 2001) Whilst patients might live longer on beta-
blockers, would there be a reduction in the quality of life so as to make their use
unacceptable?
Quality of life is a notoriously difficult measure to quantify due to its subjective
nature. In the large beta-blocker studies, variables used to make some assessment of
quality of life have included physician-assessed NYHA class and patient-assessed
quality of life. Within beta-blocker trials, quality of life assessments have not given a
clear answer as to whether the effect of beta-blockers is positive.(Reddy and Dunn
2000) In one meta-analysis of more than 3000 patients involved in large beta-blocker
trials (which had otherwise shown a beneficial mortality effect), no clear
improvement in quality of life could be discerned.(Lechat, Packer et al. 1998)Other
investigators suggest that a quality of life effect is quantifiable.(Hjalmarson, Goldstein
et al. 2000) In this 741 patient sub-study of the MERIT-HF trial, NYHA functional
class (assessed by physicians) and McMaster Overall Treatment Evaluation score
(assessed by patients) both improved in the metoprolol CR/XL group compared with
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the placebo group. At present, it cannot be conclusively stated that quality of life is
improved after treatment with beta-blockers.
As an indication of morbidity, the reduction in hospitalisation frequency is striking in
both CIBIS-II and MERIT-HF. (CIBIS-II investigators and committees 1999;
Hjalmarson, Goldstein et al. 2000) This variable is usually regarded as being least
susceptible to observer bias, and has been accepted by some observers as being
indicative of an improvement on quality of life.(Fowler, Vera-Llonch et al. 2001)
1.9. CHOICE OF BETA BLOCKER
Whether all beta-blockers have the same effect of whether there is a "best beta
blocker" remains undecided. Bisoprolol, metoprolol and carvedilol are the drugs with
most evidence to support their use at present. This thesis is obviously intended to
explore differences between metoprolol and carvedilol.
1.10. COMET STUDY
The recent publication of the Carvedilol or Metoprolol European Trial (COMET)
(Poole-Wilson, Swedberg et al. 2003) has unfortunately not helped to clarify the
situation.(Dargie 2003; Massie 2003) This study was conceived as a definitive means
of comparing clinical outcomes with metoprolol and carvedilol in CHF.
The multi-centre, double blind, randomised parallel group design assigned 1511
patients with CFIF to treatment with carvedilol (target dose 25mg twice daily) and
1518 to metoprolol tartrate (target dose 50mg twice daily). Patients were required to
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have CHF (NYHA II-IV), a previous admission for a cardiovascular reason, an
ejection fraction of less than 35%, and to have been optimally treated with diuretics
and angiotensin converting enzyme inhibitors unless not tolerated. The primary end
points were all-cause mortality and the composite end-point of all-cause mortality or
all-cause admission. The mean duration of the study was 58 months.
The composite end point of mortality or all-cause admission occurred in 1116 (74%)
of 1511 on carvedilol and in 1160 (76%) of 1518 on metoprolol (a non-significant
difference, p=0 -122). An equal number of hospitalizations occurred in both groups.
All-cause mortality was 34% (512 of 1511) for carvedilol and 40% (600 of 1518) for
metoprolol (hazard ratio 0.83, 95% confidence interval 0.74-0.93, p=0.0017). This
represented a 17% relative risk reduction in mortality for those treated with carvedilol
as compared to metoprolol. Study drug was permanently discontinued by 32% of the
subjects in both treatment groups, and the incidence of adverse effects was similar in
both groups.
COMET included a large number of endpoints due to its long duration. The first
patient was entered on December 1, 1996, and the last of the 3029 patients was
enrolled on January 15, 1999, with a mean duration of follow-up of 57.9 months. The
confidence intervals around the hazard ratio are narrow, making the effect on
mortality result highly reliable. In a population of heart failure patients with a 10%
expected annual mortality rate, the 17% mortality reduction observed in COMET
translates into approximately 1 life saved for each 60 patients treated with carvedilol
for a year compared with metoprolol in the formulation and doses studied.
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The cardiology community has, however, interpreted the result from COMET as
being far from conclusive. In particular, controversy exists as to whether the
comparison of short-acting metoprolol with carvedilol (as opposed to the long-acting
compound used in the MERIT-HF study) was appropriate. The MERIT-HF study
employed an extended-release form of metoprolol succinate (metoprolol CR/XL),
whilst COMET used more conventional metoprolol tartrate 50mg BD. In COMET a
dose of lOOmg metoprolol per day was planned (actual mean dose was 85mg). The
mean daily dose of study drug in the metoprolol CR/XL group of MERIT-HF was 159
mg once daily, equivalent to 106mg of metoprolol tartrate when the different
bioavailability of the slow-release form is taken into account. Thus the dose of
metoprolol used in COMET was somewhat less than that shown to be effective in
MERIT-HF. The mean daily dose at entry into the maintenance phase of the trial was
42 mg in the carvedilol group.
This possible lack of equivalent drug effect becomes even more important when
observing the heart rate reduction in the metoprolol arm of COMET. Despite an
identical mean heart rate at baseline in both treatment groups, a significant difference
in mean heart rate was observed at 4 months between the 2 groups. Reductions in
heart rate seen in the first few months of COMET were 13.3 bpm in the carvedilol
group and 11.7 bpm in the metoprolol group, though after longer treatment the heart
rate reduction in both COMET arms was virtually identical. Significant differences in
heart rate reduction persisted in the trial until after 16 months of follow-up. This
effect on heart rate during the first few months in COMET leaves open the possibility
that some of the difference in efficacy seen was due to differing degrees of beta
blockade, possibly due to inadequate doses of metoprolol.
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Similarly, despite an identical mean blood pressure at baseline in the 2 groups, a
significantly greater reduction in systolic blood pressure was observed at 4 months in
the carvedilol group compared with the metoprolol tartrate group (3.8 versus 2.0 mm
Hg, respectively). Significant differences in both systolic blood pressure and diastolic
blood pressure between the 2 groups were observed throughout the trial. It is thus
difficult to be certain that in COMET, metoprolol exerted a similar degree of (3i
blockade as carvedilol.
Active debate over the COMET results continues, with a number of authorities in this
field having sharply contrasting views.(Massie 2003) Some observers contend that the
dose of metoprolol used is the only reason for the difference seen,(Bristow, Feldman
et al. 2003) and there is certainly evidence to support the theory that the only effect of
a beta-blocker that matters in CHF is its (31 receptor antagonism. Other authors
maintain that the difference between the two agents must be due to the subsidiary
effects of carvedilol, with either the alpha blockade or antioxidant action being the
favoured possibilities.(Packer 2003) This argument is fundamental to the topic of this
thesis, and will be expanded upon in the individual chapters.
The objections to the findings of the COMET study can also be levelled at the study
detailed in this thesis, as compounds used and dosage regimes were based on the same
original data and thus virtually identical.
1.11. BENEFICIAL MECHANISM OF ACTION OF BETA BLOCKERS
Which particular action of beta-blockers is responsible for slowing CHF progression?
Possible mechanisms include:
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1. Blockade of the direct toxic effects of catecholamines (Imperato McGinley,
Gautier et al. 1987; Mann and Cooper 1988) (particularly with the less
selective beta-blockers).
2. Reduction of systemic vascular resistance (SVR): in the short term, most beta
blockers actually increase SVR, but the SVR is decreased after long term
administration (Waagstein, Caidahl et al. 1989) presumably due to improved
myocardial performance or a decrease in sympathetic drive.
3. Antiarrhythmic action.(Cleland and Dargie 1988)
4. Reduced renin secretion.(Holmer, Hense et al. 1998)
5. Prolonged diastolic filling permitting increased effective myocardial blood
flow.
6. Reduced myocardial ischaemia.
7. Slowing of heart rate, resulting in lower myocardial energy expenditure.
This last mechanism of action is particularly attractive, as perhaps simply "resting the
weary heart" is all that is required. Increased heart rate itself is an independent risk
factor for death in CHF (and indeed, in a variety of cardiovascular conditions (Palatini
and Julius 1996)). The relative risk of all-cause mortality increases with increasing
heart rate; this effect is restricted to cardiovascular causes of mortality and does not
apply, for example, to cancer mortality. (Kristal, Silber et al. 2000) It is of note that
the failed strategy of using positively inotropic medication to treat CHF produces
increases in heart rate. Whether increased heart rate is simply an indicator of poorly
treated CHF, or indicates increased risk, has not yet been clearly determined.
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1.12. PRACTICAL CONSIDERATIONS FOR INITIATION OF TREATMENT
WITH BETA BLOCKERS IN CHF
Initiation of treatment with beta-blockers in heart failure must be extremely
cautious.(Eichhorn and Bristow 1997) Large-scale trials so far have used patients with
stable, compensated heart failure. Beta-blockers are generally regarded as
inappropriate for those with overt pulmonary or peripheral oedema. Even in the
COPERNICUS study, patients were required to be euvolaemic.(Packer, Coats et al.
2001)
A major issue when interpreting the results of heart failure trials is the difficulty in
being certain about the severity of symptoms. Classification by NYHA class is
notoriously subjective and susceptible to bias. A much better arbiter ofpatients' true
CHF severity is to observe the mortality rate in the placebo arm of the trial. Assuming
that randomisation has been appropriately conducted, this gives a much better
indication of CHF severity. The great majority of patients enrolled in the large-scale
clinical trials have had NYHA II or NYHA III heart failure. The US
Carvedilol,(Cohn, Fowler et al. 1997) MERIT-HF(MERIT-HF investigators and
committees 1999) and CIBIS-II(CIBIS-II investigators and committees 1999) studies
were conducted in patients with mild to moderate heart failure, confirmed by the
annual placebo group mortality rates of 7.8%, 11%, and 13.2% respectively. Among
patients enrolled in these studies, 8% were said to have experienced NYHA class IV
symptoms at baseline. Only with the release of the COPERNICUS study results has
robust data become available on patients with more severe CHF, with an annual
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placebo mortality of 19.7%.(Packer, Coats et al. 2001) All patients were assessed as
having NYHA class III or IV symptoms at randomisation to the trial.
It is no surprise that less well patients are more likely to develop adverse events
during initiation and dose titration,(MacDonald, Keogh et al. 1999) but these less well
patients may also have more to gain. Certainly NYHA II and III patients should all be
treated with beta-blockers unless there are contraindications. There are no guidelines
to help identify those patients most likely to have a favourable response to therapy.
What is clear is that the initial dose of beta-blocker should be low, far less than the
dose used conventionally in hypertension or angina. Dose increases should be carried
out under careful supervision usually at 2 weekly intervals, simply because most of
the trials used a titration schedule like this. It may be possible to increase doses more
rapidly, but no data exists on this issue. By slow up-titration, the supportive role of
SNS activity for the circulation is only slowly withdrawn. Carvedilol should be
started at 3.125mg BD. and bisoprolol at 1.25mg OD.
The only two beta-blockers licensed for use in CHF in the UK are carvedilol and
bisoprolol, both of which are now commercially available in the doses employed in
the CHF studies. Metoprolol is not licensed for CHF, and indeed the long-acting
preparation used in MERIT-HF is not yet available in the UK. Whether this long-
acting form is required for the beneficial effect remains open for debate,(Kukin,
Mannino et al. 2000) particularly after the results of the COMET trial.
Even with careful initiation, physicians employing beta-blockers to treat heart failure
must be aware that there may be short-term decompensation requiring increases in the
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dose of diuretics. In the case of vasodilating beta-blockers, symptoms of hypotension
may require a decreased diuretic dose.
1.13. EVIDENCE AGAINST THE NEUROHORMONAL HYPOTHESIS
Despite the impressive achievements in the treatment of CHF with therapies which
appear to support the neurohormonal hypothesis, results of some recently completed
clinical studies call aspects of this hypothesis into question.
The centrally-acting norepinephrine-lowering agent moxonidine resulted in increased
mortality in the MOXCON trial.(Coats 1999; Cohn, Pfeffer et al. 2003)As
sympatholysis is the only known action of moxonidine, this result challenged the
whole dogma that antiadrenergic therapy is beneficial. In the BEST trial, too,
sympatholysis (marked lowering of plasma norepinephrine concentration) achieved
by the use of bucindolol seemed to result in increased mortality, at least in some
subgroups.(Bristow, Zelis et al. 2001) The existence of polymorphisms of adrenergic
receptors may explain why these subgroups fared less well during therapy. It has been
suggested that when the degree of sympatholysis is overwhelming, this removes the
important supportive role of the SNS in a manner that prevented adaptation. It is very
likely that our current understanding of the functioning of the SNS is incomplete.
However, it has not just been with relation to the SNS that the neurohormonal
hypothesis has given us apparently incomplete comprehension. The first inkling of the
phenomenon of a neurohumoral "ceiling" of effect came from the ATLAS
trial,(Packer, Poole Wilson et al. 1999) where no mortality benefits were seen with
higher dose ACE inhibitors. Furthermore, the Val-HEFT trial(Cohn, Tognoni et al.
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2001) indicated that the combination of ACE inhibition, angiotensin receptor
antagonism, and beta blockade was positively harmful.
Since these studies, there have been disappointing results from further attempts at
extrapolation of the neurohormonal hypothesis. The OVERTURE trial(Packer, Califf
et al. 2002) tried to show that use of the neutral endodpeptidase inhibitor, omapatrilat
(producing ACE inhibition, but also increasing circulating plasma concentrations of
natriuretic peptides which are normally degraded by neutral endopeptidase), would be
more beneficial than a simple ACE inhibitor. However, there was no significant
advantage with omapatrilat, and a higher rate of side effects. Trials of endothelin
receptor antagonists, bosentan and enrasanten have been disappointing. In particular,
bosentan failed to produce benefit in the ENABLE trial in severe CHF.(Kalra, Moon
et al. 2002)
The use of the neurohormonal hypothesis has certainly been helpful in stimulating
new avenues of research into the pathophysiology of CHF. However, there appears to
be a limitation as to how far the limits of the hypothesis can be taken.(Massie 2002)
When one attempts to inhibit too many pathways of neurohumoral activation, or when
one inhibits a particular pathway too much, clinical results seem to be worse. It is
certain that the complexity of neurohumoral pathways is greater than we yet
understand.
1.14. CONCLUSION
Sympathetic nervous system modulation is a current frontier in heart failure treatment.
There is much to commend the use of beta-blocker therapy for stable CHF patients as
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a means of retarding the progression of their condition: careful introduction of beta-
blockers should now be standard in management of stable CHF patients by
cardiologists. The remaining question is: which beta-blocker is best?
1.15. HYPOTHESIS
Our hypothesis was that the actions of carvedilol and metoprolol in patients with New
York Heart Association (NYHA) class II and III chronic heart failure could be
distinguished when assessing the following parameters:
i) systemic haemodynamics using intravenous infusions of adrenoreceptor
stimulants
ii) peripheral arterial effects using forearm venous occlusion
plethysmography (response to brachial intra-arterial infusion of
dobutamine, salbutamol, phenylephrine and acetylcholine)
iii) endothelium-dependent peripheral blood flow (following temporary
arterial occlusion)
iv) neuroendocrine activity using measurement of renin, angiotensin II,
aldosterone, adrenaline, noradrenaline, atrial natriuretic peptide, B-type
natriuretic peptide and endothelin concentrations
v) plasma cytokine activity using measurement of plasma concentrations of
TNF-cx and sTNFR-2
vi) cardiac (Y-adrenorcceptor density using in vitro measurement of
lymphocyte beta-receptor density
vii) antioxidant effects using LDL oxidation, plasma total antioxidant activity,
plasma vitamin E concentration and measurement of plasma concentration
of MDA






2.1. CONTEXT OF THE STUDY
When this study was first planned, the US carvedilol program (USCP) results had just
been released. (Packer, Bristow et al. 1996) Whilst controversial due to the complex
and unconventional study design, the USCP results strongly suggested a beneficial
action of carvedilol in CHF. An obvious question was whether carvedilol has unique
properties, or whether all beta-blockers produce a reduction in mortality rate in CHF.
A small-scale study such as that employed in this thesis would not be able to
demonstrate this, but would enable a detailed comparison of the properties of
individual beta-blockers when used in CHF.
Metoprolol was chosen for comparison with carvedilol. Carvedilol is an antagonist at
various different adrenoreceptors and has in vitro antioxidant activity, whilst
metoprolol has a much narrower range of action as a highly specific antagonist at the
Pi adrenoreceptor. Large studies have since confirmed a dramatic beneficial effect not
only of carvedilol but also of modified-release metoprolol and bisoprolol in
CHF.(CIBIS-II investigators and committees 1999; MERIT-HF investigators and
committees 1999) The results of a large comparative study of clinical results with
carvedilol and metoprolol in CHF (the COMET study) have recently been
released.(Poole-Wilson, Swedberg et al. 2003)
2.2. OBJECTIVE
This open label, parallel group study was designed to comprehensively compare and
distinguish the actions of carvedilol and metoprolol in patients with New York Heart
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Association (NYHA) class II and III chronic heart failure. Individual objectives of the
various study components are listed in the appropriate chapters.
2.3. OVERALL STUDY DESIGN
This study was conducted in accordance with recommendations guiding physicians in
biomedical research involving human patients as laid down by the Declaration of
Helsinki. The West Ethical Committee of Greater Glasgow Health board granted
ethical approval.
Our original protocol had baseline, acute (after first dose of the study drug), sub acute
(after full titration to target dose of study drug) and chronic (after maintenance at
target/maximum tolerated dose of study drug) study days. It had been intended to
perform forearm blood flow recordings, systemic infusions and blood sample analyses
at all four of these time points. The local ethical committee advised that this would
result in an unacceptable burden on the subjects involved and consequently the
protocol was revised to take this into account. On the advice of the ethical committee,
we restricted these more intensive study days to two in number (see section 2.4). The
first was on the first day of study drug dosing, with baseline blood samples being
taken, then forearm studies and systemic infusions taking place after the first (very
low dose) of study drug. The second intensive study day was at the end of the
maintenance phase, after twenty weeks of treatment.
Adrenergic effects of carvedilol and metoprolol on systemic haemodynamics were
studied using systemic intravenous infusions of adrenoreceptor stimulants. Peripheral
arterial effects were assessed by forearm venous occlusion plethysmography,
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assessing forearm blood flow in response to brachial intra-arterial infusion of
dobutamine, salbutamol, phenylephrine and acetylcholine. Measuring forearm blood
flow response following blood flow occlusion assessed the effect of the study drugs
on endothelium-dependent peripheral blood flow. Neuroendocrine activity was
assessed by measurement of renin, angiotensin II, aldosterone, adrenaline,
noradrenaline, atrial natriuretic peptide, B-type natriuretic peptide and endothelin
concentrations. Plasma cytokine activity was assessed by measurement of plasma
concentrations of TNF-a and sTNFR-2. Cardiac (32-adrenoreceptor density was
assessed indirectly by in vitro measurement of lymphocyte beta-receptor density.
Antioxidant effects were measured by studying LDL oxidation, plasma total
antioxidant activity, plasma vitamin E concentration and measurement of plasma
concentration of MDA. Electrocardiographic stability was assessed by collection of
QT dispersion data and by recording of signal-averaged ECGs. Safety was assessed
using routine laboratory tests and by collection of adverse event data. Assessments
during the study were made according to the schedule detailed below (see Table 2-1).
2.4. INTENSIVE STUDY DAYS
These two days were the main points at which data was collected for the study. On
arrival on intensive study days, patients first underwent phlebotomy (to glean the data
for neurohumoral measures, antioxidant measures, and lymphocyte beta-receptor
density and cytokine measures). This was followed by ECG analysis (both 12-lead
EGG for QT dispersion and signal-averaged ECG). Two hours after adminstration of
the first dose of study drug that day, forearm venous occlusion plethysmography was
performed. Three hours after the administration of the second dose of study drug,
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systemic infusions of beta agonists were administered combined with haemodynamic
assessment.
2.5. CHOICE OF DRUG DOSES
Drug doses used were chosen with the intention of producing an equivalent degree of
beta blockade. A difficulty when embarking on a trial comparing two drugs is
obviously the choice of dose. Normally the most appropriate basis for comparing
beta-blockers is their effect to reduce heart rate. This issue is made more complex by
the mechanism of action of carvedilol, as the drug has other complex actions which
have the potential to affect heart rate. Most notably, the vasodilatation caused by
metoprolol could have the potential to cause a reflex tachycardia. Nonetheless, in
deciding dose, most large scale beta blocker trials have relied on the drug effect on
resting heart rate in choosing doses for drug comparisons, even when more beta
blockers with more complex actions have been employed.
In the Metoprolol Dilated Cardiomyopathy (MDC) trial, the mean metoprolol dose
was 108 mg daily, with a mean heart rate reduction of 15 beats per minute, or a
reduction of heart rate of 0.14 bpm/mg.(Waagstein, Bristow et al. 1993) In the US
carvedilol program, the mean daily dose of carvedilol was 45 mg and the resultant
heart rate reduction was 13 beats per minute, or a 0.29 bpm/mg reduction in heart
rate.(Packer, Bristow et al. 1996) Thus a comparison of doses twice as high for
metoprolol on a milligram basis as compared to carvedilol appeared to be reasonable.
It is reassuring to note that the target doses we chose for the two agents under study
were more recently employed in the large-scale COMET study, comparing clinical
outcomes in CHF patients being treated with these drugs.
Starting doses of the study drugs were 3.125mg bd for carvedilol and 5mg bd for
metoprolol. These doses were titrated to 25mg bd or 50mg bd, respectively, or until a
maximally achieved dose has been reached by week 10, when the patients entered a
maintenance period. To remain in the study, subjects had to reach at least 12.5mg bd
carvedilol or 25mg bd metoprolol (and titration to 25mg bd carvedilol or 50mg bd
metoprolol had to have been attempted at least once). Slow titration of beta-blockers
under supervision at two weekly intervals was an essential component of the study.
This method of drug introduction followed the pattern in the US carvedilol
programme, and obviously greatly increased the number of patient visits.
2.6. DRUG ADMINISTRATION
Patients were initially screened for inclusion into the study using the criteria presented
below (sections 2.7.1, 2.7.2). Written informed consent was then obtained from the
patients who were eligible. These patients were randomised, up to 7 days later, to
receive either carvedilol or metoprolol for a total of 20 weeks.
The specific study drug employed was not revealed to the patients involved (the drug
bottles were labelled only as containing medication pertaining to the study, without
mention of whether they contained carvedilol or metoprolol). Due to the restricted
availability of usable preparations of the agents used, it was impossible to blind the
investigator to the individual drug used for a particular patient. The only available
preparation of metoprolol was not manufactured in a dosage small enough for
appropriate comparison to carvedilol 3.125mg, and thus the scored tablets were
halved. This meant that it was potentially obvious to the investigator to which drug a
patient had been randomized.
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2.6.1. RANDOMISATION
Randomisation of therapy was performed on the basis of a computer-generated
sequence. Consecutive recruits to the study were assigned to the next treatment (either
carvedilol or metoprolol) as had been generated from the random sequence (see Table
2-2). Characteristics of all patients randomised and who completed the study
treatment as planned are listed below (see Table 2-3, Table 2-4, Table 2-5).
2.6.2. UPTITRATION
Up-titration visits involved patients attending for a clinic assessment when the
opportunity to report any adverse events was provided. Compliance was checked at
each visit by counting the tablets remaining in the bottles used for drug dispensing.
Compliance is recorded below (see Table 2-6). Heart rate, blood pressure and a
clinical examination for signs of heart failure were recorded at each up-titration visit.
The next-higher dose of the study medication was then administered and the patients
were observed in a clinic setting for two hours. Pulse and blood pressure were
recorded at 30-minute intervals during this observation period. In the event, all
patients tolerated the increased dose of beta-blocker administered at these visits
without difficulty.
Having achieved the target at ten weeks, patients were then maintained on their
maximally achieved dose for 10 weeks. Chronic responses were assessed at
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Table 2-2 Randomisation sequence
Patient number Medication Patient number Medication
01 Metoprolol 18 Metoprolol
02 Metoprolol 19 Metoprolol
03 Carvedilol 20 Carvedilol
04 Carvedilol 21 Carvedilol
05 Metoprolol 22 Metoprolol
06 Carvedilol 23 Carvedilol
07 Carvedilol 24 Metoprolol
08 Metoprolol 25 Carvedilol
09 Metoprolol 26 Metoprolol
10 Carvedilol 27 Metoprolol
11 Metoprolol 28 Carvedilol
12 Carvedilol 29 Metoprolol
13 Metoprolol 30 Metoprolol
14 Metoprolol 31 Carvedilol
15 Carvedilol 32 Carvedilol
16 Carvedilol 33 Carvedilol
17 Carvedilol 34 Carvedilol
2.7. STUDY POPULATION
Patients were recruited from general cardiology outpatient clinics at the Western
Infirmary, Glasgow and at the Southern General Hospital. Glasgow. Informed consent
was obtained from all patients prior to study entry.
2.7.1. INCLUSION CRITERIA
Patients were recruited into the study if they were of at least 18 years of age and male
or female without child-bearing potential (post-menopausal) with stable chronic
symptomatic heart failure (NYHA class II-III). The criteria listed below had to be
met:
• At least a two month history of heart failure
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• An ejection fraction of <45% documented by echocardiography within the six
months prior to screening. If more than one assessment of ejection fraction had
been taken, the highest recorded value was taken to represent the true ejection
fraction.
• Unmodified cardiovascular medication for 4 weeks prior to baseline/screen
(except for beta blockers)
• Four weeks prior to screen free of hospitalisations
• Written informed consent to participate in the study
2.7.2. EXCLUSION CRITERIA
The following were regarded as exclusions from the study:
• Patients requiring continuous or intermittent outpatient inotropic therapy
• Uncorrected haemodynamically significant primary obstructive or severe
regurgitant valvular disease, non-dilated (restrictive) or hypertrophic
cardiomyopathies.
• Symptomatic ventricular arrhythmias not controlled by an allowed anti¬
arrhythmic drug or an implantable defibrillator.
• A myocardial infarction in the past two months prior to study entry
• Unstable angina
• Active myocarditis
• Atrial fibrillation, sick sinus syndrome or second or third degree heart block
with or without the presence of a pacemaker.
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• Supine systolic blood pressure < 85 mmHg; uncontrolled hypertension (i.e.
SBP greater than 180 mmHg or DBP greater than 110 mmHg)
• Heart rate less than 62 beats per minute (sitting)
• Current clinical evidence of obstructive pulmonary disease (e.g. asthma or
bronchitis) requiring inhaled or oral bronchodilator or steroid therapy
• Evidence of significant disease that could impair absorption, metabolism, or
excretion of orally administered medication, i.e. renal disease (serum
creatinine >221 pmol/1 or 2.5 mg/dl or creatinine clearance <25 ml/mm);
clinically significant hepatic disease (by laboratory i.e., ALT or AST levels
greater than three times upper limit of normal range or by clinical assessment);
or chronic biliary disorders.
• Platelet count less than 100,000/mm3 or WBC count less 3,000/mm3
• Brittle insulin-dependent or poorly controlled non-insulin-dependent diabetes
mellitus (repeated episodes of keto-acidosis and/or hyperglycaemic coma
and/or hypoglycaemic shock)
• Any condition of sufficient severity to impair co-operation in the study
• History of chronic alcohol excess
• History of drug sensitivity or allergic reaction to alpha- or beta-blockers
• Use of an investigational drug other than carvedilol within 30 days of entry
into the study or within 5 half-lives of the investigational drug (the longer
period will apply).
• Use of any of the following medications during the study period:
- Monoamine oxidase inhibitors (MAOIs)
- Non-dihydropyridine calcium channel blockers
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* Patients taking beta-blockers were permitted to continue this treatment until 1 week
prior to the screening assessments. This issue is discussed in detail in chapter 9
(section 9.4).
2.8. SUBJECTS STUDIED
This study was started with the intention of having sufficient patients with stable
chronic heart failure (NYHA class II-III) to ensure that 15 patients in each treatment
group completed the study. Initially eighteen patients were randomised to treatment
with carvedilol, and fifteen were randomised to treatment with metoprolol. There
were 29 male subjects and 4 female subjects. The mean age of study participants was
66.7 years. All subjects were Caucasian. Twenty-nine of the subjects were assessed as
having NYHA II heart failure at study commencement; the other 4 subjects were
assessed as having NYHA class III heart failure.
Seventeen patients treated with carvedilol and 12 taking metoprolol completed the
study as planned. One patient treated with carvedilol suffered a fatal cerebrovascular
accident during the course of the study. Two patients randomised to metoprolol had
vasovagal reactions during their baseline venesection and did not continue further in
the study. One further patient randomised to metoprolol withdrew after one week's
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treatment for personal reasons. Further data was not obtainable because of logistical
problems related to sample processing: vitamin E and LDL oxidation results were
eventually obtained in 10 patients from each treatment group.
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2.8.1. DEMOGRAPHICS

























































N (%) 15 (83) 14 (93)
N (%) 3 (17) 1(7)
LEFT VENTRICULAR EJECTION FRACTION (%)
Mean 27.8 30
s.d. 7.3 7.9
Table 2-3: Relevant medical history of randomised patients
Carvedilol Metoprolol
Ischaemic heart disease N (%) 17 (94) 15 (100)
Previous MI N (%) 13 (72) 12 (80)
Previous CABG N (%) 4(22) 3(20)
Cardiomyopathy N (%) 1(6) 0(0)
Hyperlipidaemia N (%) 9(50) 4(27)
Peripheral Arterial Disease N (%) 3(17) 2(13)
Diabetes (type II) N (%) 1(6) 0(0)
Table 2-4 : Prior Medication
Medication Carvedilol Metoprolol
N (%) N (%)
Total Patients Randomised 18 (100) 15 (100)
Total Patients Receiving Prior 18 (100) 15 (100)
Medication
ACE inhibitors 18 (100) 14 (93)
Antianginal agents 7 (39) 5 (33)
Isosorbide dinitrate 0 (0) 1 (7)
isosorbide mononitrate 4 (22) 3 (20)
nitroglycerin 4 (22) 3 (20)
Beta-blockers 2 (11) 6 (40)
atenolol 1 (6) 2 (13)
bisoprolol 1 (6) 2 (13)
metoprolol 0 (0) 2 (13)
Calcium channel blockers 4 (22) 3 (20)
amlodipine 4 (22) 2 (13)
nifedipine 0 (0) 1 (7)
Diuretics 13 (73) 10 (67)
amiloride/frusemide 1 (6) 2 (13)
frusemide 12 (67) 9 (60)
Gliclazide 1 (6) 0 (0)
Statins 10 (56) 4 (27)
pravastatin 1 (6) 1 (7)
simvastatin 9 (50) 3 (20)
Aspirin 17 (94) 15 (100)
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Table 2-5 : Study medication compliance
Compliance Carvedilol Metoprolol
Could not be evaluated N 0 2
<80% N 0 1
80% to 120% N 15 11
>120% N 3 1
Table 2-6 : Number of patients withdrawn from study by treatment and
phase
Reason for withdrawal Carvedilol Metoprolol
Patients withdrawn from study 1 3




Maintenance withdrawals: Adverse experience
N 1 0
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2.9. METHODS: HAEMODYNAMIC MEASURES
2.9.1. DRUG INFUSIONS AND THEIR TIMING
The timing of drug infusions with respect to administration of beta-blockers deserves
specific attention. The infusions were administered in the afternoon of intensive study
days i.e. Day 0 and after 20 weeks of treatment, and on each occasion the infusions
were carried out 3 hours after the second dose of study drug on that particular day.
This issue of the timing of the systemic infusions will be examined further in section
4.4.
Infusions of dobutamine and salbutamol were used to achieve systemic p i receptor
and P2 receptor activation respectively. These are readily available beta-receptor
agonists that are used clinically, and each has reasonable specificity for activation of
the individual receptor subtypes. Doses of dobutamine and salbutamol were prepared
(taking into account the weight of the subject) to enable infusions at the rates of
0.625, 2.5 and lOpg/kg/min (dobutamine) and 0.0125, 0.05 and 0.20pg/kg/min
(salbutamol). The doses of dobutamine chosen were based on those used in certain
clinical situations, in particular a dose of 20pg/kg/min is used during dobutamine
stress echocardiography to produce an increase in heart rate and cardiac work so as to
provoke cardiac ischaemia. The doses of salbutamol used were based on previous
investigators results.(Gibson and Coltart 1970) The relevant drug was then infused at
the three ascending doses at 5-minute intervals. Washout between the drugs, using
physiological saline at 5ml / minute, was for 10 minutes.
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2.9.2. PATIENT PREPARATION
The subjects were allowed to lie supine and 1% lignocaine was used to anaesthetise
the skin over the antecubital fossa of the non-dominant arm. A sixteen gauge
intravenous cannula with injection ports was placed into the antecubital vein. A
second cannula was already present in the dominant arm from the blood sampling
performed earlier in the day. Physiological saline was infused at 5ml/minute for 30
minutes into the non-dominant arm to permit equilibration.
2.9.3. MEASUREMENTS
We collected heart rate, systolic and diastolic blood pressure, left ventricular stroke
volume and cardiac output data during this study. Heart rate and blood pressure
readings were assessed using a "Dinamap" automated blood pressure recorder (GE
Healthcare, Chalfont St. Giles, United Kingdom). Cardiac output and stroke volumes
were assessed using an "NCCOM 3" bioimpedance cardiography monitor (Bomed
Medical Manufacturing Ltd, Cheshire, UK), as described below (section 2.9.4). These
parameters were assessed at baseline and during systemic infusion of the incremental
doses of salbutamol and dobutamine (as described in section 2.9.1).
2.9.4. TRANSTHORACIC IMPEDANCE CARDIOGRAPHY
Of major concern with using beta-blockers, particularly in CHF patients, is the
possible deleterious effect of these medications on cardiac output. In addition, any
beneficial effect of long term beta blockade would be of great interest. The technique
of impedance cardiography is a convenient and non-invasive means of assessing
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cardiac output, and was therefore employed in this study. The principles behind this
technique are discussed in section 4.2. Briefly, the technique requires attachment of
eight standard ECG gel electrodes to the subject's thorax, four at neck level and four
at diaphragm level. The bioimpedance cardiography monitor computes an estimate of
cardiac output based on fluctuation in transthoracic impedance, heart rate, and patient
data (gender, height and weight).
2.9.5. SPECIFIC PRECAUTIONS
As there was a small risk of precipitating cardiac arrhythmias when administering
adrenergic stress, a standard cardiac ECG monitor was also attached to the patient as a
safety precaution, with the intention of terminating the study if any arrhythmia
occurred. Monitoring was continued for 30 minutes after completion of the study
protocol for safety reasons. In the event, no such arrhythmia occurred during the
study.
2.10. METHODS: PERIPHERAL ARTERIAL MEASURES
Beta-blockers are known to influence peripheral arterial tone, and peripheral arterial
tone is altered in CHF. It is thus of interest to known the differential effects of
metoprolol and carvedilol on this parameter.
One method of comprehensively assessing the receptor-specific actions of antagonist
drugs (in this case metoprolol and carvedilol) is to attempt to activate these receptors
(in this case aj. (31 and P2 receptors) in the presence of the antagonists using specific
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agonists. This is a widely used approach in pharmacological studies. Thus one can
discern the individual degrees of antagonism of metoprolol and carvedilol at these
receptors.
2.10.1. VENOUS OCCLUSION PLETHYSMOGRAPHY
Measurement of the action of these agents on forearm blood flow was by forearm
venous occlusion plethysmography performed two hours after administration of the
beta-blockers on each of the two intensive study days. Precedent exists for the
assessment of the effects of carvedilol at this time interval.(Morgan, Snowden et al.
1987; Hryniewicz, Androne et al. 2003) The principles of venous occlusion
plethysmography are described in detail in section 5.3. Briefly, this technique allows
in vivo assessment of the action of vasoactive drugs by measuring small changes in
forearm size caused by changes in arterial in-flow to the forearm.
We infused the agonist drugs into the non-dominant brachial arteries of our patients
who had either just started treatment with the beta-blockers or after 20 weeks of
treatment. As explained in section 2.3, a more detailed investigation had been
originally intended but was abandoned due to ethical considerations.
The agents used were dobutamine (relatively specific (3i receptor agonist), salbutamol
(P2 receptor agonist) and phenylephrine (ai agonist). We also infused acetylcholine,
which produces endothelium-dependent vasodilatation, to decide if either metoprolol
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or carvedilol produced some of their action via an endothelium-dependent
mechanism.
Finally, reactive hyperaemia was used as another assessment of endothelial function:
application of ischaemia to the forearm results in a hyperaemic response, which can
also be measured by forearm venous occlusion plethysmography.
2.10.1.1 EQUIPMENT SET-UP
The hands were excluded from the circulation during measurement period by
application of tight wrist cuffs (Hokanson SC5, PMS instruments, Maidenhead,
Berkshire) that were inflated to suprasystolic pressure; hand blood flow is
predominantly through the skin and is therefore not representative of the rest of the
body.
Arrest of forearm venous return was achieved by inflating an upper arm cuff
(Hokanson SC10, PMS instruments) to 40 mm Hg for 10 seconds, which does not
alter arterial inflow or pressure. The pressure cuffs were connected to a pair of rapid
cuff inflators (Hokanson E20, PMS instruments) connected to an air source
(Hokanson AG101, PMS instruments). An air inflation system (rather than a fluid
inflation system) was necessary to enable rapid inflation and deflation (Hokanson
AG101, PMS instruments) (see Figure 2-1).
Rate of swelling of the forearm (change in forearm circumference) in millimetres per
minute was measured. This was achieved using a strain gauge (Indium/gallium in
silastic, Hokanson forearm set, PMS instruments) placed around the forearm at about
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a third of the way from the elbow to the wrist (at the widest point of the forearm). A
voltage plethysmograph (Hokanson plethysmograph, PMS instruments) accepted the
signal from the strain gauge, which was transferred via an analogue-to-digital
converter (MacLab 4e, AD Instruments, Hampstead, London) to a personal computer
(PowerMac, Apple Computer Incorporated, USA). The data was plotted using the
Chart software programme (Chart version 3.2.8, AD Instruments) and basic analysis
carried out using Excel software (Excel version 7.0, Microsoft Corporation, USA).
Further statistical analysis was performed using the Minitab statistical software
package (Minitab Inc.) on an IBM-compatible personal computer.










Of major importance in performing the study was to ensure that arterial blood
pressure (and hence forearm perfusion pressure) did not vary. The subject attended
having abstained from alcohol, caffeine and tobacco for 24 hours, from food for 6
hours, and having emptied their bladder. Subjects thus abstained from any potentially
vasoactive stimulants, and digestion was not active (so as not to divert blood flow
from the limbs). Subjects were made comfortable and relaxed in a quiet temperature
controlled room at 24°C. As far as possible, sudden noise was avoided as this can also
alter blood flow.
The patient under study lay on a comfortable bed for at least 20 minutes before any
drug infusion while haemodynamics adjusted to the supine position. The subject's
forearms were supported on foam pads above the level of the right atrium, and the
cuffs and strain gauges were applied. After local anaesthesia with 1% lignocaine
(Pheonix Pharma, Gloucester), a 27 standard wire gauge steel needle (Terumo
Medical Corporation, Tokyo, Japan) was inserted into the non-dominant brachial
artery. The non-dominant arm was used so as to minimise the consequences in the
event of complications. A constant rate infusion pump was used (IVAC PI000, Alaris
Medical Systems, San Diego, California, USA) via a 16-gauge epidural catheter
(Portex Limited, Hythe, Kent). Physiological saline (0.9%, Baxter Healthcare
Corporation, USA) was infused for 20 minutes before drug infusion, enabling
equilibration of forearm blood flows after needle insertion.
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2.10.1.3 MEASUREMENTS
To measure blood flow, the wrist cuffs were inflated to suprasystolic pressure (220
mmHg) for 2/4 minutes whilst the upper arm cuffs were repeatedly inflated to venous
occlusion pressure (40 mmHg) for about 10 seconds and deflated for about 5 seconds.
Of the resultant 9 or so separate plethysmographic recordings from each arm the first
minute or so of each set were disregarded as forearm blood flow adjusted to wrist
arterial occlusion. Thus 5 recordings were available for analysis. A schematic
representation of the resultant plethysmographic recordings that are captured by the
Chart software is shown in Figure 5-2.
After measuring the gradient of slope within the Chart programme, the data was
converted to a spreadsheet of data within Microsoft Excel. Gradients due to forearm
circumference changes in the infused arm were compared to those in the non-infused
arm in the form of ratios, and then analysed using the Mintab statistical software
package (Minitab inc.) on an IBM compatible personal computer.
2.10.2. ISCHAEMIC VASODILATATION
Ischaemic vasodilatation is an additional assessment of endothelial-dependent
vasodilatation, and is performed with a near-identical set up in terms of equipment
and subject preparation. The main difference is that no drug is infused during this
assessment.
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We performed ischaemic vasodilatation after the drug infusion protocol had been
completed, and after the brachial cannula had been removed. The upper arm cuff was
inflated for 10 minutes to induce forearm ischaemia. Previous investigators have
reported that this duration is well tolerated and yet results in a maximal ischaemic
stimulus to hyperaemia.
Due to the mild discomfort of this procedure, it was felt appropriate to perform only a
single recording on each patient (on day one of the study, repeated after 20 weeks).
This meant that accurate recording was essential. On a few occasions it proved
impossible to achieve good quality recordings, which were free of artefact, and thus
the numbers of subjects in this part of the study are small. Eight patients completed in
the carvedilol group and five in the metoprolol group.
As soon as the upper arm cuff was released, forearm blood flow was recorded for the
next 3 minutes or so in a manner similar to that described in section 2.10.1.3.
However in this component of the protocol repeated measurements were made
throughout the 3 minutes, rather than stopping after 5 tracings. To measure blood
flow, the wrist cuffs (which had been deflated during the induction of ischaemia) were
inflated to suprasystolic pressure (220 mmHg) whilst the upper arm cuffs were
repeatedly inflated to venous occlusion pressure (40 mmHg) for about 10 seconds and
deflated for about 5 seconds. The ischaemia is an intense stimulus for blood flow,
which becomes maximal immediately on release of the upper arm cuff and then
quickly returns to normal levels.
After capturing the data in the Chart software, a ratio of forearm circumference in the
infused arm compared to that in the non-infused arm could be calculated. Plotting of
these ratios at the various time points after release of occlusive pressure (out to 3
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minutes) allows construction of a curve. The larger the area under the curve in any
resultant results, the slower the arm has been to recover from the hyperaemia. An
increase in AUC after administration of an agent would suggest that agent had
impaired the endothelial function.
2.10.3. PROTOCOL LIMITATION DURING PERIPHERAL ARTERIAL
MEASUREMENTS
This component of the overall study was severely hampered by factors out with the
investigator's control. Due to a major adverse event involving forearm intra-brachial
infusions occurring in an entirely separate study, a temporary local ban was
implemented by the West Ethical Committee of Greater Glasgow Health board on the
use of the technique for further investigations.
The timing of this interruption was unfortunate, as the protocol required completion
of the second forearm study day within a limited period of time. This greatly reduced
the number of patients who completed the entire study protocol. This factor, in
addition to a few patients being unable to comply with the full protocol, meant that
only 10 patients completed in the carvedilol-treated arm and only 6 patients
completed in the metoprolol-treated arm. Only those patients who had complete sets
of data from both study days had their data analysed. For the reactive hyperaemia
protocol, only 8 patients in the carvedilol arm completed both studies and only 5 in
the metoprolol arm.
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2.11. METHODS REQUIRING BLOOD ANALYSIS
Analysis of blood samples was required for neurohumoral measures, antioxidant
measures, cytokine measures and for measurement of lymphocyte beta receptor
density.
2.11.1. SAMPLING
Blood sampling was performed at three points during the study:
- Just prior to initiation of first dose of beta-blocker therapy
- After 10 weeks (at the end of the titration period)
- After 20 weeks (at the end of the maintenance period)
Subjects attended the study day having abstained from alcohol, caffeine and tobacco
for 24 hours, from food for 6 hours, and having emptied their bladder. Under local
anaesthesia (to minimise neurohumoral activation) a 16-gauge cannula was sited in
the antecubital vein of the dominant arm to enable blood sampling. This cannula was
also employed later the same day as part of the haemodynamic measures component
of the study (see section 2.9.2). The subjects were then allowed to lie supine on a
couch for 20 minutes for equilibration to occur: this is important to prevent postural
variation in neurohumoral activation, which could theoretically invalidate the results
of samples taken. Blood samples were then taken into chilled tubes containing the
appropriate preservatives for neurohumoral tests and antioxidant tests.
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2.11.2. NEUROHUMORAL ASSAYS
Dianne Hillyard performed these assays in the laboratory of Dr Ian Morton in the
department of Medicine and Therapeutics at the Western Infirmary, Glasgow.
2.11.2.1 NATRIURETIC PEPTIDES
Brain natriuretic peptide was assayed without prior extraction of plasma by means of
a direct, specific monoclonal antibody radioimmunoassay kit supplied by Shionogi &
Co, Ltd (Settsu-shi, Osaka, Japan), as previously described.(Murdoch, Byrne et al.
1997) Plasma N-terminal atrial natriuretic peptide (ANP 1 -30) was assayed by
radioimmunoassay after extraction from acidified plasma with CI8 reverse-phase
columns (Sep-Pak, Waters Associates Ltd, Watford, UK) with the use of a
modification of a previously described method. (Richards, Tonolo et al. 1987;
McDonagh, Robb et al. 1998) A Peninsula Laboratories antibody, RAS 9129
(Belmont, California, USA), was used for identification ofN-terminal atrial
natriuretic peptide. The between-assay coefficients of variation were 15% for the N-
terminal atrial natriuretic peptide assay and <10% for the brain natriuretic peptide
assay, respectively.
2.11.2.2 PLASMA RENIN ACTIVITY
Plasma renin activity was measured by an in-house antibody trapping technique in the
presence of added excess renin substrate.(Millar, Leckie et al. 1980) The coefficient
of variation was 3.4%.
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2.11.2.3 ANGIOTENSIN II
An in-house radioimmunoassay was used for plasma angiotensin II as previously
described.(Morton and Webb 1985) Angiotensin II was preextracted from plasma
before assay. The coefficient of variation was 10%.
2.11.2.4 ALDOSTERONE
Plasma aldosterone was measured with a solid-phase (coated tube) radioimmunoassay
kit supplied by Diagnostic Products (UK) Ltd. The coefficient of variation was
<8.3%.
2.11.2.5 NOREPINEPHRINE
Plasma norepinephrine (nmol/1) was extracted from plasma and assayed by high
performance liquid chromatography and electrochemical detection as previously
described.(Goldstein, Feuerstein et al. 1981; McAlpine, Morton et al. 1988) The
within assay and between assay coefficients of variation are both < 10%.
2.11.2.6 EPINEPHRINE
Plasma epinephrine was extracted from plasma and assayed by high performance
liquid chromatography and electrochemical detection as previously
described.(Goldstein, Feuerstein et al. 1981; McAlpine, Morton et al. 1988) The
within assay and between assay coefficients of variation are both < 10%.
2.11.2.7 ENDOTHELIN
Plasma endothelin concentration was measured by the method of Davenport et al.
(Davenport, Ashby et al. 1990)as previously described.(McMurray, Ray et al. 1992)
The lower limit of detection of the assay is 0.5pmol/l.
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2.11.3. ANTIOXIDANT ASSAYS
Three assays were used to assess oxidant status by assessing the condition of
antioxidant defences, and one assay (malondialdehye) was used to indirectly assess
oxidant status (see explanation in section 7.2.3).
2.11.3.1 LAG TIME TO LDL OXIDATION
The lag-time to induction of low-density lipoprotein oxidation was employed, as
previously reported,(Godfrey, Stewart et al. 1994) to assess the inherent anti-oxidant
resistance of plasma to an external oxidant (copper chloride).
2.11.3.2 PLASMA VITAMIN E CONCENTRATION
Plasma concentration of the endogenous anti-oxidant vitamin E was also measured as
this varies according to the level of oxidative stress (increased oxidative stress reduces
vitamin E concentration). Vitamins E (a-tocopherol) was measured by high
performance liquid chromatography with ultraviolet detection at 295 nm using a
commercial kit (Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire ElK).
Intra-assay and inter-assay variability was <8%.
Both of the above assays were analysed in the department of biochemistry at the
Western Infirmary, Glasgow, under the auspices of Dr Marek Dominiczak. Dianne
Hillyard performed the next two assays in the laboratory of Dr Ian Morton in the
department of Medicine and Therapeutics at the Western Infirmary, Glasgow.
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2.11.3.3 TOTAL PLASMA ANTIOXIDANT ACTIVITY
A commercial assay, reported to measure the total anti-oxidant capacity of plasma
(Randox Ltd., Crumlin, N.Ireland), was also used. This assay relies on the production
of the radical cation azinodiethyl-benxthiazoline sulphate*+ (ABTS*+) from incubation
of ABTS with a peroxidase (metmyoglobin) and hydrogen peroxide.(Miller, Rice-
Evans et al. 1993) Production of the radical results in the development of a blue-green
colour detectable at 600 nm. Anti-oxidants present in patient plasma inhibit the
reaction and (reduce the development of the blue-green colour) to a degree
proportional to their concentration. A spectrophotometer is used to quantify the result.
2.11.3.4 PLASMA MALONDIALDEHYDE CONCENTRATTION
Malondialdehyde concentration in patient plasma was also considered a measure of
oxidative stress (see section 7.2.3.1 ).(McMurray, Chopra et al. 1993) This is not a
measure of antioxidant defence capacity, but is rather a measure of the effect of
oxidative stress by assessing lipid peroxidation. Plasma for a thiobarbituric acid-
reactive substances (TBARS) assay was collected in sodium heparin tubes and placed
on ice. Thiobarbituric acid reacts with malondialdehyde to produce a stable compound
that can be quantified using either spectrophotometry or high-performance liquid
chromatography (HPLC). The plasma was then cold centrifuged at lOOOg for 20
minutes. Aliquots (1.5 mL) were placed in Eppendorf tubes and frozen at 270°C.
Assays were run in batches within 2 months of collection by a technician who was
blinded to both treatment assignment and collection date.
TBARS were measured by a modification of a colorimetric assay described by
Satoh.(Satoh 1978) Briefly, an aliquot of plasma was mixed with 20% trichloroacetic
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acid and 0.67% thiobarbituric acid (in a 2 mol/L sodium sulfate solution). After they
were agitated in a vortex mixer, the samples were placed in a boiling water bath for
30 minutes and allowed to cool, and butanol was added. The samples were mixed
vigorously over a 45 minute period to facilitate extraction of the colored pigments by
butanol. Before absorbance of the butanol phase was measured, the sample was
centrifuged at 1000g for 10 minutes to ensure purity. Absorbance was measured at
530 nm in comparison to a water blank by use of a spectrophotometer. A
malondialdehyde (Sigma Chemical Co; model T-1642) standard curve was shown to
be linear up to 20 nmol/mL for this assay. Malondialdehyde standards of 5 and 10
nmol were included with every assay batch, and plasma values of TBARS were
expressed in reference to these standards.
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2.11.4. CYTOKINE ASSAYS
Dr David Shapiro performed the cytokine assays at the Department of Clinical
Biochemistry, Gartnavel General Hospital in Glasgow.
Plasma TNF-a (pg/ml) was measured using a commercially available solid phase
enzyme amplified sensitivity immunoassay kit supplied by BioSource Europe SA
(Fleurus, Brussels, Belgium). The within assay and between assay coefficients of
variation are 3.7% to 5.2% and 8.0% to 9.9% respectively. The minimum detectable
concentration and approximate normal range for this assay in healthy subjects are 3
pg/ml and 0 to 20 pg/ml, respectively. All assays were run in duplicate and the
average of the two measurements reported.
Plasma sTNFR-2 was measured using a commercially available ELISA test kit
(Quantikine) from R&D Systems (Minneapolis, Minnesota). The minimal detectable
level is 5pg/ml. The within assay and between assay coefficients of variation are
<5.1% and <10% respectively. All assays were run in duplicate and the average of the
two measurements reported.
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2.11.5. LYMPHOCYTE BETA RECEPTOR DENSITY ASSAY
Dr J.J. Morton in the Department of Medicine and Therapeutics, Western Infirmary,
Glasgow, performed these assays in conjunction with Dianne Hillyard.
A 40 ml venous blood sample was collected in an EDTA tube and lymphocytes
separated from other blood components by density gradient centrifugation. Briefly,
blood was layered over Lymphoprep, centrifuged and the lymphocytes collected from
the appropriate band. They were then washed in PBS, collected by low-speed
centrifugation and finally resuspended in Tris buffer pH 7.4 at a final concentration of
5 million cells/ml.
The radioligand [l24I] iodocyanopindolol (ICYP) (Du Pont) was used for identifying
(3-adrenergic receptors using the Gilbert modification(Gilbert, Sandoval et al. 1993) of
a well established method.(Bristow, Minobe et al. 1988) Total binding capacity of the
lymphocytes was measured by adding 100pi of phentolamine (an alpha receptor
antagonist) solution to lOOpl of lymphocyte preparation and 50pl of ICYP. Non¬
specific beta receptor binding capacity was measured by adding lOOpl of CGP 12177
(4-(3-tertiary-butylamino-2-hydroxypropoxy)-benzimidazol-2-one hydrochloride, a [fi
and (Y antagonist with high affinity for the receptors) to lOOpl of lymphocyte
preparation and 50pl of ICYP. Total B-receptor density and Kd were estimated from
ICYP saturation curves, with eight increasing concentrations of ICYP between 6.25
and 300 pmol/L.
After mixing and incubation of the preparations for 60 minutes at 37°C, further
binding was quenched by placing the preparations on ice. An automated cell harvester
was used to harvest the cells on to filter paper disks. The disks were then pressed out
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and bound radiolabel quantitated in a gamma counter. An aliquot of the original cell
suspension was counted using a Coulter cell counter (automated cell counter), thus
allowing calculation of bound radiolabel per cell.
Maximum bound ICYP (Bmax) and the ICYP dissociation constant (Kd) were
determined by analysis of saturation isotherm data. Non-linear least-squares
regression analysis of one form of the Michaelis-Menten equation was performed,
where:




2.12.1.1 MEASUREMENT OF QT DISPERSION
All patients had ECG recordings made at the same paper speed and gain setting (25
mm/sec and 10 mm/mV). We were fortunate in the overall study exclusion criteria in
that usual exclusions for QT dispersion studies were already present. A single
observer digitised all ECGs using a digitising board (Calcomp, Anaheim, California,
USA) connected to an IBM-compatible personal computer and running customised
QT dispersion software (Academic Cardiology Unit, Freeman Hospital, Newcastle
upon Tyne). QT interval was measured from the beginning of the QRS complex to the
end of the T wave, defined as the return to T-P baseline. When U waves were present,
the QT interval was measured to the nadir of the curve between the T and U waves.
QT intervals were measured in all leads if technically possible. For each lead, two or
three consecutive cycles were measured and the arithmetic mean of the QT interval
for that lead was used in all future calculations for QT dispersion. The measured
values were then expressed as both uncorrected and rate-corrected QT intervals (QT
and QTc).
2.12.2. METHODS: SIGNAL-AVERAGED ECG
2.12.2.1 MEASUREMENT OF SIGNAL-AVERAGED ECG
The propensity to ventricular arrhythmias is an important determinant of prognosis in
cardiac failure. In several of the large-scale beta-blocker studies, sudden cardiac death
(believed to be due to ventricular arrhythmia in most cases) was an end-point that was
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particularly susceptible to the influence of beta-blockers.(Chadda, Goldstein et al.
1986; Packer, Bristow et al. 1996; 1999; 1999; Hjalmarson and Fagerberg 2000)
The signal-averaged ECG was initially developed to allow recording of low-
amplitude ventricular depolarisations on the surface ECG of myocardial infarct
patients who are susceptible to ventricular tachycardia,(Kuchar, Thorburn et al. 1987;
Farrell, Bashir et al. 1991) and has since been applied to many different groups of
patients.(Gomes, Cain et al. 2001) The link between these ventricular "'late potentials"
recorded in the SAECG and re-entrant ventricular tachycardia in a wide variety of
conditions is well established. (Breithardt, Cain et al. 1991) Viable cells within or
surrounding myocardial infarct regions are believed to produce these late potentials
which represent slow or delayed conduction and are believed to represent a fixed
substrate for re-entrant ventricular tachycardia. Given the susceptibility of CHF
patients to ventricular arrhythmia, it was thus of particular interest to determine
whether a difference exists between the effect of metoprolol and carvedilol on signal-
averaged ECG in this study.
A Megacart ECG machine (Siemens, UK) with signal averaged ECG (SAECG)
recording software installed was used to record all SAECGs. SAECGs were recorded
immediately after the 12 lead ECG recordings.
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CHAPTER 3: STATISTICAL ANALYSIS
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3.1. HAEMODYNAMIC MEASURES
All data was examined using scatterplots and was also subjected to the Anderson-
Darling analysis (using Minitab statistical software, Minitab Inc.) to assess whether it
was normally distributed. Examples of these graphs are shown below. As the
haemodynamic data was all normally distributed, the paired Student's t-test was used
to evaluate differences in baseline parameters between a group at the first visit (just
before introduction of a beta-blocker) and the same group at the final visit (after 20
weeks of therapy). Comparisons were also made between haemodynamic parameters
at the peak dose of the adrenoreceptor agonist administered measured at these two
visits. During the analysis, all "washout period" variables (between the two active
infusions) were confirmed by paired Student's t-test to have returned to levels not
significantly different from the original baseline. Values of p<0.05 were considered
significant in all analyses. The data was processed using the Minitab statistical
software package (Minitab Inc.) on an IBM-compatible personal computer.
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Example scatterplot of normally-distributed data
Example of Anderson-Darling analysis of normally distributed data
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3.2. PERIPHERAL ARTERIAL MEASURES
Data from the Chart software package on the PowerMac (points at the start and finish
of gradients measuring forearm circumference) were converted to a spreadsheet of
data within Microsoft Excel, and then analysed using the Mintab statistical software
package (Minitab inc.) on an IBM compatible personal computer.
Each gradient representing forearm swelling of the infused arm was divided by the
gradient representing swelling of the non-infused arm, thus producing a ratio at each
precise time point when measurements were being made. The mean of five
measurable gradient ratios was then used to represent the effect of the agonists on
blood flow to the infused forearm at that specific dose level.
Cumulative dose response curves were then constructed of forearm blood flow against
individual dose of the individual vasoactive substance. Area under the curve (AUC)
was calculated for each dose-response curve. All data was examined using scatterplots
and was also subjected to the Anderson-Darling analysis to assess whether it was
normally distributed. As the data was indeed normally distributed, the carvedilol
group AUCs for all four vasoactive agents at the start of treatment were compared to
the AUCs at the end of 20 weeks of treatment using the paired t-test. Similar
comparisons were made within the metoprolol group. This is believed to be the most
appropriate way of comparing serial measurements of this type.
Finally, area under the curve was calculated for ischaemic vasodilatation, and the
reactive hyperaemic response of forearm blood flow at the start of the study was
compared to that at the end of the study using paired t-test. Data was again analysed
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using the Mintab statistical software package (Minitab inc.) on an IBM compatible
personal computer.
3.3. NEUROHUMORAL MEASURES
Due to the small numbers involved in the study, the means of the two groups
(carvedilol-treated and metoprolol-treated patients) were not equal at baseline. Thus
all neurohumoral measures are presented as per cent change from baseline. All data
was examined using scatterplots and was also subjected to the Anderson-Darling
analysis to assess whether it was normally distributed. When the data was confirmed
to be normally distributed, paired t-tests were used to compare the results at 10 weeks
(end of titration period) and at twenty weeks (end of maintenance period) with
baseline measures. When the data was found not to be normally distributed (example
shown below), the 1 -sample sign test was employed instead. A p-value of less than
0.05 was regarded as significant. Data was analysed using the Mintab statistical
software package (Minitab inc.) on an IBM compatible personal computer. Results
are presented in graphical form as mean ± standard error of the mean for parametric
data, and as median ± 95% confidence intervals for non-parametric data.
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Example scatterplot of non-parametric data
Example of non-parametric data assessed by Anderson-Darling method
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3.4. ANTIOXIDANT MEASURES
Due to the small numbers involved in the study, the means of the two groups
(carvedilol-treated and metoprolol-treated patients) were not equal at baseline. Thus
all anti-oxidant measures are also presented as per cent change from baseline. All
data was examined using scatterplots and was also subjected to the Anderson-Darling
analysis to assess whether it was normally distributed. When the data was confirmed
to be normally distributed, paired t-tests were used to compare the results at 10 weeks
(end of titration period) and at twenty weeks (end of maintenance period) with
baseline measures. When the data was found to be non-parametric, the 1-sample sign
test was employed instead. A p-value of less than 0.05 was regarded as significant.
Data was analysed using the Mintab statistical software package (Minitab inc.) on an
IBM compatible personal computer. Results are presented in graphical form as mean
± standard error of the mean for parametric data, and as median ± 95% confidence
intervals for non-parametric data.
3.5. CYTOKINES MEASURES
All cytokine measures are also presented as per cent change from baseline. Data was
analysed using the Mintab statistical software package (Minitab inc.) on an IBM
compatible personal computer. All data was examined using scatterplots and was also
subjected to the Anderson-Darling analysis to assess whether it was normally
distributed. When the data was confirmed to be normally distributed, paired t-tests
were used to compare the results at 10 weeks (end of titration period) and at twenty
weeks (end of maintenance period) with baseline measures. When the data was found
to be non-parametric, the 1 -sample sign test was employed instead. A p value of less
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than 0.05 was regarded as significant. Results are presented in graphical form as mean
± standard error of the mean for parametric data, and as median ± 95% confidence
intervals for non-parametric data.
3.6. LYMPHOCYTE BETA RECEPTOR DENSITY
As the mean baseline lymphocyte beta-receptor densities in the two groups were
different, it was decided to analyse the data as the percentage change from baseline.
Data was entered into an Excel (Microsoft Corporation) spreadsheet. The data was
processed using the Minitab statistical software package (Minitab Inc.) on an IBM-
compatible personal computer. All data was examined using scatterplots and was also
subjected to the Anderson-Darling analysis to assess whether it was normally
distributed. For parametrically-distributed data, within group paired student t-tests
were performed to look at the effects of the drugs individually over time. When the
data was found to be non-parametric, the 1 -sample sign test was employed instead.
Values of p<0.05 were considered significant in all analyses. Results are presented in
graphical form as mean ± standard error of the mean for parametric data, and as
median ± 95% confidence intervals for non-parametric data.
3.7. QT DISPERSION
As the mean baseline QT dispersion in the two groups were different, it was decided
to analyse the data as the percentage change from baseline. Data was entered into an
Excel (Microsoft Corporation) spreadsheet. The data was processed using the Minitab
statistical software package (Minitab Inc.) on an IBM-compatible personal computer.
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All data was examined using scatterplots and was also subjected to the Anderson-
Darling analysis to assess whether it was normally distributed. For parametrically-
distributed data, within group paired student t-tests were performed to look at the
effects of the drugs individually over time. When the data was found to be non-
parametric, the 1-sample sign test was employed instead. Values of p<0.05 were
considered significant in all analyses. Results are presented in graphical form as mean
± standard error of the mean for parametric data, and as median ± 95% confidence
intervals for non-parametric data.
3.8. SIGNAL AVERAGED ELECTROCARDIOGRAM
Again, as the mean baseline parameters in the two groups were different, it was
decided to analyse the data as the percentage change from baseline. Data was entered
into an Excel (Microsoft Corporation) spreadsheet. The data was processed using the
Minitab statistical software package (Minitab Inc.) on an IBM-compatible personal
computer. All data was examined using scatterplots and was also subjected to the
Anderson-Darling analysis to assess whether it was normally distributed. For
parametrically-distributed data, within group paired student t-tests were performed to
look at the effects of the drugs individually over time. When the data was found to be
non-parametric, the 1-sample sign test was employed instead. Values of p<0.05 were
considered significant in all analyses. Results are presented in graphical form as mean
± standard error of the mean for parametric data, and as median ± 95% confidence





The objective of this component of the study was to compare the haemodynamic
effects of treatment with carvedilol and metoprolol in patients with CHF. All
haemodynamic parameters were compared at rest and in response to two forms of
pharmacological (adrenergic) stress, with a pi agonist and with a P2 agonist. The
effects of the two beta-blockers on heart rate and blood pressure were measured, and
their influence on cardiac output was assessed using the a bioimpedance monitor (as
described in sections 2.9.3, 2.9.4 and 4.2). Measurements were made both early after
initiation of beta-blocker therapy and also after chronic therapy (after 20 weeks of
drug administration).
Metoprolol is a relatively selective Pi blocker without vasodilator activity. Carvedilol
is a non-selective beta-blocker with vasodilator action mediated via ai adrenoreceptor
blockade. It has been suggested that the vasodilator action of carvedilol may help
offset the reduction in cardiac output anticipated in response to its beta-blocking
action, so making the agent less likely to provoke worsening heart failure in CHF
patients. With this action there is a risk that the vasodilator action might precipitate
symptomatic postural hypotension.
The response of subjects to adrenergic activation (achieved by administration of the
relatively specific agonists dobutamine and salbutamol) is of particular interest, as this
enables the characterisation of the individual P adrenoreceptor components of
adrenergic blockade produced by carvedilol and metoprolol.
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4.2. PRINCIPLES OF IMPEDANCE CARDIOGRAPHY
Impedance cardiography employs Ohm's law, where resistance in an alternating
current is called impedance (Z) and can be calculated as Z=V/I, where V is the
voltage and I is the current. The human body is assumed to behave as a "parallel
conductor" (the electrical model generally used for the human body), and the
assumption is also made that the impedance of thoracic tissue is parallel to that of
blood. A sinusoidal current of 50-100 kHz is passed between electrodes on the thorax,
and the resultant voltage measured between other electrodes. As current strength is
known, the impedance can be calculated.
Other than fluctuations caused by respiration, the impedance of thoracic tissue
remains constant. However, impedance changes across the thorax with every heart
beat due to alteration in the quantity of blood within the thorax, and this variation in
impedance permits estimations of cardiac output to be made.
Several variations in the technique of recording transthoracic signals exist, but one of
the most popular in current usage is the eight spot or lateral spot array, where two
electrodes are placed at both top and bottom of each side of the thorax. Whilst popular
and easier to use than some of the alternative methods, values found for baseline
thoracic impedance (necessary for stroke volume calculation) are not comparable
between individuals. The "NCCOM" apparatus negotiates this problem by inputting
data such as the patient height, weight and gender to the equation and so adjusting
calculations as appropriate to the individual.
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The impedance signal, its first derivative, and their relationship to the ECG are shown
in the diagram (see Figure 4-1). Precise physiological correlates for the different
features of the impedance signal shown remain controversial.
Heart cycle-related impedance changes are superimposed on impedance changes
caused by respiration. The computer-supported ensemble averaging technique
eliminates the effects of respiration on impedance, but at the same time eliminates the
possibility of making beat-to-beat measurements of stroke volume. Digital filtering
techniques preserve the beat-to-beat variation but are far more complex, in part due to
the difficulty in filtering out movement artefact, which can overlap the impedance
signal spectrum.
To explain the pulsatile variations in the impedance signal, certain assumptions are
made:
1. The impedance of thoracic tissue is parallel to that of intrathoracic blood
2. The resistivity of blood is constant during the cardiac cycle
3. The thorax from the base of the neck to the xiphoid process is a truncated
cone which encompasses an elastic cylindrical tube of the same length (the
aorta)
4. Electrical current distribution in the truncated cone is homogeneous
5. The maximal change in impedance (dZ/dtmax) multiplied by the left
ventricular ejection time is directly proportional to the systolic pulsatile
change in aortic blood volume.
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That point one is valid is well established. Point 2 is more controversial, but probably
makes a very small impact on the overall magnitude of the dZ/dtmax. The third
assumption is a clear simplification but alternative models have not yet been
validated. The basic thoracic impedance is ultimately linear, related to the inner
distance between the voltage detecting electrodes. The fifth assumption is
mathematically correct.
The Sramek-Bernstein equation is the most widely used means of calculating the
stroke volume, and is the means employed in the commercially available apparatus
used in this study: the NCCOM, produced by BoMed medical manufacturing Ltd.,
Irvine, CA, USA. Stroke volume estimation is based on the following equation:
SV=S*((0.17*H)3*(dZ/dtmax)*LVET)/(4.25*Z0) , where:
1) Stroke volume is measured in ml
2) 8 is a weight correction factor, and is affected also by the subject's gender
3) L is the distance between the voltage measuring electrodes (cm), and equals about
17% of a subject's height (H)
4) V is the volume of the electrical conductor (the truncated cone), and is estimated as
L3/4.25
5) Zo is the basic thoracic impedance (Q)
6) dZ/dtmax is the maximal impedance change (Q/s)
7) LVET is the left ventricular ejection time (s)
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Most validation studies found a significant correlation between impedance
cardiography and other methods of measuring the stroke volume,(Drazner, Thompson
et al. 2002) but the assumptions do not hold under all conditions. Although the exact
source of the impedance cardiogram is still unknown, the method is regarded as an
accurate means of measuring the stroke volume, and consequently of measuring
cardiac output.
4.3. RESULTS
The specific baseline characteristics pertaining to haemodynamic measurements are
recorded below (see Table 4-1).
4.3.1. EFFECT OF TREATMENT ON BASELINE VARIABLES
4.3.1.1 RESTING HEART RATE
Seventeen patients in the carvedilol group had a complete set of heart rate data to
analyse, and eleven in the metoprolol group. There was a highly significant decrease
(p<0.0001) in the baseline heart rate of the carvedilol group between the start and the
end of the study. There was a highly significant decrease (p<0.0001) in the baseline
heart rate of the metoprolol group between the start and the end of the study (see
Table 4-4).
The degree of resting heart rate reduction in the metoprolol group was slightly greater
than in the carvedilol group (mean 14.55 bpm reduction for metoprolol versus 10.12
bpm reduction for carvedilol) but this effect did not reach statistical significance
(p=0.12). This is illustrated in figure 4-2.
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Figure 4-1 : Impedance signal, its first derivative, and their relationship to
ECG
The middle trace shows the variation in the impedance signal over time.
A - downward deflection due to contraction of the atria
B = start of left ventricle ejection
C = the major upward deflection occurring during systole
X = closure of the aortic valve
O = diastolic upward deflection
LVET = left ventricular ejection time (s)
dZ/dtmax = maximal impedance change during systole
135
4.3.1.2 RESTING SYSTOLIC BLOOD PRESSURE
Baseline systolic blood pressure readings were not significantly altered in the
carvedilol group or in the metoprolol group, comparing study start with study end (see
Table 4-4).
4.3.1.3 RESTING DIASTOLIC BLOOD PRESSURE
Baseline diastolic blood pressure readings were not significantly altered in the
carvedilol group or in the metoprolol group, comparing study start with study end (see
Table 4-4).
4.3.1.4 RESTING CARDIAC OUTPUT
No significant change over the course of the study was seen in baseline cardiac output
in either the carvedilol group or the metoprolol group (see Table 4-4).
4.3.1.5 RESTING STROKE VOLUME
There was no significant difference in stroke volume in the carvedilol group nor in the
metoprolol group between the start and the end of the study (see Table 4-4).
4.3.2. EFFECT OF TREATMENT ON RESPONSE TO DOBUTAMINE
4.3.2.1 HEART RATE
There was no significant difference between the start and end of the study in the heart
rate recorded during infusion of the highest dose of dobutamine to the carvedilol
group i.e. the increase in heart rate caused by dobutamine was not blunted despite 20
136
weeks of treatment with carvedilol. There was a significant decrease (p=0.009)
between the start and the end of the study in the heart rate recorded in the metoprolol
group during infusion of the highest dose of dobutamine (Figure 4-3 and Table 4-5).
4.3.2.2 SYSTOLIC BLOOD PRESSURE
There was no significant effect of long-term treatment on the systolic blood pressure
achieved during the highest dose dobutamine infusion in either the carvedilol or the
metoprolol group (see Table 4-5 and Figure 4-4).
4.3.2.3 DIASTOLIC BLOOD PRESSURE
There was no significant effect of long-term treatment on the diastolic blood pressure
achieved during the highest dose dobutamine infusion in either the carvedilol or the
metoprolol group (see Table 4-5 and Figure 4-5).
4.3.2.4 CARDIAC OUTPUT
In the carvedilol group, there was a significant (p=0.03) decrease of cardiac output
between that measured during infusion of the highest dose of dobutamine at the start
of the study as compared with the same dose of dobutamine at the end of the study.
There was no significant difference in cardiac output in the metoprolol group between
study start and end (see Table 4-5 and Figure 4-6).
4.3.2.5 STROKE VOLUME
In the carvedilol group, there was a significant (p=0.047) decrease between the start
and the end of the study in the stroke volume measured during infusion of the highest
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dose of dobutamine (see Table 4-5 and Figure 4-7). There was no significant effect on
the stroke volume of the metoprolol group.
4.3.3. EFFECT OF TREATMENT ON RESPONSE TO SALBUTAMOL
4.3.3.1 HEART RATE
The decrease, between study start and end, in mean heart rate during infusion of the
highest dose of salbutamol in the carvedilol group (mean decrease of 4.75 beats per
minute) just failed to reach significance (p=0.051). The equivalent decrease (10.27
bpm) in the metoprolol group was highly significant (p=0.007) (see Table 4-6 and
Figure 4-8).
4.3.3.2 SYSTOLIC BLOOD PRESSURE
There was no significant effect of long-term treatment on the systolic blood pressure
achieved during the highest dose salbutamol infusion in either the carvedilol or the
metoprolol group (see Table 4-6 and Figure 4-9).
4.3.3.3 DIASTOLIC BLOOD PRESSURE
There was no significant effect of long-term treatment on the diastolic blood pressure
achieved during the highest dose salbutamol infusion in either the carvedilol or the
metoprolol group (see Table 4-6 and Figure 4-10).
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4.3.3.4 CARDIAC OUTPUT
There was no significant difference between the start and end of the study in the
cardiac output recorded during infusion of the highest dose of salbutamol in either
group (see Table 4-6 and Figure 4-11).
4.3.3.5 STROKE VOLUME
There was no significant difference between the start and end of the study in the
stroke volume measured during infusion of the highest dose of salbutamol in either
group (see Figure 4-12 and Table 4-6).
4.4. DISCUSSION
In this study, both drugs produced a significant decrease in resting heart rate after 20
weeks of treatment as might be expected. There was no distinct difference between
the agents in the degree of reduction in resting heart rate. There was no statistically
significant decrease in either resting systolic or resting diastolic blood pressure in
either carvedilol or metoprolol groups over the same period. There was also no
statistically significant change in resting cardiac output or stroke volume in either
group.
Differences appear when the responses to peak dose dobutamine and salbutamol are
analysed. The heart rate response of the carvedilol group to peak dose dobutamine
was surprisingly not significantly attenuated after 20 weeks treatment. The carvedilol
effect on heart rate response to salbutamol only just failed to reach statistical
significance (p=0.051). Metoprolol, on the other hand, produced significant
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attenuation in the heart rate response to both dobutamine and salbutamol after this
period of treatment. Thus metoprolol produced more complete beta-blockade in
response to beta agonism than carvedilol.
Blood pressure responses to the agents were not significantly different from baseline.
In the carvedilol group, there was actually a significant decrease in both cardiac
output and in stroke volume in response to peak dose dobutamine. There was no such
response seen during peak dose salbutamol infusion. In the other group, no significant
changes in cardiac output or in stroke volume were produced after chronic therapy
with metoprolol.
4.4.1. HEART RATE
The patients enrolled in this study had a considerably lower baseline resting heart rate
than those enrolled in studies such as COMET (see Table 4.2). Despite this, the
magnitude of heart rate reduction, expressed as percentage reduction from baseline, is
similar in this study to the other studies listed which also used metoprolol and
carvedilol (Table 4.2). Indeed, the reduction in resting heart rate with metoprolol is if
anything slightly greater than that seen in large studies.
One possible explanation for the lower baseline heart rate in the patients in this study
is that the use of beta-blockers had been permitted prior to study entry. However,
review of the demograhic data (see Table 2-4) reveals that only 11% of carvedilol-
treated patients had been on beta-blockers prior to study entry, and only 40% of
metoprolol-treated patients. In addition, these agents were withdrawn a few days prior
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to baseline assessments, so if anything an increased resting heart rate might have been
expected.
Another obvious possibility is that the patients were clinically better than those
enrolled in the large studies. All patients had good clinical and echocardiographic
evidence to support the diagnosis of chronic heart failure, but it may be that they were
suffering from a less severe degree of CHF, or were better compensated.
A final factor may be the care taken in this study to ensure the patients were assessed
after a period of rest. The intention of this was to permit neurohumoral measures
rather than heart rate to settle to baseline, but it would obviously have had an effect on
heart rate also.
Both carvedilol and metoprolol caused a highly significant decrease in baseline heart
rate between the start and the end of the study (see Table 4-4). These actions would of
course be entirely anticipated when administering beta-blockers. The magnitude of
effect on resting heart rate of chronic treatment with the individual beta-blockers is
very similar, suggesting the doses used were a reasonable comparison. The effect of
metoprolol on the resting heart rate is slightly greater than that of carvedilol, in both
absolute terms and in percentage reduction from baseline (see Table 4.2), but this
effect is far from being statistically significant (p=0.12). The metoprolol action is
somewhat greater, and the carvedilol action somewhat less, than other large studies
involving these agents (see Table 4.2 for figures and for comparison with other
studies).
Metoprolol also seemed to produce a more profound degree of beta blockade in
response to beta agonism. There is some support for this finding in the literature.
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(Stoschitzky, Koshucharova et al. 2001) One possible explanation for the apparently
greater beta blocking effect of metoprolol compared to carvedilol would be
differences in the timing of onset of the maximal effect of the two beta blockers.
Metoprolol, most particularly the short-acting form employed in our study, might be
expected to reach maximal effect more quickly, but would obviously not have such a
prolonged effect. In fact, both agents actually reach maximum plasma concentrations
within a similar time frame of one to two hours.(Luzier, Killian et al. 1999; Dulin and
Abraham 2004) As the timing of heart rate measures in our study was 3 hours after
dosing, both drugs were at peak effect and if anything the effect of metoprolol
(shorter-acting) might have been expected to have been waning.
A possible explanation for a differential effect of the two drugs on heart rate is an
unusually high incidence of a specific beta-receptor polymorphism in one of our
treatment groups (not present in the other) resulting in different heart rate responses.
Such a dichotomy of response to beta-blockers has been noted in the MERIT-HF
study, in that instance resulting in similar degrees of heart rate reduction with
different doses (and different resultant plasma concentrations) of
metoprolol.(Wikstrand, Hjalmarson et al. 2002) About one third of patients in this re-
analysis had a marked heart rate response to a low dose of metoprolol. Despite the
low dose of active drug, these same patients had a similar magnitude of heart rate
reduction and of reduction in mortality as those who tolerated a high dose of
metoprolol. It is conceivable that more patients with a small heart rate response to
beta-blocker were present in our metoprolol group. This effect would of course be
more marked in a study with small numbers of patients.
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We do not appear to have used a dose of metoprolol which is too large. The MERIT-
HF study had a target daily dose of metoprolol, albeit in a slow-release preparation, of
200 mg (as opposed to 100 mg in this study) and the achieved dose of metoprolol
succinate (slow release) was 159mg per day. This equates to 106 mg of metoprolol
tartrate per day when the lower bioavailability of the succinate form is taken into
account.(Dargie 2003) Some other large-scale carvedilol studies have employed the
same target dose for carvedilol as we did (25 mg BD).
It is possible that the vasodilating action of carvedilol produces a reflex tachycardia.
As both dobutamine and salbutamol are peripheral vasodilators, the combined action
of either drug plus that of carvedilol might result in a reflex tachycardia of sufficient
magnitude to counteract some of the beta-blocker induced heart rate reduction.
With the publication of the COMET trial results,(Poole-Wilson, Swedberg et al. 2003)
data from a large number of CHF patients undergoing treatment with these two beta
blockers has become available. In COMET, the mean daily dose of carvedilol in the
maintenance phase of the study was 41.8 mg a day. In the metoprolol group, the mean
daily dose was 85 mg a day. These dosages compare very closely with the doses used
in this study (44.4 mg/day carvedilol and 91.7 mg/day metoprolol). However, as a
consequence of criticisms about the relative degrees of beta blockade in the two
groups, the COMET authors have been at pains to stress that the magnitude of heart
rate reduction with both agents was very similar. We also made this observation in
our study (see Table 4.2).
Carvedilol did not reduce the increase in heart rate seen in response to dobutamine
even after 20 weeks of treatment. Carvedilol is less specific at the pi receptor than
metoprolol, and thus would not necessarily be expected to have such a potent effect as
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metoprolol. Other observers contradict our findings with carvedilol in response to
dobutamine.(Metra, Nodari et al. 2002; Bollano, Tang et al. 2003) In both of these
studies, carvedilol had a profound effect to suppress the heart rate increase normally
seen with dobutamine, even though the dose of dobutamine employed in both studies
was greater: Metra et al. used 20mcg/kg/min whilst Bollano et al. used 15mcg/kg/min.
The dose used in our study was lOmcg/kg/min at peak. Bollano certainly used a very
large dose of carvedilol (mean 85mg compared to our mean 44.4mg per day) which
might explain the findings of that study.(Bollano, Tang et al. 2003) However, Metra
used a very similar dose to that employed by us (mean 43mg per day).(Metra, Nodari
et al. 2002) It is difficult to reconcile this discrepancy.
The carvedilol effect to reduce the heart rate response to salbutamol was also less than
that of metoprolol: note that the mean reduction with carvedilol was 4.75 bpm,
p=0.051, whilst the mean reduction with metoprolol was 10.27 bpm, p=0.007. This is
surprising as carvedilol is definitely active at the P2 receptor and more so than
metoprolol. This might suggest that metoprolol has important p2 receptor actions as
well as the anticipated p 1 receptor action. In fact, it is clear that metoprolol is by no
means entirely specific to pi receptors (see Table 4-3).
Based on the results of previous very large-scale studies, the doses of metoprolol and
carvedilol we employed would in fact be expected to produce similar degrees of heart
rate reduction, and indeed were used in the COMET trial. This issue is discussed
further in section 11.2, and is also illustrated in Table 4.2.
Metoprolol is a selective antagonist of adrenergic Pi receptors whereas carvedilol is a
non-selective beta-blocker with additional ai blocking effects. Both drugs are used as
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racemates in clinical practice, consisting of equal amounts of (R)- and (S)-
enantiomers. The beta blocking effects of both drugs reside in the (S)-enantiomers,
but both (R) and (S) enantiomers of carvedilol act as a-blockers. Consequently, the
metoprolol used clinically consists of 50% beta-blocker and 50% of a compound, the
(R)-enantiomer, with no adrenergic activity. Carvedilol consists of 50% of an
antagonist at at and P receptors, (S)-carvedilol, and 50% of a pure at blocker, (R)-
carvedilol.(Stoschitzky, Koshucharova et al. 2001)
If one accepts that metoprolol is a "classic" beta-blocker with relative specificity for
the p i receptor subtype, there are in fact three possible explanations for the lesser
effect of carvedilol on beta agonist-induced increase in heart rate:
1. Insufficient beta blockade produced by carvedilol in clinical practice.
2. Intrinsic sympathomimetic activity of (R, S)-carvedilol.
3. Reflex activation of sympathetic tone caused by the ai blocking properties of
both (R) and (S) carvedilol.
This last possibility is the most likely. In support of this theory, optically pure
carvedilol actually increases resting heart rate in healthy individuals, supporting the
third hypothesis.
As mentioned above in the results section, our findings are in agreement with at least
one other study,(Stoschitzky, Koshucharova et al. 2001) though it must be stressed
that the study in question was on normal individuals rather than in patients with CHF.
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4.4.2. BLOOD PRESSURE
One of the most surprising aspects of the effects of both agents on blood pressure is
that resting blood pressure is not significantly affected by treatment with beta-
blockers. There is slight reduction in both systolic and diastolic blood pressure with
metoprolol but a slight increase with carvedilol (see Table 4-4). The anticipated
antihypertensive action of both drugs was not evident in this study. As no obvious
blood pressure drop was detectable with carvedilol, concerns previously voiced about
its vasodilating properties having the potential to cause postural hypotension seem
unfounded in our hands.
4.4.3. CARDIAC OUTPUT AND STROKE VOLUME
The patients enrolled in this study had baseline left ventricular ejection fractions,
cardiac outputs and stroke volumes that were not significantly different from each
other (see Table 4-1). Carvedilol was much more effective than metoprolol at
suppressing the increase in cardiac output and stroke volume normally seen in
response to dobutamine (see Figure 4-6, Figure 4-7, Figure 4-11 and Figure 4-12).
Metoprolol tends to decrease stroke volume at rest, and this effect just fails to reach
significance (p=0.073). It would appear that carvedilol, presumably through its broad
anti-adrenergic action, acts to protect the heart from increased workload. If the
neurohumoral hypothesis were taken as the paradigm, this action would be beneficial.
Previous comparisons of the haemodynamic actions of carvedilol and metoprolol have
focused either on hypertensive patients employing the parameters used in our study,
(Weber, Bohmeke et al. 1996; Weber, Bohmeke et al. 1998) or on CHF patients but
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using parameters such as left ventricular ejection fraction (Sanderson, Chan et al.
1999) or left ventricular stroke volume as means of assessing haemodynamic
differences.(Metra, Giubbini et al. 2000) The most extensive publication detailing the
comparative effects of carvedilol and metoprolol on left ventricular ejection fraction
is a meta-analysis.(Packer, Antonopoulos et al. 2001) In this paper, 19 CHF trials of
carvedilol or metoprolol were amalgamated. All were randomized and controlled and
all assessed LVEF before and after treatment. The findings were that carvedilol
seemed consistently to increase LVEF more than metoprolol. We deliberately did not
reassess the LVEF in our small groups after treatment, as it unlikely that a significant
difference could have been demonstrated due to the small numbers.
In hypertension, it has been shown that peripheral vascular resistance tends to be
increased and cardiac output decreased with "conventional" beta blockers, particularly
in the short term. In previous comparisons of metoprolol and carvedilol in
hypertension, the mechanisms by which blood pressure reduction was achieved was
found to differ between the two drugs. Metoprolol reduces cardiac output, and there is
a substantial increase in systemic vascular resistance due to reflex stimulation of a-
adrenoreceptors. This increase in vascular resistance persisted for the duration of the
studies (4 weeks in both studies). (Weber, Bohmeke et al. 1996; Weber, Bohmeke et
al. 1998)
In these hypertension studies the reduction in blood pressure with carvedilol was
achieved without a reduction in cardiac output due to a-adrenoreceptor mediated
vasodilatation of systemic resistance vessels. Normally a sympathetically mediated
reflex tachycardia would accompany this phenomenon, but this was prevented
apparently due to the broad beta blocking action of this agent. Interestingly, the
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peripheral vasodilating action was seen to be somewhat attenuated at 4 weeks, in
keeping with the usual observation that haemodynamic tolerance develops to
persistent a-adrenoreceptor blockade. More recently, other authors have confirmed
the loss of the a-blocking action of carvedilol after 6 months in CHF.(Hryniewicz,
Androne et al. 2003)
In CHF, two studies compare the haemodynamic responses of carvedilol and
metoprolol-treated patients to beta agonists. In one study dobutamine was used as part
of a dobutamine stress echo protocol.(Bollano, Tang et al. 2003) This single blind
cross-over study in ten patients found that dobutamine produced an increase in cardiac
output in metoprolol-treated patients that was due to an increase in heart rate: the
heart rate increase is accompanied by a very comparable cardiac output increase, as
assessed echocardiographically. The heart rate increase occurred in the metoprolol
group but not in the carvedilol group. This finding would seem to be at odds with our
data. The finding is all the more surprising as the target dose of metoprolol succinate
was actually 100 mg BD. A mean dose of 160mg of metoprolol succinate per day was
achieved (equivalent to about 107 mg metoprolol tartrate) and would obviously have
been expected to produce a greater degree of beta blockade than we achieved,
abolishing both heart rate and cardiac output increases. The dose of carvedilol used in
the above study (Bollano, Tang et al. 2003) was almost twice that which we used
(85mg per day compared to 44.4mg). This very large dose of carvedilol probably
explains the marked effect of carvedilol to suppress increase in heart rate and cardiac
output as compared with our study. In this respect the findings agree with ours,
indicating a marked effect of carvedilol to inhibit the agonist-induced increase in
cardiac output.
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The second study where cardiac output in response to inotropes has been compared in
patients treated with carvedilol and metorpolol also does not compare well with our
data. (Metra, Nodari et al. 2002) Here, a very comparable dose of carvedilol was used
(43mg per day) and a higher dose of metoprolol. The effect of carvedilol was again
very much to supress any heart rate or stroke volume index increases with dobutamine
(as assessed by invasive haemodynamic monitoring). Despite employing a larger dose
of metoprolol (129mg per day) the metopolol did nothing to supress heart rate and
stroke volume increases with dobutamine. This finding is clearly at odds with our
results.
4.5. CONCLUSION
This study involved a small number of patients, so there was a large variance for some
measures making it impossible to be certain that there is no difference between the
groups in some measures. It is also possible some of the apparently statistically
significant changes shown are spurious.
In our study, carvedilol and metoprolol at the doses used have very similar effects on
resting heart rate, and these actions are comparable to larger studies. It is notable,
however, that chronic treatment with carvedilol at the doses employed in our study
permits a greater increase in heart rate in response to adrenergic activation than
metoprolol. Chronic metoprolol therapy in our hands exerts a more profound beta
blocking action with regard to heart rate response to adrenergic activation, even
(surpringly) in response to salbutamol. Thus in pure heart rate terms, carvedilol would
appear to be the less effective agent. Possible explanations for this are given above
and the issue is also examined in sections 11.2 and 11.3.2.
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It is of course already clear that the beneficial clinical effect of both carvedilol and
metoprolol in CHF is of a similar magnitude. It may be that something other than pure
heart rate reduction is occurring to produce the beneficial results seen with carvedilol.
This is a finding of intense interest in terms of dissecting the differences between the
two agents.
Carvedilol cartainly suppresses the normal increase in cardiac output and in stroke
volume caused by adrenergic stimulation. In this way, carvedilol seems more
effective at preventing increased cardiac workload in CHF in times of stress. This
action is supported by data from other studies.(Metra, Nodari et al. 2002; Bollano,
Tang et al. 2003)
Table 4-1: Baseline haemodynamic measures
Carvedilol s.d. Metoprolol s.d. Statistical
n=17 n=l 1 difference
Heart Rate (bpm) 71.4 7.31 69.2 11.00 NS (p=0.562)
Systolic Blood Pressure (mm Hg) 112.81 16.69 117.82 20.31 NS (p=0.508)
Diastolic Blood Pressure (mm Hg) 62.12 6.77 66.73 8.52 NS (p=0.146)
Cardiac Output (1/min) 4.44 1.19 3.70 1.19 NS (p=0.125)
Stroke Volume (mis) 70.50 21.94 59.27 16.24 NS (p=0.140)
Left ventricular ejection fraction (%) 27.8 7.3 30.5 7.9 NS (p=0.247)
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Table 4-3 : Relative specificity of various beta blockers at Pi/ P2 receptors
Class K(P,) K(p2) P1/P2 selectivity K(a,) Pl/Oti
nmol/L nmol/L nmol/L selectivity
Nonselective Propranolol 4.1 8.5 2.1 - -
Selective Pi Metoprolol 45 3345 74 - -
Bisoprolol 121 14390 119 - -
Piblocker/ vasodilator Carvedilol 4.0 29 7.3 9.4 2.4
Table 4-4: Effects of treatment on resting haemodynamic measures
Treatment comparison n Mean s.d. s.e. 95% CI P value
Carvedilol: heart rate on Day 0 vs 17 -10.12 6.14 1.49 6.96- 13.28 <0.0001
final day
Metoprolol: heart rate on Day 0 vs 11 -14.55 7.53 2.7 9.49-19.60 <0.0001
final day
Carvedilol : systolic BP on Day 0 vs 17 2.44 11.91 2.98 -3.91-8.78 0.426
final day
Metoprolol: systolic BP on Day 0 vs 11 -3.55 17.09 5.15 -15.03-7.94 0.507
final day
Carvedilol : diastolic BP on Day 0 vs 17 0.69 4.92 1.23 -1.94-3.31 0.585
final day
Metoprolol : diastolic BP on Day 0 vs 11 -1.27 8.00 2.41 -6.65-4.10 0.609
final day
Carvedilol: cardiac output on Day 0 17 0.206 1.000 0.250 -0.326- 0.422
vs final day 0.739
Metoprolol: cardiac output on Day 0 11 0.218 0.703 0.212 -0.254- 0.327
vs final day 0.690
Carvedilol : stroke volume on Day 0 17 -0.88 16.48 4.12 -9.66-7.91 0.835
vs final day
Metoprolol : stroke volume on Day 0 11 -7.00 11.58 3.49 -14.78-0.78 0.073
vs final day
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Table 4-5 : Effects of treatment on response of haemodynamic measures to
peak dose Dobutamine
Treatment comparison n Mean s.d. s.e. 95% CI P value
Carvedilol: heart rate on Day 0 vs final 17 -1.75 8.27 2.07 2.65-6.15 0.410
day
Metoprolol : heart rate on Day 0 vs 11 -10.64 10.94 3.30 3.29-17.99 0.009
final day
Carvedilol : systolic BP on Day 0 vs 17 -4.75 24.66 6.17 -17.89-8.39 0.453
final day
Metoprolol : systolic BP on Day 0 vs
final day
11 -4.73 16.29 4.91 -15.67-6.22 0.359
Carvedilol : diastolic BP on Day 0 vs 17 0.56 11.94 2.99 -5.80-6.93 0.853
final day
Metoprolol: diastolic BP on Day 0 vs 11 -0.91 10.73 3.23 -8.12-6.30 0.784
final day
Carvedilol : cardiac output on Day 0 vs 17 0.650 1.082 0.270 0.073-1.227 0.030
final day
Metoprolol : cardiac output on Day 0 11 -0.136 0.507 0.153 -0.477-0.204 0.393
vs final day
Carvedilol : stroke volume on Day 0 vs 17 10.19 18.88 4.72 0.13-20.25 0.047
final day
Metoprolol : stroke volume on Day 0 11 -7.91 15.08 4.55 -18.04-2.22 0.113
vs final day
Table 4-6 : Effects of treatment on response to peak dose Salbutamol
Treatment comparison n Mean s.d. s.e. 95% CI P value
Carvedilol : heart rate on Day 0 vs
final day
17 -4.75 8.96 2.24 -0.03-
9.53
0.051
Metoprolol : heart rate on Day 0 vs
final day
11 -10.27 10.07 3.04 3.51-
17.04
0.007
Carvedilol : systolic BP on Day 0 vs
final day
17 -4.00 18.63 4.66 -13.93-
5.93
0.404
Metoprolol : systolic BP on Day 0
vs final day
11 -1.55 17.43 5.26 -13.26-
10.17
0.775
Carvedilol: diastolic BP on Day 0
vs final day
17 -2.56 10.59 2.65 -8.21-
3.08
0.348
Metoprolol : diastolic BP on Day 0
vs final day
11 -0.91 4.78 1.44 -4.12-
2.31
0.543
Carvedilol: cardiac output on Day 0
vs final day
17 0.425 1.002 0.250 -0.109-
0.959
0.110
Metoprolol : cardiac output on Day
0 vs final day
11 0.127 0.728 0.220 -0.362-
0.616
0.575
Carvedilol : stroke volume on Day 0
vs final day
17 1.94 13.38 3.34 -5.19-
9.07
0.571
Metoprolol : stroke volume on Day
0 vs final day
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Key for Figures 4-3 to 4-12:
B= baseline (prior to infusion of drug)
1 = first level of infused drug
2= second level of infused drug
3= third level of infused drug
DOSE indicates level of infused drug
C day 0= first day of treatment with carvedilol/first prolonged study day
C final= final prolonged study day (carvedilol-treated patient)
M day 0= first day of treatment with metoprolol/first prolonged study day
M final= final prolonged study day (metoprolol-treated patient)
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Figure 4-3 (see key above)
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Figure 4-4 (see key above)
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Figure 4-5 (see key above)
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Figure 4-6 (see key above)
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Figure 4-7 (see key above)
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Figure 4-10 (see key above)
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Figure 4-11 (see key above)
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Figure 4-12 (see key above)
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A cardinal haemodynamic feature of the syndrome of chronic heart failure is
peripheral vasoconstriction and increased systemic vascular resistance.(Cowley,
Stainer et al. 1986; Kubo, Rector et al. 1991; Katz, Biasucci et al. 1992) This is one
of the mechanisms by which cardiac workload is increased in CHF and whereby the
syndrome progresses (see Figure 5-1). Therefore, for a treatment to be of benefit, a
desirable property of the agent would be an ability to reduce peripheral arterial tone.
This was indeed the rationale behind the landmark "V-Heft" study,(Cohn, Archibald
et al. 1986) which investigated the use of vasodilators for the treatment of CHF on
the basis of the "haemodynamic hypothesis" of CHF. The subsequent introduction of
ACE inhibitors, based in part on the results of the V-Heft II study,(Cohn, Johnson et
al. 1991) meant that standard vasodilator therapy was thereafter largely obsolete.
Nonetheless, there is still a place for the use of vasodilators in the management of
some patients with CHF, especially those intolerant of agents acting on the renin-
angiotensin-aldosterone axis, and possibly also in some patients with end-stage
CHF.(Fonarow, Chelimskyfallick et al. 1992)
The ability to reduce arterial tone is an especially desirable property of agents acting
on the adrenoreceptors, as in untreated CHF raised levels of circulating
norepinephrine and increased sympathetic tone both contribute greatly to the
increased systemic vascular resistance. Unfortunately, beta-blockers are known for
their action to further increase peripheral vascular tone: by blocking the Pi and P2
adrenoreceptors (activation of which mediate vasodilatation in the periphery), the a-
agonism of any endogenous adrenergic compound is unopposed resulting in further
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increased vascular resistance. Quantifiable differences would be expected to exist
between metoprolol and carvedilol in terms of their peripheral arterial Pi and P2
specificities.













Of great importance in interpretation of the peripheral arterial effects of drugs acting
via these adrenoreceptors is the recognition that the peripheral adrenoreceptors have
a very different population balance than cardiac adrenoreceptors. Whilst cardiac
effects of adrenergic agonists are predominantly p i induced, the peripheral effects
are mainly P2.
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Carvedilol might be thought to have an advantage here, as its ai-adrenoreceptor
blocking action may balance the (3 adrenoreceptor effect. In practice, it seems that the
action of conventional beta-blockers to increase vascular tone does not cause a
quantifiable effect in terms of worsening cardiac prognosis; the large trials of the
more specific beta-blockers have achieved great success despite this theoretical
increase in peripheral vascular tone. The most important clinical problem brought
about by the beta-blocker effect is probably worsening symptoms of claudication in
those with peripheral vascular disease.
A peripheral action to vasodilate via a receptors has long been thought to be worth
pursuing. However, results with specific a receptor antagonists have been thoroughly
disappointing, with the development of tachyphylaxis with prazosin in CHF(Packer,
Meller et al. 1979) and with an increased incidence of clinical CHF being seen in the
doxazosin arm of the ALLHAT trial.(ALLHAT Collaborative Research Group 2000)
The use of a receptor antagonists to attempt to vasodilate in CHF has been
abandoned.
The concept that a short term benefit can result from a receptor antagonism has
evolved to try to explain the success of carvedilol; the theory is that short term
vasodilatation reduces cardiac preload and afterload, so making the introduction of
carvedilol (with its beta-blocking negative inotropism) more likely to be successful.
Thus a component of this study was conceived to investigate the peripheral arterial a
receptor antagonism of the two drugs under investigation.
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5.2. OBJECTIVES
The objective of this part of the study was to investigate the actions of our
investigational drugs on the peripheral arteries. By infusing relatively specific
agonists for the three main adrenoreceptor types under study (ai, pi and P2 receptors)
we hoped to dissect out the various components of anti-adrenergic action of
carvedilol and metoprolol on arterial tone. By using acetylcholine infusions and by
inducing post-ischaemic hyperaemia, we also to wished to determine if there were
inherent differences between carvedilol and metoprolol on endothelial function.
5.3. PRINCIPLES OF VENOUS OCCLUSION PLETHYSMOGRAPHY
The technique of venous occlusion plethysmography (VOP) has been widely used to
study forearm blood flow, as a model for general peripheral blood flow.(Whitney
1953; Greenfield, Whitney et al. 1963)Using this technique, one is able to study
clinical pharmacology of vasoactive drugs in vivo rather than in vitro.(Benjamin,
Calver et al. 1995) Of particular value in our study was the ability to assess the
clinical pharmacology of patients suffering from CHF, rather than using a model of
CHF.
The principle of the technique is that the rate of swelling of the forearm during
occlusion of venous return is used to assess arterial inflow to the forearm. Provided
perfusion pressure does not alter, changes in flow represent changes in smooth
muscle tone in the small arteries and arterioles. Use of the brachial artery to infuse
drugs permits investigation into the action of these agents on vascular tone, and in
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this study the antagonist effect of a systemically administered drug (carvedilol or
metoprolol) can be studied by administration of various specific agonists at the
adrenoreceptor subtypes. The technique is most powerful, as in this study, when used
to construct dose-response curves to different drugs within the same study.
VOP has been used to study forearm blood flow for more than 80 years, but modern
technical developments have made the technique much less cumbersome. In
particular, the use of mercury in silastic strain gauges was a great advance. A hollow
loop of elastic filled with liquid mercury is used, the electrical conductance of which
depends on the degree of distension. A voltage plethysmograph measures the minute
changes in resistance. Due to safety concerns over the use of mercury, a liquid alloy
of indium and gallium is now most commonly used. Analogue to digital signal
converters (which permit almost immediate analysis of data on personal computers)
accelerate analysis of recordings.
Total forearm blood flow is measured, which is comprised of skeletal muscle blood
flow (50-70% of total) and skin blood flow. In this way, an approximation of total
body blood flow is made. Strain-gauge plethysmography measures total flow in the
forearm from wrist cuff to collecting cuff, and is not a measure of flow in the cross
section of the arm immediately underneath it. The hands are excluded from
assessment by tight wrist cuffs, as the blood flow in the hands is mainly cutaneous
and its inclusion would detract from the accuracy of the procedure. Flow can be
expressed per unit volume of forearm. The technique is well validated and is often
used as the standard against which other methods are judged.(Benjamin, Calver et al.
1995)
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The relationship between rate of increase in forearm volume and arterial flow only
holds true if the forearm veins are not fully distended. Consequently, venous
occlusion is performed for only approximately ten seconds at a time. When the veins
are full, pressure will rise and blood will escape under the congesting cuff, so
forearm volume no longer increases in proportion to arterial flow. If pressure in the
forearm veins reaches 40 mm Hg, this begins to restrict arterial inflow.
The forearm is placed above the level of the right atrium so as to allow unimpeded
venous return. Inflation of the upper arm venous occlusion cuff for 10 seconds in
every 15 seconds causes a linear increase in forearm volume. After each inflation
period, a 5 second deflation period allows emptying of the forearm veins. If flow
rates become very high, it may sometimes be necessary to decrease the duration of
the inflation period and increase the duration of the deflation period to avoid an
excessive rise in venous pressure.
Vasoactive drugs alter the tone of the circular smooth muscle layer of the vessel wall,
and only indirectly affect flow or resistance to flow. As it is not possible to directly
assess tone of the vascular smooth muscle, the response to vasoactive substances is
assessed indirectly by measuring changes in flow or derived changes in resistance.
The extent to which altered contractile state of the vascular smooth muscle is
translated into a change in flow depends on various factors: thickness of the muscle
layer, vessel geometry, and initial conditions of resistance and flow.
Flow is a reasonable estimate of the smooth muscle tone provided arterial perfusion
pressure does not change significantly in the course of the experiment. Due to
autoregulation of circular smooth muscle tone (there is evoked contraction in
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response to increased pressure), significant changes in arterial pressure make the
results unreliable.
Use of simultaneous flow measurement in both the infused and the non-infused arm
provides an internal control to the arrangement. The ratio of flow in the two arms
approaches unity and stays constant even if blood flow alters markedly in response to
changes in systemic arterial pressure or sympathetic arousal. Thus, the only
difference in readings between the two arms will be as a consequence of the
intervention being made on the infused arm. Any change in ratio of the blood flow
between the two arms is a direct reflection of the change in local vascular tone in the
test arm. In this way, if results are expressed in terms of the ratio of blood flow in the
two arms, there is minimal variation and consistent and reproducible results are
obtained. In this thesis, a comparison of the two arms is used rather than expression
of the absolute values of forearm blood flow.
Recordings produced are of an upward slope during venous occlusion, the gradient of
which is proportional to blood flow (see Figure 5-2). As mentioned above, the ratio
of gradient of the slope from the infused (non-dominant) arm to that in the non-
infused arm was equivalent to the ratio of blood flow between the two arms. The
effect of drug infusion was expressed as percentage increase or decrease in blood
flow, and was calculated by dividing the ratio of blood flow between the two arms at
baseline. Due to the use of the non-infused arm as a control, extraneous influences
(e.g. variations caused by temperature change, noise) were cancelled out and the only
difference between the two arms was the difference between drug infusion and no
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drug infusion. The technique has been shown to be highly reproducible with intra-
subject variability of 19% between studies.
Figure 5-2: Schematic representation of plethysmographic recordings -
effect of a vasodilator infusion
Drugs administered systemically have central effects, induce hormonal responses,
change sympathetic output and alter blood pressure making changes in forearm blood
flow difficult to interpret. Drug infusion through a 27 standard wire gauge needle
placed in the brachial artery permits study of the direct vascular effects without
affecting systemic arterial pressure. Doses used are often 100-1000 times lower than
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systemically effective doses. Intermittent arterial pressure measurements were taken
using a standard sphygmomanometer to demonstrate lack of systemic effects.
A cumulative dose-response curve can be produced to demonstrate the action of
vasoactive substances. A linear relationship exists between the response and the log
of the dose infused over a wide dose range. It is possible to construct dose-response
curves for constrictors and for dilators with short half-lives. All the substances used
in this study: phenylephrine, (Imaizumi, Harada et al. 1992; Sakai, Imaizumi et al.
1993; Indolfi, Maione et al. 1994) dobutamine, (Dawes, Chowienczyk et al. 1997)
salbutamol (Dawes, Chowienczyk et al. 1997) and acetylcholine (Makimattila,
Mantysaari et al. 1997; Tamai, Matsuoka et al. 1997)) have been shown to be
appropriate for study in this manner. The area under the curve method can then be
used for statistical comparison of dose response curves (see section 3.2).
Absolute values of forearm blood flow within an individual have a circadian rhythm,
and changes can occur with a sudden change in sympathetic tone. These changes can
affect the absolute response to drugs but will not alter the ratio of flow between the
infused and the non-infused arm. Some variation of the response to drugs which are
unstable in the blood e.g. acetylcholine, can occur even in the same subject on
different days. It is generally recommended that results be expressed as a ratio of
flow in the two arms.
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5.4. RESULTS
It should be noted that all of the results here compare the effects of the various
infusions on patients who have, at baseline on day 0, already received the first dose
of study medication (carvedilol or metoprolol). As a result there is no true baseline
value. This was an unavoidable consequence of the study design (see section 2.3). In
addition to presenting area under the curve data, figures are also provided of data
showing percentage change from baseline data (Figures 5-3 to Figure 5-6).
5.4.1. AREA UNDER THE CURVE ANALYSIS
5.4.1.1 EFFECT OF DOBUTAMINE
There is a significant effect of chronic treatment with carvedilol on the dose response
of forearm blood flow to infusion of dobutamine (mean FBF reduced from 122 units
to 37.6 units, p=0.007, 95% confidence limits for difference 29.7 - 139.4 units
reduction) (see Table 5-1 and Figure 5-7). Metoprolol has no significant effect on the
FBF response to dobutamine.
5.4.1.2 EFFECT OF SALBUTAMOL
There is also a highly significant effect of carvedilol on the dose response of forearm
blood flow to infusion of salbutamol (mean FBF reduced from 1772 units to 566
units, p=0.03, 95% confidence limits for difference 150 - 2262 units reduction, see
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Figure 5-8 and Table 5-2. Metoprolol has no significant effect on the FBF response
to salbutamol.
5.4.1.3 EFFECT OF PHENYLEPHRINE
Again, after AUC analysis, neither chronic treatment with carvedilol nor metoprolol
produce any significant change in the FBF response to intra-brachial phenylephrine
infusion (see Table 5-3 and Figure 5-9).
5.4.1.4 EFFECT OF ACETYLCHOLINE
Chronic treatment with carvedilol nor metoprolol produces no significant change in
the FBF response to intra-brachial acetylcholine infusion as assessed by AUC
analysis (see Table 5-4 and Figure 5-10). There appears to be a slight trend for
acetylcholine's vasodilatation to be inhibited by carvedilol.
5.4.1.5 EFFECT OF BETA-BLOCKERS ON ISCHAEMIC
VASODILATATION
After 20 weeks of treatment both agents cause a significant reduction in the AUC
(p=0.012 for carvedilol, p=0.025 for metoprolol). This indicates that forearm blood
flow does not increase so much, and returns to normal more rapidly, after ischaemia
when the subject is treated with either beta-blocker (see Table 5-5 and Figure 5-11).
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5.5. DISCUSSION
This is the first time that the peripheral vascular effects of these two agents have
been investigated in this comprehensive manner. Venous occlusion plethysmography
has been widely used to study forearm blood flow as a model for general peripheral
blood flow. Using this technique, one is able to study clinical pharmacology in vivo
rather than in vitro. Of particular value in our study was the ability to assess the
clinical pharmacology of patients suffering from CHF, rather than substituting a
model for CHF. Use of the brachial artery to infuse drugs permitted investigation
into the action of these agents on vascular tone, and in this study the antagonist effect
of a systemically administered drug (carvedilol or metoprolol) was studied by
administration of various agonists.
5.5.1. p ADRENORECEPTOR ACTIONS
Carvedilol acts in an anticipated manner to attenuate the vasodilator action of both
dobutamine and salbutamol. This is much in keeping with the broad anti-adrenergic
action expected of carvedilol, and is also be consistent with the findings in section
4.4. There it was found that carvedilol, whilst having less beta-blocking action than
metoprolol in terms of heart rate reduction, nevertheless produced a definite blunting
of the increase in stroke volume and cardiac output in response to stress.
Carvedilol appears to act against the general effect of dobutamine to a degree that
exceeds metoprolol when one looks at cardiac output and forearm blood flow. The
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action to inhibit the peripheral effect of dobutamine is corroborated in the few other
studies to assess vascular tone (usually with systemic vascular reisitance monitored
invasively) during dobutamine infusion in carvedilol-treated patients. (Lowes, Simon
et al. 2000; Lowes, Tsvetkova et al. 2001; Metra, Nodari et al. 2002)
Metoprolol has no significant effect on the FBF response to dobutamine, an effect
that is at first glance unexpected. It would have been anticipated that the dobutamine
action on forearm blood flow would have been attenuated after chronic metoprolol
therapy, as metoprolol is much the more specific agent on the (31 adrenoreceptor.
Other investigators, who found that the systemic vascular resistance response to
dobutamine was essentially unaltered despite treatment with metoprolol, again
corroborate this finding. (Metra, Nodari et al. 2002) It seems that carvedilol is indeed
very much more effective than metoprolol in attenuating the peripheral response to
dobutamine.
The marked difference seen between the effects of the two beta-blockers may be
ascribed to their different mechanisms of action. Unlike metoprolol, carvedilol does
not cause Pi adrenergic receptor upregulation and it also blocks P2 adrenergic
receptors.(Bristow 2000) These properties, although potentially useful in the long-
term,(Metra, Giubbini et al. 2000) may result in greater inhibition of the effects of
dobutamine. In addition to its more comprehensive antiadrenergic action, carvedilol
also exhibits "tight binding" to beta-adrenergic receptors, making it more difficult for
an agonist to displace it.(Asano, Zisman et al. 2001)
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Vasodilatation may have already occurred in the carvedilol-treated subjects to a
degree that cannot be increased by the action of dobutamine, due to the action of
carvedilol itself. Another explanation is the relative paucity of Pi adrenoreceptors in
the peripheral vasculature. This receptor subtype is well recognised to be important
for positive inotropism and positive chronotropism, and much less important in terms
of vasodilatation.
Metra also makes two suggestions:
1. Long-term metoprolol therapy may increase the pi adrenoreceptor density
and improve signal transduction, so sensitizing the heart to Pi activation. The
sudden removal of metoprolol from the receptors by dobutamine then reveals
the preserved or even accentuated dobutamine response.
2. Dobutamine has a reasonably high affinity for P2 adrenoreceptors(Leier and
Binkley 1998) which are left unoccupied by metoprolol. In addition, during
chronic metoprolol administration, P2 adrenoreceptors show improved
coupling to intracellular transduction mechanisms through cross-
regulation.(Hall, Kaumann et al. 1990) Thus chronic metoprolol therapy may
actually accentuate the dobutamine effect.
Surprisingly, metoprolol attenuates the vasodilatory action of salbutamol more than it
attenuates the vasodilatory effect of dobutamine. The effect is seen both during
individual agonist level administrations and is also present during the AUC analysis,
though fails to reach statistical significance. This effect is the converse of what
174
would be expected given the known beta-receptor actions of metoprolol. This finding
is intriguing and is difficult to explain by simple adrenoreceptor specificities.
The most likely explanation is the distribution of the receptor subtypes with a relative
paucity of peripheral (3i receptors and of measurable Pi receptor-induced peripheral
action. Dobutamine may actually having very little peripheral pi effect, and the
vasodilating effect it does may be manifested via its action on P2 receptors rather
than on p 1 receptors. Our observations are probably due to the lack of pure
specificity of both metoprolol and dobutamine at pi receptors.
This peripheral vascular effect of metoprolol is certainly less surprising when its
effects on heart rate are taken into account (see section 4.4). Within the confines of
this study, there would appear to be a broader effect of metoprolol on beta-receptors
than would be expected based only on its adrenoreceptor specificity.
5.5.2. a ADRENORECEPTOR ACTIONS
The comparison of carvedilol and metoprolol on phenylephrine-mediated
vasoconstriction shows no statistically important differences between the two agents.
There are number of possible explanations for this. It may be that the aj antagonism
by carvedilol is very mild. It is also very possible that the main time of action of this
effect has been missed by the study. At the start of the study, a very small dose of
carvedilol is employed, which is likely to produce a negligible effect on ai receptors.
It is also well recognised that tachphylaxis develops to pure ai antagonism after
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several weeks of therapy with specific ai antagonists in CHF (prazosin), so it is
likely that any ai action of carvedilol has disappeared by the time of the repeat study
at 20 weeks.
Other investigators have found that in normal individuals, acute administration of
both carvedilol and metoprolol significantly attenuated the increased heart rate
response to adrenergic stimuli when compared with effects of placebo.(Hryniewicz,
Androne et al. 2003) Vascular resistance in the contralateral forearm during
sustained isometric handgrip exercise is regulated by alpha-adrenergic-mediated
vasoconstriction and concomitant neurogenic vasodilation.(Eklund and Kaijser 1976;
Sanders, Mark et al. 1989) The cold pressor test induces sympathetic activation by a
reflex neural pathway that augments a-adrenergic-mediated vasoconstriction in
skeletal muscle circulations.(Greene, Boltax et al. 1965) In patients with heart
failure, forearm blood flow response to isometric handgrip and cold pressor test did
not change from baseline values in either treatment group and did not differ between
treatment groups before or after 6 months of therapy. These data indicate that the a-
adrenergic receptor blockade effects of carvedilol do not appear to play an important
role in chronic therapy in subjects with heart failure. Indeed, other investigators have
also deduced a decline in the alpha-blocking effect of carvedilol after chronic
therapy. (Metra, Nardi et al. 1994; Kubo, Azevedo et al. 2001)
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5.5.3. ENDOTHELIUM-DEPENDENT ACTIONS
5.5.3.1 ACTIONS ON ACETYLCHOLINE-MEDIATED VASODILATATION
Metoprolol has no effect on acetylcholine-mediated vasodilatation. This finding is as
anticipated, as one would not expect an action of this agent on the cholinergic
system, nor on the endothelium-dependent vasodilatation produced by acetylcholine.
There is a small but non-significant effect for long-term treatment with carvedilol to
reduce acetylcholine-mediated vasodilatation. This effect of carvedilol is contrary to
expectations: as an antioxidant, carvedilol would be expected to enhance nitric
oxide-mediated vasodilatation, as the drug prevents the action of superoxide which
normally neutralises nitric oxide. A number of publications have shown this effect.
(Lopez, Christopher et al. 1995; Giugliano, Marfella et al. 1998; Matsuda, Akita et
al. 2000) Carvedilol may also block production of factors counteracting nitric oxide-
mediated vasodilatation e.g. endothelin-l.(Ohlstein, Arleth et al. 1998)
Some data exists to suggest there may be a component of the action of p2 agonists
that is actually mediated via endothelium-dependent mechanisms. Observers have
reported a possible action of sympathetic ligands to alter endothelium-dependent
vasodilatation.(Graves and Poston 1993; Wang, Poon et al. 1993; Ito, Yamamoto et
al. 1997)
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5.5.3.2 ACTIONS ON POST-ISCHAEMIC VASODILATATION
In contrast to this finding, carvedilol and metoprolol both reduce the area under the
curve produced by measuring FBF post-ischaemic vasodilatation. This would
suggest impairment of endothelial function with beta-blockade, or at least
interference of the beta-blockers with some mechanism upon which endothelial-
dependent dilatation relies. The magnitude of change is similar with carvedilol and
metoprolol.
There is apparently contradictory evidence in this area. In one study of patients with
coronary artery disease, carvedilol improved endothelial-dependedent dilatation.
.(Matsuda, Akita et al. 2000) However, other investigators have shown that varoius
sympathetic ligands such as isoprenaline (via ai), salbutamol and dobutamine all act
via endothelium (nitric oxide)-dependent pathways to induce vasodilatation.(Graves
and Poston 1993; Wang, Poon et al. 1993; Ito, Yamamoto et al. 1997) One might
therefore expect that beta blockers would impair this ability to relax vessels via
enothelium-dependent paths.
The fact that there appears to be a contradiction here is not so surprising, as the
action of acetylcholine to vasodilate is of course mediated via nitric oxide (and
probably via other endothelial-derived products). This mechanism is well elucidated,
and there would be no obvious point at which a beta-blocker might interfere. Whilst
the main stimulus for vasodilatation during acetylcholine infusion is always the
acetylcholine, the main stimulus after ischaemia is a generalised activation of




This study involved a small number of patients, so there was a large variance for
some measures making it impossible to be certain that there is no difference between
the groups in some measures. It is also possible some of the apparently statistically
significant changes shown are spurious.
Metoprolol has a much more limited action on peripheral Pi-receptor-mediated
vasodilatation than is expected from its pharmacological properties. However, this
finding is consistent with other observers. Carvedilol significantly inhibits peripheral
vasodilatation in response to both dobutamine and salbutamol to a statistically
significant degree. In having this action, carvedilol has a very much more significant
generalised beta-blocking action on the periphery than does metoprolol. This would
have been anticipated from the known adrenoreceptor specificities of the drug. The
p2 receptor is a far more important subtype than Pi in the periphery, and is obviously
much more influenced by carvedilol than by metoprolol.
If any significant vasodilating alpha-receptor-mediated action of carvedilol exists,
this study was not able to detect this effect. It is conceivable that this is due to the
timing of the study observations.
The action of carvedilol to vasodilate has been much vaunted as a means of better
carvedilol tolerability during initiation, the theory being that vasodilatation reduces
cardiac workload and so means that a patient having a beta-blocker initiated would
be less likely to go into worsening heart failure. In this study, no important
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vasodilating action of carvedilol was found possibly due in part to the limited time
points at which observations were made. The action of carvedilol is rather to prevent
adrenergic agonist-mediated vasodilatation at least after chronic therapy.
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Table 5-1: areas under the curve for dobutamine infusions
n Mean s.d. % change s.e. 95% CI for diff. T-value P-value
Carvedilol 10 122.3 75 24
Day 0
Carvedilol 10 37.6 78.9 25
Final day
difference 10 84.6 76.6 -69.3% 24.2 29.7, 139.4 3.49 0.007
Metoprolol 6 214.8 160 65.3
Day 0
Metoprolol 6 195.1 89.4 36.5
Final day
difference 6 19.7 100.5 -9.2% 41 -85.8, 125.1 0.48 0.652
Table 5-2: areas under the curve for salbutamol infusions
n Mean s.d. % change s.e. 95% CI for diff. T-value P-value
Carvedilol 10 1772 1463 462
Day 0
Carvedilol 10 566 553 175
Final day
difference 10 1206 1476 -68.1% 467 150,2262 2.58 0.030
Metoprolol 6 2138 991 404
Day 0
Metoprolol 6 1257 848 346
Final day
difference 6 881 945 -41.2% 386 -110, 1873 2.29 0.071
Table 5-3: areas under the curve for phenylephrine infusions
n Mean s.d. % change s.e. 95% CI for diff. T-value P-value
Carvedilol 10 78.7 75.7 23.9
Day 0
Carvedilol 10 40.4 26.7 8.4
Final day
difference 10 38.4 74.9 -48.8 23.7 -15.2, 92.0 1.62 0.140
Metoprolol 6 50.1 43.1 17.6
Day 0
Metoprolol 6 38.7 18.5 7.6
Final day
difference 6 11.4 43.5 -22.8 17.8 -34.3, 57.0 0.64 0.550
181
Table 5-4: areas under the curve for acetylcholine infusions
n Mean s.d. % change s.e. 95% CI for diff. T-value P-value
Carvedilol 10 -1.953 0.932 0.295
Day 0
Carvedilol 10 -1.475 1.061 0.336
Final day
difference 10 -0.478 1.106 24.5% 0.350 -1.269, 0.313 -1.37 0.205
Metoprolol 6 -1.825 1.536 0.627
Day 0
Metoprolol 6 -1.097 1.050 0.429
Final day
difference 6 -0.727 1.772 39.8% 0.723 -2.587, 1.132 -1.01 0.361
Table 5-5: Paired T tests for ischaemic vasodilatation (area under the
curve analysis)
n Mean s.d. % change s.e. 95% CI for diff. T-value P-value
Carvedilol 8 9922 3088 1092
Day 0
Carvedilol 8 6332 2535 896
Final day
difference 8 3590 3017 -36.2% 1067 1066,6114 3.37 0.012
Metoprolol 5 13097 2583 1155
Day 0
Metoprolol 5 8654 2065 923
Final day
difference 5 4443 2843 -33.9% 1272 913,7973 3.49 0.025
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Figure 5-3
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CHAPTER 6: NEUROHUMORAL MEASURES
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6.1. OBJECTIVE
We aimed to examine the neurohumoral alterations in CHF caused by treatment with
carvedilol and metoprolol.
Neurohumoral responses to reduced cardiac output participate in the pathogenesis of
CHF (see section 1.4.2). Both basal and exercise-induced concentrations of
endogenous neurohumoral substances are elevated in patients with CHF compared
with normal controls.(Kjaer, Appel et al. 2004) Plasma concentrations of several
neurohumoral factors have also been extensively studied with regard to their
prognostic value in CHF.(Cohn, Levine et al. 1984; Francis, Cohn et al. 1993;
Parmley 1995; Frey, Pacher et al. 2000; McDonagh, Cunningham et al. 2001)
It is of obvious interest to determine whether there are differential actions by
carvedilol and metoprolol on these parameters. Assuming the neurohormonal
hypothesis of chronic heart failure is at least partly true, the influence of proven
beneficial CHF therapies on neurohumoral measures should be predictable.
There are in fact very few placebo-controlled studies of the neurohumoral actions of
beta-blockers in CHF.(Holmer, Hense et al. 1998; Jansson, Dahlstrom et al. 1999) We
know of only two other comparisons of the neurohumoral effects of carvedilol
compared to metoprolol, (Hirooka, Yasumura et al. 2001; Fung, Yu et al. 2003) and in
neither of these studies was therapy blinded in any way. The first study examines only
the effects of the twoi drugs on natriuretic peptide concentrations. Fung et al.
performed a much more comprehensive study, investigating a much broader panel of




As explained in chapter 2, blood sampling was performed at three points during the
study:
- Just prior to initiation of first dose of beta-blocker therapy
- After 10 weeks (at the end of the titration period)
- After 20 weeks (at the end of the maintenance period)
Subjects attended the study day having abstained from alcohol, caffeine and tobacco
for 24 hours, from food for 6 hours, and having emptied their bladder. Under local
anaesthesia (to minimise neurohumoral activation) a 16-gauge cannula was sited in
the antecubital vein of the dominant arm to enable blood sampling. The subjects were
then allowed to lie supine on a couch for 20 minutes for equilibration to occur: this is
important to prevent postural variation in neurohumoral activation, which could
theoretically invalidate the results of samples taken. Blood samples were then taken
into chilled tubes containing the appropriate preservatives for neurohumoral tests.
6.2.1. NEUROHUMORAL ASSAYS
Dianne Hillyard performed these assays in the laboratory of Dr Ian Morton in the
department of Medicine and Therapeutics at the Western Infirmary, Glasgow.
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6.2.1.1 NATRIURETIC PEPTIDES
Brain natriuretic peptide was assayed without prior extraction of plasma by means of
a direct, specific monoclonal antibody radioimmunoassay kit supplied by Shionogi &
Co, Ltd (Settsu-shi, Osaka, Japan), as previously described.(Murdoch, Byrne et al.
1997) Plasma N-terminal atrial natriuretic peptide (ANP 1-30) was assayed by
radioimmunoassay after extraction from acidified plasma with CI8 reverse-phase
columns (Sep-Pak, Waters Associates Ltd, Watford, UK) with the use of a
modification of a previously described method. (Richards, Tonolo et al. 1987;
McDonagh, Robb et al. 1998) A Peninsula Laboratories (Belmont, California, USA)
antibody, RAS 9129 was used for identification ofN-terminal atrial natriuretic
peptide. The between-assay coefficients of variation were 15% for the N-terminal
atrial natriuretic peptide assay and <10% for the brain natriuretic peptide assay,
respectively.
6.2.1.2 PLASMA RENIN ACTIVITY
Plasma renin activity was measured by an in-house antibody trapping technique in the
presence of added excess renin substrate.(Millar, Leckie et al. 1980) The coefficient
of variation was 3.4%.
6.2.1.3 ANGIOTENSIN II
An in-house radioimmunoassay was used for plasma angiotensin II as previously
described.(Morton and Webb 1985) Angiotensin II was preextracted from plasma
before assay. The coefficient of variation was 10%.
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6.2.1.4 ALDOSTERONE
Plasma aldosterone was measured with a solid-phase (coated tube) radioimmunoassay
kit supplied by Diagnostic Products (UK) Ltd. The coefficient of variation was
<8.3%.
6.2.1.5 NOREPINEPHRINE
Plasma norepinephrine (nmol/l) was extracted from plasma and assayed by high
performance liquid chromatography and electrochemical detection as previously
described.(Goldstein, Feuerstein et al. 1981; McAlpine, Morton et al. 1988) The
within assay and between assay coefficients of variation are both < 10%.
6.2.1.6 EPINEPHRINE
Plasma epinephrine was extracted from plasma and assayed by high performance
liquid chromatography and electrochemical detection as previously
described.(Goldstein, Feuerstein et al. 1981; McAlpine, Morton et al. 1988) The
within assay and between assay coefficients of variation are both < 10%.
6.2.1.7 ENDOTHELIN
Plasma endothelin concentration was measured by the method of Davenport et al.
(Davenport, Ashby et al. 1990)as previously described.(McMurray, Ray et al. 1992)
The lower limit of detection of the assay is 0.5pmol/l.
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6.3. RESULTS
There are a number of significant differences in the neurohumoral effects of
carvedilol and metoprolol during the course of this study.
6.3.1. BASELINE NEUROHUMORAL MEASURES
Baseline measurements of neurohumoral activity for patients completing the study are
shown in Table 6-1.
Table 6-1: baseline neurohumoral levels
NEUROHUMORAL MEASURES
Metoprolol Carvedilol P value
mean ± s.d. mean ± s.d. for difference
norepinephrine (nmol/L) 4.71 + 1.53 4.0311.12 0.204
epinephrine (nmol/L) 0.30±0.39 0.1510.13 0.213
renin (pU/ml) 299±341 3911632 0.619
angiotensin II (pg/ml) 8.8±10.3 7.517.2 0.697
aldosterone (ng/ml) 11.1 ±4.5 17.5116.4 0.209
ANP (ng/ml) 8.3±8.7 6.614.9 0.555
BNP (pg/ml) 80±97 85165 0.881
ET-1 (fmol/ml) 0.37±0.22 1.2112.60 0.201
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6.3.2. ATRIAL NATRIURETIC PEPTIDE
Carvedilol produces a statistically significant increase in plasma atrial natriuretic
peptide concentration after both ten and twenty weeks of treatment. No clear effect is
seen with metoprolol (see Table 6-2 and Figure 6-1).





























n Median 95% CI 95% CI P-
(lower) (upper) value
16 31.75% 18.36 49.37 0.0018
16 14.59% 6.52 44.42 0.0074
12 48.53% -13.2 192.9 0.3877
Mean s.e. T-value P-
value
12 -8.1% 16.34% 0.49 0.631
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Figure 6-1. Effect of treatment on plasma atrial natriuretic peptide
concentration
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.
Percentage change from baseline of
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6.3.3. B-TYPE NATRIURETIC PEPTIDE
Both beta-blockers produce marked increases in plasma BNP concentration and the
increases are of similar magnitude. The effects are seen at both 10 and twenty weeks
though the metoprolol effect fails to reach statistical significance at 20 weeks (see
Table 6-3 and Figure 6-2).




































17 62.9% 20.08% -3.13
17 52.6% 13.91% -3.78













Figure 6-2. Effect of treatment on plasma B-type natriuretic peptide
concentration
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.
Percentage change from baseline of
















































Carvedilol has no effect on plasma renin activity. Metoprolol markedly reduces
plasma renin activity (see Table 6-4 and Figure 6-3).




































































Figure 6-3. Effect of treatment on plasma renin activity
For normally distributed data, the points represent means and bars represent standard
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6.3.5. ANGIOTENSIN II
Carvedilol tends to increase plasma angiotensin II concentration, whilst metoprolol
tends to decrease the concentration (see Table 6-5 and Figure 6-4). Neither effect
reaches statistical significance.
















































Figure 6-4. Effect of treatment on plasma angiotensin II concentration.
The points represent medians and bars represent 95% confidence intervals.
Percentage change from baseline of
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6.3.6. ALDOSTERONE
Both carvedilol and metoprolol produce a decrease in plasma aldosterone
concentration, and this effect is of similar magnitude in both groups (see Table 6-6
and Figure 6-5). The effect is, however, only statistically significant in the carvedilol
group at both 10 and 20 weeks.










































Figure 6-5. Effect of treatment on plasma aldosterone concentration.
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.
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Carvedilol significantly increases plasma norepinephrine concentration at twenty
weeks. No such effect is seen with metoprolol (see Table 6-7 and Figure 6-6).
















































12 0% -6.546 9.291 1.000
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Figure 6-6. Effect of treatment on plasma norepinephrine concentration.
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.
Percentage change from baseline of
plasma norepinephrine concentration
120 / NON-PARAMETRIC
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6.3.8. EPINEPHRINE
There was no statistically significant change in plasma epinephrine concentration over
the course of the study in the individual groups. Due to the nature of the assay for
plasma epinephrine concentration, the data appears skewed(see Table 6-8 and Figure
6-7).
Table 6-8 : Effect of treatment on plasma epinephrine concentration
Epinephrine
NON-PARAMETRIC n Median 95% CI 95% CI P-value
DATA (lower) (upper)
(1-sample sign test)
Carvedilol 16 0% 0 0 1.0000
Week 10*
Carvedilol 16 0% 0 6.971 0.7266
Week 20*
Metoprolol 12 0% -54.29 0 0.2188
Week 10
NORMALLY n Mean s.e. T-value P-value
DISTRIBUTED DATA
(t-test)
















* single outlier excluded
during analysis
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Figure 6-7. Effect of treatment on plasma epinephrine concentration
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.

































Carvedilol Carvedilol Metoprolol Metoprolol
Week 10 Week 20 Week 10




Neither agent has a significant influence on plasma endothelin concentration (see
Table 6-9 ad Figure 6-8).
Table 6-9: Effect of treatment on plasma endothelin concentration
NON-PARAMETRIC
DATA
(1 -sample sign test)
































Figure 6-8. Effect of treatment on plasma endothelin concentration.
The points represent medians and bars represent 95% confidence intervals.
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6.4. DISCUSSION
As with the other analyses, this study involved a small number of patients, so there
was a large variance for some measures making it impossible to be certain that there
is no difference between the groups in some measures. It is also possible some of the
apparently statistically significant changes shown are spurious.
Interpretation of the effects of drugs on neurohumoral measures is difficult. Untreated
CHF patients are likely to have high levels of e.g. norepinephrine or BNP. However,
whether the action of a treatment is beneficial depends on whether the individual
neurohormone is harmful or whether an elevated level of a beneficial neurohormone
is an indication that homeostatic mechanisms are trying to oppose the effects of other
potentially harmful mechanisms.
Taking the examples of norepinephrine and BNP, conventional wisdom is that a drug
action to bring down plasma norepinephrine concentration is desirable. The desired
action of a treatment on BNP concentration, however, is controversial. Some
investigators like to see a fall in plasma BNP concentration with treatment, and might
even titrate the dose of a treatment against the observed BNP response.(Murdoch,
McDonagh et al. 1999) An alternative theory is that a drug that increases BNP
concentration is beneficial by "releasing" a self-protective mechanism. The natriuretic
peptide system is itself a homeostatic mechanism, with beneficial actions of high
concentrations of BNP in the pathological state of CHF; the action of elevated BNP
levels is to oppose vasoconstriction and fluid retention. Thus, raising BNP is actually
desirable, even though the presence of a supra-normal level of BNP is a marker for
the existence of CHF. Indeed, pharmacological measures have been taken both in
acute (Publication Committee for the VMAC Investigators (Vasodilatation in the
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Management of Acute CHF) 2002) and chronic heart failure (Packer, Califf et al.
2002) to increase BNP concentration as a means of therapy.
In interpreting the results of alterations to neurohumoral measures, one approach is to
classify the measures themselves as being either harmful or helpful. For example,
norepinephrine is harmful due to increasing heart rate, causing peripheral
vasoconstriction, and generally increasing cardiac workload. B-type natriuretic
peptide is helpful, causing vasodilatation and natriuresis.
In general, the effect of metoprolol in this study was to reduce the plasma
concentrations of "harmful" neurohormones. This effect was consistent across the
renin/ angiotensin/ aldosterone system (where renin, angiotensin II, and aldosterone
were all reduced) and the sympathetic system (where plasma epinephrine was
reduced, while plasma norepinephrine was not increased). Very little effect on
endothelin was seen. Metoprolol treatment was also associated with raised levels of
the "helpful" neurohormone BNP, but no effect was noted on ANP.
The action of carvedilol was not so clear-cut. Epinephrine and norepinephrine
concentrations both increased with carvedilol. There was no effect on renin, a
reduction in aldosterone, and an increase (non-significant) in angiotensin II. However
carvedilol did increase both ANP and BNP to significant degrees. Endothelin level
was unaffected. Taken together, the overall neurohumoral action of metoprolol would
appear to be more beneficial than that of carvedilol. A possible reason for this
difference would be that the vasodilating action of carvedilol performs some of the
actions that would require the activation of protective neurohumoral mechanisms in
metoprolol-treated patients.
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There have been a number of previous publications examining the effects of
metoprolol and carvedilol on various members of the panel of neurohormones we
chose to examine in this study. However, these studies generally examine the effects
of an individual beta-blocker on one or two members of the panel in isolation. The
only other comparable study examining the action of carvedilol and metoprolol on
components of the renin-angiotensin and natriuretic paptide systems differs somewhat
from our findings.(Fung, Yu et al. 2003) This study found a short term (12 week)
reduction in plasma renin activity and in aldosterone concentration, effects which
disappeared at one year. Decreases in both natriuretic peptides were found.
In one of the largest neurohormone profile studies so far published, the placebo-
controlled Randomized Evaluation of Strategies for Left Ventricular Dysfunction
(RESOLVD) pilot study (426 patients randomized), the effect of 24 weeks of
metoprolol therapy on a broad panel of neurohormones was measured.(RESOLVD
study investigators 2000) This study remains a reference for metoprolol's action, and
it is of note that the actions seen were very similar to those in the metoprolol arm of
our study.
The main difference between our study and RESOLVD is that in that study, 24 weeks
of metoprolol therapy increased both plasma BNP and N-terminal ANP
concentrations. Only one other small study, like ours comparing metoprolol and
carvedilol, assesses the effect of carvedilol on natriuretic peptide
concentrations.(Hirooka, Yasumura et al. 2001; Fung, Yu et al. 2003) In this study, a
decrease in both N terminal BNP and in ANP was found, clearly at odds with our
results and with those of RESOLVD. In one small uncontrolled study, metoprolol
produced a decrease in BNP and ANP.(Hara, Hamada et al. 2000) In our study, both
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BNP and N-terminal ANP were increased during therapy with carvedilol. Given the
potentially favourable actions of natriuretic peptides in CHF, this action may
contribute to the beneficial effects of beta-blockers in CHF.
In our hands, metoprolol also suppressed plasma renin concentration whereas
carvedilol did not. This action of beta blockers to reduce plasma renin activity is well
known.(Holmer, Hense et al. 1998) Previous studies, including RESOLVD,
(RESOLVD study investigators 2000) have consistently demonstrated this action of
metoprolol in CHF.(Jansson, Dahlstrom et al. 1999) Until recently, little was known
about the effect of carvedilol on renin: another small study has now demonstrated an
early significant reduction in plasma renin activity with both beta-blockers, but this
reduction disappears after one year of treatment. (Fung, Yu et al. 2003)The relative
lack of suppression of renin in the carvedilol group may also have reflected the
increase in plasma norepinephrine with this treatment, as norepinephrine is known to
elevate plasma renin. The changes in plasma angiotensin II concentrations tended to
mimic those in plasma renin concentrations, though these were not significant for
either beta-blocker.
Aldosterone was, therefore, a surprise, in that it appeared to be reduced similarly by
both beta-blockers, but only significantly so by carvedilol. There is some support for
this. (Fung, Yu et al. 2003) In the paper by Fung et al, the absolute reduction in
aldosterone concentration at one year is considerably greater in the carvedilol group
than in the metoprolol group. Aldosterone secretion is, however, controlled by factors
other than angiotensin II and often does not necessarily change in parallel with the
other components of the renin-angiotensin axis. (Foster, MacFarlane et al. 1997) The
findings of RESOLVD are consistent with this view in that aldosterone was not
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suppressed by metoprolol whereas both renin and angiotensin II were.(Krum, Gu et
ah; 2000) Teisman et al performed a retrospective observation of chronic beta-
blocker effects (in moderate to severe chronic heart failure with a mean treatment
period of 3.8 years) and showed a similar tendency to reduce plasma aldosterone,
though the effect did not reach statistical significance.(Teisman, van Veldhuisen et al.
2000) The literature contains no other reports of the effects of beta-blockers on
aldosterone in CHF. One study in hypertensive patients showed that chronic
carvedilol reduced plasma aldosterone concentration.(Dupont 1990) This suggests
that the effect we observed with carvedilol may be a real one and may distinguish
carvedilol from metoprolol.
While neither beta-blocker had a significant effect on epinephrine (as found in other
studies), there was a differential action on norepinephrine. Plasma norepinephrine
concentration increased significantly after carvedilol, whereas it did not with
metoprolol. The existing literature on the effect of beta-blockers on norepinephrine in
CHF is conflicting.(Swedberg, Hjalmarson et al. 1979; Nemanich, Veith et al. 1990)
The largest neurohumoral study with metoprolol, RESOLVD, showed no significant
difference from placebo.(RESOLVD study investigators 2000) We can find no well-
controlled carvedilol-placebo comparisons. Other studies suggest that carvedilol
either does not change or reduces circulating norepinephrine concentrations.(Gilbert,
Abraham et al. 1996; Azevedo, Kubo et al. 2001)
Two studies show that carvedilol seems to reduce coronary sinus norepinephrine
concentration. Together these two studies also suggest that carvedilol reduces cardiac
and whole body norepinephrine release to a greater extent than metoprolol.(Gilbert,
Abraham et al. 1996; Azevedo, Kubo et al. 2001) In one of these studies (an amalgam
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of subjects from two larger studies with different entry criteria) there was a high
proportion of patients with idiopathic dilated cardiomyopathy (IDC) and the baseline
heart rates from the two groups differed significantly, suggesting different baseline
characteristics.(Gilbert, Abraham et al. 1996) In the other study, no details are given
about the underlying cause of CHF.(Azevedo, Kubo et al. 2001) As IDC has a
different natural history than CHF due to ischaemic heart disease results from studies
on these patients may well not be comparable to the patient group we studied.
In two further studies comparing carvedilol to metoprolol in CHF, there was either a
trend to a reduction in venous plasma norepinephrine concentrations,(Kukin, Kalman
et al. 1999) or a significant reduction,(Hirooka, Yasumura et al. 2001) with both
carvedilol and metoprolol but no difference between treatment groups. There are
however two studies in hypertensive patients that show that carvedilol increases
plasma norepinephrine concentration.(Meyer-Sabellek, Schulte et al. 1985;
Tomlinson, Smith et al. 1986) It is thus possible that carvedilol is more likely than
metoprolol to increase plasma norepinephrine concentration, perhaps because of its
additional alpha-adrenoreceptor blocking activity. For example, the selective al-
adrenoreceptor antagonist prazosin increases norepinephrine in patients with
CHF.(Colucci, Williams et al. 1980)
We found that plasma endothelin-1 (ET-1) concentration did not significantly change
with either beta-blocker. Metoprolol did not reduce ET-1 in RESOLVD,(RESOLVD
study investigators 2000) but there is one report that carvedilol does reduce plasma
ET-1 concentration.(Krum, Gu et al.) This study, however, used very small numbers
of patients (only 10 patients were treated with carvedilol, with 5 control patients). The
larger retrospective observation of chronic beta-blocker effects mentioned above
216
revealed a tendency to reduce plasma endothelin though even in this larger group, as
in our study, the effect did not reach statistical significance.(Teisman, van Veldhuisen
et al. 2000)
As mentioned above, the findings from RESOLVD are largely in agreement with
ours. Whilst we had no placebo group, the general change in the plasma
concentrations of these neurohormones in patients treated with metoprolol was
replicated in our study. Published data on the influence of carvedilol is more difficult
to glean.
6.5. CONCLUSION
As drawn out in the haemodynamics chapter, the effect of metoprolol and carvedilol
in beta-blocking terms was not the same in our study. However, this study is in
general agreement with the reference RESOLVD study in its observation of the
neurohumoral influence of metoprolol, and elements of other studies support most of
the findings with carvedilol.
Definite differences exist in the actions of the two agents on neurohumoral systems.
As the neurohumoral hypothesis is the cornerstone of our modern understanding of
the pathophysiology of CHF, this raises difficulties in comprehending the actions of
metoprolol and carvedilol in CHF. If neurohumoral influences are all-important in
terms of prognosis, why is an almost identical benefit seen with both agents in large-
scale trials? Perhaps the mode of action of both agents is actually quite different,
though the magnitude of the end result on prognosis is similar.
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CHAPTER 7: ANTIOXIDANT EFFECTS
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7.1. OBJECTIVE
Carvedilol is known to have antioxidant properties in vitro and in vivo,(Yue, Cheng
et al. 1992; Maggi, Marchesi et al. 1996; Nakamura, Kusano et al. 2002) and it has
been postulated that this may be beneficial in CHF. No data exists to suggest that
metoprolol is an antioxidant. Chronic heart failure is regarded as a condition in
which an oxidative state exists,(McMurray, Chopra et al. 1993; Keith,
Geranmayegan et al. 1998) and some observers suggest that this contributes to
progression of the condition. A drug with antioxidant properties might therefore be
advantageous in CHF.
We wished to compare the effects of chronic treatment with the two beta-blockers on
a panel of measures of oxidant activity, to see if the in vitro antioxidant action of
carvedilol is measurable in vivo and specifically to see if the effect is measurable in
CHF patients. The antioxidant parameters are compared in CHF patients at baseline
and after treatment with carvedilol or metoprolol for 10 and 20 weeks.
7.2. BACKGROUND
7.2.1. DEFINING OXIDATIVE STRESS
Many disease states ranging from aging to cancer and coronary heart disease have
been associated with excess free-radical activity, or oxidative stress, and antioxidants
have received attention as a potential therapy for these conditions.(Cross, Halliwell et
al. 1987) A free radical is any molecule possessing an unpaired electron. In
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biological systems the most important free radicals result from the addition of
electrons to molecular oxygen.(Fridovich 1978)
Normally reduction of oxygen to water requires four electrons and occurs in
mitochondria via the cellular respiratory chain: there is no production of reactive
intermediates. However, univalent reduction of oxygen also takes place one electron
at a time in a variety of physiologic as well as potentially pathologic processes,
liberating partially reduced intermediates. These include free-radical superoxide
anion, the non-radical hydrogen peroxide, and the highly reactive hydroxyl radical.
These highly reactive species are referred to collectively as reactive oxygen species
(ROS). Examples of ROS reactions with other biological molecules include the
removal of electrons (oxidation) that can result in bond scission as well as the
abstraction of hydrogen atoms. The resultant modification of organic molecules by
ROS can be referred to as oxidative injury. Because of the reactivity of ROS, several
enzymatic and non-enzymatic defenses such as superoxide dismutase (SOD),
catalase, glutathione peroxidase (GPX), vitamin E, and vitamin C exist to protect
against oxidative damage to other organic molecules.(Halliwell 1994) Oxidative
stress, which may result in oxidative tissue damage, occurs when there is an
imbalance between ROS production and antioxidant defenses such that either ROS
production is increased and/or defense mechanisms are impaired.
7.2.2. OXIDATIVE STRESS AND CHF IN HUMANS
Based on extensive non-human evidence, the biological plausibility of the oxidative
stress hypothesis of CHF is well established.(Dhalla, Hill et al. 1996; Hill and Singal
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1997) In humans there are only a few specific disorders in which a clear link between
oxidative stress and chronic ventricular dysfunction has been established:
anthracycline-mediated cardiomyopathy,(Singal, Deally et al. 1987) alcoholic
cardiomyopathy,(Edes, Toszegi et al. 1986) and prolonged selenium deficiency or
Keshan disease.(Xu, Wang et al. 1997)
In these examples there are clear mechanisms that account for oxidative stress, either
due to increased ROS generation, or impaired antioxidant defenses. However,
whether free-radical processes have a pathophysiological role in the vast majority of
patients with CHF due to other causes is unclear. No large observational
epidemiological studies and prospective longitudinal cohort studies linking free-
radical activity to CHF in humans exist. The evidence is limited to observational
case-controlled studies that have demonstrated an association between markers of
oxidative stress and clinical CHF.(McMurray, McLay et al. 1990; Belch, Bridges et
al. 1991; McMurray, Chopra et al. 1993; Diaz-Velez, Garcia-Castineiras et al. 1996;
Keith, Geranmayegan et al. 1998; Mak, Lehotay et al. 2000)
The reported studies for which appropriate control data are available are small and
overall include about 200 patients with CHF. Aside from small sample size,
limitations of many of these studies were confounding factors within the patient
population. In some reports, evidence of oxidative stress was likely not specific to
the heart failure state because of the presence of other conditions in the study
population associated with oxidative stress, such as coronary artery disease or risk
factors for atherosclerosis. In other studies, risk factors for atherosclerosis were not
well characterized.
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Diaz-Velez et al. compared patients with CHF to patients with cardiovascular risk
factors and normal LV function as well as to healthy control subjects.(Diaz-Velez,
Garcia-Castineiras et al. 1996) These investigators found no difference in markers of
oxidative stress between the two patient groups, suggesting the risk factors
themselves are associated with an oxidative state. Aging may also be associated with
increased oxidative stress.(Stadtman and Berlett 1998) To address some of these
issues, McMurray et al stratified patients with CHF by the presence or absence of
coronary artery disease and found that, regardless of aetiology, CHF was associated
with markers of oxidative stress when compared to age-matched control
subjects.(McMurray, Chopra et al. 1993) CHF patients have also been compared to
age-matched control subjects with normal LV function and found increased markers
of oxidative stress in CHF despite the presence of atherosclerosis in both
groups.(Mak, Lehotay et al. 2000) The available evidence that oxidative stress is
specific to CHF in humans is, however, not yet conclusive.
7.2.3. BIOCHEMICAL MEASURES OF OXIDATIVE STRESS
There is no direct means to measure free-radical species in human in vivo studies, as
they are highly reactive and short-lived. Thus human studies have quantified the
consequences of free-radical reactions. The next two sections explain the two most
widely used approaches, techniques which were employed in this project.
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7.2.3.1 MEASURING LIPID PEROXIDATION
Polyunsaturated lipids are susceptible to free-radical attack, or "lipid peroxidation".
Stable decomposition products are produced, including aldehyde compounds that can
then be measured in plasma as an indirect index of free-radical activity.(Gutteridge
and Halliwell 1990) Malondialdehyde is one of many aldehyde compounds produced
by lipid peroxidation and is frequently measured in plasma by the thiobarbituric acid-
reactive substances (TBARS) assay. Thiobarbituric acid reacts with malondialdehyde
to produce a stable compound that can be quantified using either spectrophotometry
(as described in section 2.11.3) or high-performance liquid chromatography (HPLC).
7.2.3.2 MEASURING ANTIOXIDANT DEFENCES
Most investigators have attempted to quantify antioxidant defences as another means
of detecting oxidative stress in humans.(Belch, Bridges et al. 1991; McMurray,
Chopra et al. 1993; Keith, Geranmayegan et al. 1998) In patients with CHF,
decreased thiol groups in plasma as well as those associated with erythrocyte
membranes have been consistently demonstrated, (Belch, Bridges et al. 1991;
McMurray, Chopra et al. 1993) possibly reflecting increased interaction between free
radicals and membrane-associated proteins.
The activities of various antioxidant enzymes have been measured in plasma with
inconsistent results. Reduced glutathione (GSH) as an important part of the
antioxidant defense system by scavenging free radicals and regenerating other
antioxidants. In CHF, both significant increases of plasma GSH and decreases of
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whole-blood reduced GSH have been demonstrated.(McMurray, Chopra et al. 1993;
Yucel, Aydogdu et al. 1998) The activity of erythrocyte SOD (eSOD) has been
generally found to be depressed, although one report showed no difference in eSOD
activity compared to control.(Nishiyama, Ikeda et al. 1998) The activity or serum
concentrations of a variety of other antioxidants published in small reports include
plasma ceruloplasmin (increased in CHF),(McMurray, Chopra et al. 1993) GPX
(decreased in CHF)(Keith, Geranmayegan et al. 1998), vitamin E (not different from
control in CHF)(Keith, Geranmayegan et al. 1998), and vitamin C (decreased and not
different from control in CHF)(Keith, Geranmayegan et al. 1998). Thus, there is
apparently little consensus regarding which plasma index of antioxidant status is
most useful, and the data available have been inconsistent.(Mak and Newton 2001)
7.2.4. ASSESSMENT OF OXIDATIVE STRESS IN CHF: CONCLUSION
The existing evidence for a role of oxidative stress in the pathophysiology of CHF in
humans is incomplete and measurement of free-radical activity in vivo in humans is
not straightforward. Clinical trials of antioxidant therapy for CHF are few in number




7.3.1. EFFECTS ON LDL OXIDATION LAG TIME
There was no statistically significant effect of either carvedilol or metoprolol to alter
LDL oxidation lag time, though there was a slight effect of carvedilol to increase the
LDL oxidation lag time (see Figure 7.1). The LDL oxidation lag time stayed almost
exactly the same during treatment with metoprolol.
Table 7.1. Effect of treatment on LDL oxidation lag time.
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Figure 7.1. Effect of treatment on LDL oxidation lag time.
The points represent means and bars represent standard errors.
Percentage change from baseline of
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7.3.2. EFFECTS ON PLASMA CONCENTRATION OF VITAMIN E
Vitamin E concentration increased slightly after 20 weeks of carvedilol therapy
(though not after 10 weeks). Metoprolol did not stop the decrease in plasma vitamin
E concentration, which was a non-significant effect at 10 weeks but became highly
significant at 20 weeks of treatment (mean reduction of 18.7% from baseline,
p=0.004) (see Figure 7.2).
Table 7.2 Effect of treatment on plasma vitamin E concentration.
Plasma Vitamin E
concn.
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Figure 7.2. Effect of treatment on plasma Vitamin E concentration.
The points represent the means, the error bars represent the standard
errors.
Percentage change from baseline of
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7.3.3. EFFECTS ON PLASMA MALONDIALDEHYDE
CONCENTRATION
Malondialdehyde concentration was significantly increased by ten weeks treatment
with carvedilol, but this effect disappeared after 20 weeks. Metoprolol had no
significant effect on malondialdehyde concentration.













































Figure 7.3. Effect of treatment on plasma malondialdehyde
concentration
Points represent means, error bars represent standard errors.
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7.3.4. EFFECTS ON TOTAL PLASMA ANTIOXIDANT ACTIVITY
Carvedilol also appeared to have a slight effect on total plasma antioxidant activity,
increasing this parameter but again failing to reach statistical significance.
Metoprolol had no effect at 10 weeks, but very slightly (but not statistically
significantly) increased total plasma antioxidant activity at 20 weeks (see Figure 7.4).

























































Figure 7.4. Effect of treatment on total plasma antioxidant activity.
For normally distributed data, the points represent means and bars represent standard
errors. For non-normally distributed data, the points represent medians and bars
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7.4. DISCUSSION
Again, due to the small number of patients involved in this study, there was a large
variance for some measures making it impossible to be certain that there is no
difference between the groups in some measures. It is also possible some of the
apparently statistically significant changes shown are spurious.
There were trends to increased resistance to LDL oxidation and increased total
plasma anti-oxidant capacity in the carvedilol group that were not apparent in the
metoprolol group. These were not, however, statistically significant. Conversely,
plasma vitamin E concentrations fell in the metoprolol group (significantly so after
20 weeks treatment, consistent with consumption of this anti-oxidant) but not in the
carvedilol group. Malondialdehyde concentration was significantly increased by 10
weeks treatment with carvedilol, going against its supposed action as an antioxidant.
Overall, our findings do not suggest that carvedilol has an anti-oxidant action in vivo.
Kukin et al did not find any difference in anti-oxidant activity between carvedilol and
metoprolol in CHF though only used plasma thiobarbituric acid-reactive substances
(TBARS) as an indirect marker of lipid peroxidation.(Kukin, Kalman et al. 1999)
Other biochemical pathways and treatments can also influence TBARS.
Arumanayagam et al. noted a reduction in the results from assays of glutathoine
peroxidase and sodium dismutase with carvedilol (and no effect of metoprolol) in
CHF patients, suggesting carvedilol might exert an anti-oxidant
effect.(Arumanayagam, Chan et al. 2001) Total plasma anti-oxidant activity was not
significantly reduced in this study, in keeping with our findings.
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Our findings, and those of other studies, show that metoprolol is an effective anti-
adrenergic drug as evidenced particularly by its effect to reduce heart rate (see
section 4.4.1). The toxic effect of catecholamines per se may be important in the
pathophysiology, and particularly the progression, of CHF.(Singal, Beamish et al.
1983; Obata and Yamanaka 1997; Qin, Rounds et al. 2001) As catecholamines exert
some of their deleterious effects by oxidation, anti-oxidant agents would be expected
to reduce some of this harmful effect. The only significant effect we were able to
demonstrate with metoprolol was a reduction in vitamin E concentration, suggesting
rather that metoprolol does little to reduce oxidation.
It could be that it is due to its anti-oxidant effect, rather than its anti-adrenergic
effect that carvedilol has a part of its beneficial action. However, we were unable to
confirm this effect here. There appeared to be trends for carvedilol to act as an
antioxidant when assessed by LDL oxidation, vitamin E concentration and by total
plasma antioxidant activity. However, the only statistically significant effect seen
with carvedilol was a short-lived effect to increase malondialdehyde concentration,
suggesting carvedilol did little to prevent oxidation at ten weeks.
7.5. CONCLUSION
Our findings suggest, but cannot confirm, that carvedilol has an anti-oxidant action
in vivo, as well as in vitro when three out of four parameters are assessed. However,
the carvedilol group increased ten-week amlondialdehyde concentration, suggesting
carvedilol was permitting an increased oxidative state at this time point. It is still
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conceivable that the antioxidant action of carvedilol in the setting of CHF explains
part of its beneficial clinical effect.
Metoprolol, despite being an anti-adrenergic drug only has a significant effect to
permit an increase in plasma vitamin E concentration, suggesting it does nothing to






It has been recognised that chronic heart failure is associated with increased plasma
cytokine concentrations,(Levine, Kalman et al. 1990) and it is suggested that the
syndrome of heart failure is in part an inflammatory condition in which cytokines
play a pathological role.(Mann and Young 1994; Anker and Rauchhaus 1999)
Cytokines tend to become elevated in patients with severe CHF, when cachexia is
present.
We decided to investigate whether there were differential effects of carvedilol and
metoprolol on the plasma concentrations of TNF-a and of its soluble receptor
sTNFR-2 after 20 weeks of treatment.
8.2. BACKGROUND
Cytokines are low molecular weight proteins with both autocrine and paracrine
actions. Unlike hormones, they are not stored but are secreted in response to specific
stimuli. Tumour necrosis factor was first identified as a substance that exerted
profound anti-tumour effects in vitro and in vivo. Besides its cytostatic and cytotoxic
effects, TNF influences growth, differentiation and/or function of virtually every cell
type studied, including cardiomyocytes. Elevated levels of TNF-a have been
documented in the circulation(Levine, Kalman et al. 1990) and in the myocardium of
patients with CHF.(Torre-Amione, Kapadia et al. 1996)
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Nucleated cell types within the myocardium, including cardiomyocytes, synthesize
TNF in response to noxious stimuli, including myocardial ischaemia/infarction and
left ventricular pressure or volume overload. TNF does not exist in unstressed
mammalian myocardium, but is rapidly expressed under conditions of stress. When
the inciting stress is removed, levels return rapidly toward baseline. Expression of
cytokines in response to stress can occur in the absence of immune system activation.
TNF-a is a 51 kiloDalton trimeric molecule with a half-life of 30 minutes. Its plasma
concentration is most readily measured by an immunoreactive assay. TNF-a is
known to promote left ventricular remodelling(Suffredini, Fromm et al. 1989) and is
negatively inotropic.(Torre-Amione, Kapadia et al. 1995) In advanced CHF, high
levels of TNF-a are found in cachectic patients.(McMurray, Abdullah et al. 1991;
Anker, Chua et al. 1997) Animal experiments have shown that TNF-a is capable of
inducing skeletal muscle wasting and apoptosis,(Tracey, Morgello et al. 1990;
Krown, Page et al. 1996) and the levels of TNF found in cachectic patients have been
found to be the strongest predictors of the degree of weight loss in these patients.
There is also an inverse relationship between serum level of TNF-a and peripheral
blood flow (which is diminished in CHF).(Anker, Volterrani et al. 1998) These
characteristics of TNF make it a candidate for producing some of the less well-
understood clinical abnormalities present in advanced CHF.
The actions of TNF-a are mediated by binding to one of two specific receptors
(TNFR-1 and TNFR-2), which are present on most cell types. (Bolger and Anker
2000)The extracellular domain fragments of both receptors are shed from cell
surfaces and can be detected as soluble forms (sTNFR-1 and sTNFR-2), the roles of
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which are as yet unclear. At high concentrations, sTNFRs inhibit the activity of TNF-
a and thus it has been proposed that they may be involved in regulation of immune
status in CHF.
It is thought that high plasma concentrations of sTNFRs primarily indicate a history
of raised TNF-a values. Elevated sTNFRs concentrations have been positively
correlated with clinical class of CHF.(Keith, Geranmayegan et al. 1998) The
reproducibility of plasma concentrations of sTNFRs is higher than that of TNF-a
itself. This may be the reason why sTNFRs predict short term and long term
prognosis better than TNF-a in CHF patients. Several untoward effects seem to be
associated with raised TNF-a production in CHF.
At the time this study was conceived, sTNFR-2 was believed to be the most accurate
cytokine predictor of prognosis in CHF, and hence its choice as our investigational
marker.(Ferrari, Bachetti et al. 1995) Since then, an elevated level of sTNFR-1 has
also been cited as the strongest and most accurate predictor of poor survival in CHF,
independent of established parameters.(Rauchhaus, Doehner et al. 2000)
8.3. RESULTS
We were unable to demonstrate any significant influence of either of our two beta
blocking agents on the plasma concentrations of TNF-a and sTNFR-2. As shown (in
Table 8-1, Table 8-2, Figure 8-1 and Figure 8-2), analysis of the percentage change
in plasma concentrations of TNF-a and sTNFR-2 (analysed in this way to correct for
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differences in baseline concentrations between groups) did not show meaningful
changes over the course of the study.
8.4. DISCUSSION
As with the other analyses, this study involved a small number of patients, so there
was a large variance in all measures making it impossible to be certain that there is
no difference between the groups.
As our study involved stable patients with CHF, baseline plasma concentrations of
the two substances were not very high. None of our patients were, for instance,
cachectic. Consequently, the likelihood of seeing a significant shift in the
concentrations of either TNF-a or sTNFR-2 was not great. This may be the main
reason that no change in cytokine concentrations could be demonstrated in this study.
It has been shown previously that metoprolol and bisoprolol can lower TNF-a in an
uncontolled study in patients with idiopathic dilated cardiomyopathy
(IDC).(Ohtsuka, Hamada et al. 2001) A more recent study from the same group
compares the effect of carvedilol and metoprolol on cytokine levels (TNF-a and
interleukin-6) in idiopathic dilated cardiomyopathy.(Ohtsuka, Hamada et al. 2002) In
this study, both drugs acted to reduce TNF-a over a 12-week period. The numbers of
patients involved in the study were very similar to those involved in ours. Carvedilol
differed from metoprolol in also reducing the concentration of interleukin-6. Clearly,
these TNF-a results differ from ours.
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This discrepancy may be due to the fact that our patients had different baseline
characteristics (almost all of our patients had ischaemic heart failure as opposed to
IDC), and the overall neurohumoral responses of our patients were different.
Natriuretic peptide levels in our patients increased, whereas in the IDC study the
plasma concentrations decreased. It is conceivable that these differences are due to
the different underlying conditions, or due to differences in the severity of CHF in
the two groups studied. Idiopathic dilated cardiomyopathy is, at least in theory, a
much more "inflammatory" condition than ischaemic heart disease, and none of our
patients were by definition in the early period after an ischaemic insult when any
inflammatory process would be likely to be in progress. It is also possible that the
changes in neurohormones and in cytokines seen in the IDC study reflected
spontaneous improvement of the underlying condition amongst some subjects. This
view is supported by a sub-study of MERIT-HF, a large placebo-controlled study
with metoprolol, which showed no effect of metoprolol on cytokines.(Gullestad,
Ueland et al. 2001)
Cytokines are known to have important interactions with neurohormones in CHF. In
particular, elevated levels of noradrenaline and adrenaline act as catabolic stress
hormones in advanced heart failure, and high levels are closely associated with high
levels of inflammatory cytokines. Whilst some successful drugs reduce TNF,(Liu
and Zhao 1999; Tsutamoto, Wada et al. 2000) a number of agents that successfully
reduce cytokine levels cause increased mortality in CHF.(Matsumori, Shioi et al.
1994; Iwasaki, Matsumori et al. 1999) Indeed, recently there have been reports of the
use of anti-cytokine drugs (being used to treat arthritis) resulting in new onset heart
failure.(Kwon, Cote et al. 2003)
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By protecting the myocardium from the action of catecholamines, beta-blockers are
more likely simply protecting myocardium from part of the ongoing stimulus for the
production of cytokines.
8.5. CONCLUSION
Our investigation reveals no significant effect of either carvedilol or metoprolol on
plasma concentrations of TNF-a and sTNFR-2. There may be a slight trend for
carvedilol to reduce TNF-a, but this is not statistically significant. It is possible that
the stability of our patient population makes quantification of the effects of cytokine-
modulating medication difficult.
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Figure 8-1. Effect of treatment on plasma TNF-alpha concentration
For normally distributed data, the points represent means and bars represent standard
errors. For non-normally distributed data, the points represent medians and bars
represent 95% confidence intervals.
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Figure 8-2. Effect of treatment on plasma TNF-R2 concentration.
Points represent means, bars represent standard errors.
Percentage change from baseline of
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CHAPTER 9: LYMPHOCYTE ft RECEPTOR DENSITY
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9.1. OBJECTIVE
Changes in beta-receptor density are an acknowledged feature of CHF.(Colucci,
Alexander et al. 1981; Bristow, Ginsburg et al. 1986; Fowler, Laser et al. 1986) The
influence of some beta-blockers on beta-receptor density has been
investigated,(Heilbrunn, Shah et al. 1989; Yoshikawa, Handa et al. 1996) and
differences are known to exist between beta-blockers with different receptor
specificities.(Yoshikawa, Port et al. 1996)
Using carteolol, there is an early (2 week) effect to reduce lymphocyte beta receptor
density which is abolished by 6 months of treatment.(Yoshikawa, Handa et al. 1996)
Heilbrunn et al. (Heilbrunn, Shah et al. 1989)showed that treatment with metoprolol
leads to receptor up-regulation in myocardial tissue, whilst Yoshikawa et
al.(Yoshikawa, Port et al. 1996) showed that carvedilol does not lead to this up-
regulation.
In this part of the study, we sought to confirm whether differences exist between the
influence of metoprolol and carvedilol on lymphocyte beta-receptor density. As it is
difficult to directly measure the beta-receptor density on cardiomyocytes (the
invasive technique of myocardial biopsy is required), lymphocyte beta-receptor
density has often been used as a surrogate measure.(Colucci, Alexander et al. 1981;
Yoshikawa, Handa et al. 1996) A difference in the effect of the two agents on this
parameter would suggest a mechanism by which metoprolol and carvedilol vary in
their action on beta-receptors in cardiomyocytes.
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9.2. BACKGROUND
When the heart fails, chronic sympathetic activation results in selective down-
regulation of P i adrenoreceptors and uncoupling of both Pi and P2 adrenoreceptors
from G proteins, markedly blunting P-adrenergic receptor signalling.(Bristow 2000)
In end-stage heart failure, 50%-60% of the total signal-transducing potential is lost,
but substantial signalling capacity remains. We now speculate that these changes are
in fact adaptive, as the heart tries to reduce the harmful effects of adrenergic
overactivity.
9.2.1. MECHANISM OF NOREPINEPHRINE CARDIOTOXICITY
There are 3 well-characterised adrenergic receptors in human cardiomyocytes (Pi,P2
and ai) coupled to a positive inotropic response and cell growth.(Bristow, Ginsburg
et al. 1986; Brodde, Schuler et al. 1986; Bristow 1993) These P-Adrenoreceptors are
coupled via the stimulatory G-protein Gs to adenylate cyclase, activation of which
results in the production of cyclic AMP. This is a positive inotrope and chronotrope,
and is strongly growth promoting. In non-failing human ventricles, the P1/P2 ratio is
70-80/ 20-30. but in failing ventricles the number of P2 adrenoreceptors increases to
35-40% because of selective downregulation of the Pi adrenoreceptor
subtype.(Bristow, Ginsburg et al. 1986; Brodde, Schuler et al. 1986) The G-protein
Gq couples a 1-adrenoreceptors to the effector enzyme phospholipase C and diacyl
glycerol is produced on activation of this system. Diacyl glycerol activates the
growth-promoting protein kinase C family. As a1-adrenoreceptors are up-regulated
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in heart failure, the cardiomyocyte profile changes from predominantly (31 to a more
mixed 2:1:1 ratio in end stage heart failure.(Bristow 1993)
Norepinephrine is highly cardiotoxic,(Mann, Kent et al. 1992) producing
cardiomyocyte injury at concentrations found in failing human heart. It is mildly pi
selective (10- to 30-fold compared to the affinity to P2 receptors), and its cytotoxicity
appears to be mediated through (3 rather than a-adrenergic receptors.(Mann, Kent et
al. 1992) In transgenic mice, cardiac over expression of human Pi receptors(Port,
Weinberger et al. 1998; Engelhardt, Hein et al. 1999) or of the stimulatory G proteins
Gas (Iwase, Bishop et al. 1996)or Gaq produces an overtly cardiomyopathic
phenotype,(D'Angelo, Sakata et al. 1997) resulting in chamber dilatation and systolic
dysfunction. Over expression of the stimulatory G protein Gas is also associated with
increased markers of apoptosis, which can be produced in adult rat cardiomyocytes
by p agonist exposure.(Bristow 2000) In adult rat cardiomyocytes, the Pi receptor
mediates apoptotic signalling, whereas the P2 receptor is anti-apoptotic via coupling
to the inhibitor protein, Gj.(Communal, Singh et al. 1999) High levels of cardiac over
expression of the human P2 receptor eventually result in depressed systolic function
and a cardiomyopathic phenotype,(Liggett, Tepe et al. 2000) and cardiac expression
of a constitutively activated ai receptor produces concentric hypertrophy.(Milano,
Dolber et al. 1994) Thus data from model systems indicate that chronic adrenergic
signalling, especially Pi receptor signalling, is a harmful compensatory mechanism in
the failing human heart.
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9.2.2. MECHANISM OF DOWN REGULATION OF BETA RECEPTORS
Families of regulator and adaptor molecules control the amplitude, duration and
targeting of adrenergic receptor signals and are intimately involved in the blunting of
(3-adrenergic receptor signalling. There are many mechanisms for turning off signals
transduced by G-protein-coupled receptors. Members of the G-protein-coupled
receptor kinase family (GRK1 up to GRK6) phosphorylate adrenergic receptors
when occupied by an agonist. This phosphorylation increases the affinity of
adrenergic receptors for cytosolic proteins, known as p-arrestins, which prevent
further G-protein coupling. The P-arrestins also act as scaffold molecules, coupling
the adrenergic receptors to different downstream effectors. In end-stage heart failure,
50 to 60% of the total signal transducing potential is lost, but substantial signalling
capacity remains:(Bristow 1993) the suggestion is that the P-adrenergic receptor
desensitisation seen is adaptive, so an effective therapeutic strategy is to add to this
action.
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Key to Figure 9.2
Mechanism of down-regulation of beta adrenoreceptor sensitivity in CHF
NORMAL HEART:
High membrane density of ^-adrenoceptors ((3-ARs). Stimulatory G proteins (Gsa)
activate adenylate cyclase (AC), raising cAMP levels to induce protein kinase A
(PKA). Activated PKA phosphorylates phospholamban (PLB), releasing its
inhibitory function on the sarcoplasmic reticulum (SR) calcium ATPase pump
2"F
(SERCA). This enhances Ca~ transport from the cytosol to the SR. The removal of
94- 9+
Ca" from the cytosol augments relaxation, and adequate release of Ca" from the
SR stores increases contractility.
HEART FAILURE:
Down-regulation of (3-ARs (mainly the (3i-AR subtype) and desensitization by
phosphorylation occurs, impairing activation of Gsa. (3-arrestin couples to the
receptor, uncoupling of the (3 -AR from Gsa. There is also upregulation of the
inhibitory G protein (Gia) and receptor internalization. Together, these mechanism
inhibit the (3-adrenergic-PKA pathway, and the impaired Ca2+ cycling decreases
contractility and relaxation.
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Figure9.2Mechanismofdown-regulationbetad norec ptors tivityiCHF
9.3. RESULTS
Administration of neither metoprolol nor carvedilol produced a statistically
significant change in the lymphocyte beta-receptor density after 10 or 20 weeks. The
effect of metoprolol just failed to reach significance (p=0.06) at 20 weeks, with a
reduction in density of 13.9% (see Figure 9.2 and Table 9.1).
9.4. DISCUSSION
9.4.1. TIME COURSE OF EFFECTS
During the week prior to screening assessments, the dose of beta-blocker therapy was
halved and then stopped immediately before the first dose of study medication. This
decision, taken at an early stage of study design, was intended to permit recruitment
of patients who had been treated with beta blockers for indications other than CHF,
such as angina, previous myocardial infarction or hypertension. In the group of
patients studied, there was a high prevalence of these comorbidities. Without this
decision it would have extremely unlikely that recruitment could have been
completed in the population available to the study. The rationale for the short
reduction in dose and then removal of any prior beta blockade was to minimise any
potential risk to these patients.
The consequences of the prior use of beta blockers may well have been important
with regard to eventual study results and in particular the effect on the measured
lymphocyte beta receptor density. Unfortunately this aspect of the study design may
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have obscured the true effects of the study drugs. Whilst the short term action of the
beta blockers may no longer have been present by the time of starting the study
drugs, it is very likely that some residual alteration in beta adrenoreceptor density
and function caused by earlier beta blocker treatment was present at the time of
initiation of the study drugs. The receptor desensitisation which accompanies CHF
and the change in beta receptor density requires fundamental changes in intracellular
mechanisms, including receptor synthesis. Previous studies have investigated the
time-course of change in beta adrenoreceptor function, though mainly in relation to
the P2 adrenoreceptor, and found that the effect of an agonist (presumably similar to
the effect of removal of an antagonist) took up to 2 weeks to exert its maximum
effect on beta adrenoreceptor density.(Bruck, Leineweber et al. 2003) A similar two
week period was noted by another group investigating the effects of beta blocker on
lymphocyte beta receptor density.(Yoshikawa, Handa et al. 1996) Thus it may well
be that the time period used for withdrawal of the prior beta blocker was too brief
and the reduction in dose should have been a complete withdrawal. Due to this
unfortunate aspect of study design, the measured effects of the study drugs on beta
adrenoreceptor density are difficult to decipher.
9.4.2. INFLUENCE OF LYMPHOCYTE VARIATION
A considerable body of evidence points to the modulation of immune responses by
the autonomic nervous system.(Baerwald, Burmester et al. 2000) Lymphoid organs
are densely innervated by noradrenergic neurones,(Felten, Felten et al. 1985) and as
mentioned lymphocytes express mainly p2 adrenergic receptors.(Brodde, Engel et al.
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1981) However, there is great variability in the numbers of P2 adrenergic receptors
between lymphocyte subpopulations. CD8+ T cells, B cells and natural killer cells
express more P2 adrenergic receptors than do CD4+ T cells.(Landmann, Burgisser et
al. 1984; Van Tits, Michel et al. 1990) As the proportions of these differing sybtypes
are influenced by many other factors (such as the presence of asthma or other
immune-mediated conditions, exposure to allergen, treatment with asthma
medication such as beta agonists, or intense sympathetic nervous system activation),
it is likely that the very blunt tool of measuring overall lymphocyte beta receptor
density was a poor surrogate for cardiomyocyte receptor density. Other work has
shown considerable variation between and within individuals in P adreneroreceptor
density.(Anstead, Hunt et al. 1998) Despite this further major caveat, the use of
peripheral blood lymphocyte beta receptor density as an alternative to
endomyocardial biopsy has continued to be used by some groups even to the present
day, with reported results which appear to speak to the value of the assessment.(Hata,
Williams et al. 2006)
9.4.3. OTHER LIMITATIONS
As this study involved a small number of patients, there was a large variance for
some measures making it impossible to be certain that there is no difference between
the groups in some measures. Despite the lack of a statistically significant change,
observation of the raw data does appear to show a tendency for carvedilol to increase
beta receptor density, whilst the effect of metoprolol in either direction is not
marked, with a possible reduction noted.
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This component of the study has other definite limitations. Although it has been
postulated that peripheral lymphocyte beta receptors may reflect alterations in beta
receptor density and overall beta adrenergic responsiveness of less accessible tissue
such as heart, human lymphocytes contain few if any Pi receptors an are therefore
not a reliable surrogate system for the heart.(Brodde, Michel et al. 1989) The
measurements made, therefore, can be presumed to be of the effect of the agents
primarily on P2 receptors. For the purposes of this study, an effect of metoprolol
would not be anticipated, whilst one might reasonably expect to see some change in
receptor density in carvedilol-treated patients.
Lymphocyte beta receptors are not innervated, which thus leads to a lack of
concordance between behaviour of myocardial and lymphocyte beta receptors in
disease conditions manifested by increased adrenergic neurotransmitter activity, or
during pi receptor specific therapeutic interventions.
As the predominant change in myocardial beta-receptor density is the decrease in Pi
receptors, it is debatable whether measurement of lymphocyte beta-receptor density
is really valid.(Brodde, Michel et al. 1989) One of the effects of end-stage heart
failure, as stated above, is for the density of myocardial P2 receptors to increase.
Carvedilol, whilst not having a statistically significant effect, does tend towards
increasing lymphocyte beta-receptor density (and therefore P2 receptors). It is not
known whether or not this is a favourable influence.
It has previously been clearly shown that administration of metoprolol results in an
increase in myocardial beta-receptor density, which results in a return of beta-
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adrenergic sensitivity.(Heilbrunn, Shah et al. 1989) Based on current understanding,
this is indeed a favourable influence of the agent. Whether a similar action of
carvedilol occurs has unfortunately not been adequately addressed in this study.
9.5. CONCLUSION
No significant differences appear to exist in the effects of metoprolol and carvedilol
on lymphocyte beta-receptor density. There is an apparent trend for carvedilol to
increase P2 receptor density on lymphocytes, which could represent a real action of
the drug to up-regulate p2 receptors.
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(1 -sample sign test)




















































Figure 9.2. Effect of treatment on lymphocyte beta receptor density
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.
Percentage change from baseline of



















































Approximately 50% of CHF sufferers die of sudden cardiac death, which is believed
to be due to ventricular arrhythmias in most cases.(Narang, Cleland et al. 1996)
Patients with CHF may be predisposed to the development of arrhythmia when an
underlying inhomogeneity of myocardial repolarisation exists. As CHF progresses,
the reduction in number and function of p i receptors means that the importance of p2
receptors increases. Some data suggests that it is particularly antagonism at the P2
receptors which protects against arrhythmia.(Billman, Castillo et al. 1997)
We wished to examine the effects of treatment with carvedilol and metoprolol on
markers of cardiac electrical stability (signal averaged ECG and QT dispersion).
Both of these measures have been shown to have prognostic importance in patients
with heart failure and in patients following myocardial infarction.(McClements and
Adgey 1993; Somberg and Molnar 2002) We wanted to know if the two
investigational drugs had differential effects on these parameters, suggesting that
differences in the pharmacological properties of the drugs might have clinically
important consequences on cardiac electrical stability.
10.1.1.1 QT DISPERSION: BACKGROUND
QTc dispersion is a surrogate marker of the inhomogeneity of myocardial
repolarisation and predicts arrhythmias and sudden death in those with ischaemic
heart disease, hypertrophic cardiomyopathy, long QT syndrome, CHF and other
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conditions.(Somberg and Molnar 2002) Clinical and electrophysiological studies
have shown the importance of inhomogeneous myocardial repolarisation
characteristics in the genesis of ventricular arrhythmias. Increased dispersion of
repolarisation provides a substrate for ventricular arrhythmias by generating areas of
functional unidirectional block, thereby predisposing to reentry which appears to be
the major mechanism by which ventricular arrhythmia occurs. (Zipes and Wellens
1998)
QT dispersion in the 12-lead ECG, defined as the difference between the longest and
the shortest QT interval,(Cowan, Yusoff et al. 1988) is a validated measure of
dispersion of repolarisation.(Somberg and Molnar 2002) It reflects regional
differences in myocardial repolarisation and provides indirect evidence of
arrhythmogenicity.
Increased QT dispersion and corrected QT dispersion have been reported in patients
with CHF compared to controls, and are considered as potential markers for
predicting drug effects on mortality.(Bonnar, Davie et al. 1999) A strong association
of increased QT dispersion with sudden cardiac death has been identified.(Barr, Naas
et al. 1994)
A number of trials of beta-blockers have shown that the incidence of sudden cardiac
death is reduced during treatment with beta-blockers, most notably in CIBIS-
II.(CIBIS-II investigators and committees 1999) Beta-blocker therapy in CHF has
also been shown to reduce QT dispersion.(Bonnar, Davie et al. 1999; Fesmire,
Marcoux et al. 1999) Our intention was to determine if QT dispersion is affected to
different degrees by the two investigational drugs, metoprolol and carvedilol.
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10.1.1.2 QT DISPERSION: METHODS
After resting to allow settling of any skeletal muscle activity, all patients had ECG
recordings made at the same paper speed and gain setting (25 mm/sec and 10
mm/mV) using a Megacart ECG machine (Siemens, UK). Standard 12-lead ECGs
were recorded with leads attached in the conventional positions. The usual
exclusions for QT dispersion studies were already present due to the overall study
exclusion criteria.
A single observer (SM) digitised all ECGs using a digitising board (Calcomp,
Anaheim, California, USA) connected to an IBM-compatible personal computer and
running customised QT dispersion software (Academic Cardiology Unit, Freeman
Hospital, Newcastle upon Tyne). QT interval was measured from the beginning of
the QRS complex to the end of the T wave, defined as the return to T-P baseline.
When U waves were present, the QT interval was measured to the nadir of the curve
between the T and U waves. QT intervals were measured in all leads if technically
possible. For each lead, two or three consecutive cycles were measured and the
arithmetic mean of the QT interval for that lead was used in all future calculations for
QT dispersion. The measured values were then expressed as both uncorrected and
rate-corrected QT intervals (QT and QTc).
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10.1.1.3 SIGNAL AVERAGED ECG: BACKGROUND
The signal-averaged ECG was initially developed to allow recording of low-
amplitude ventricular depolarisations on the surface ECG of myocardial infarct
patients who are susceptible to ventricular tachycardia.(Kuchar, Thorburn et al. 1987;
Farrell, Bashir et al. 1991) Although first used in this setting, the SAECG has since
been applied to many different groups of patients.(Gomes, Cain et al. 2001) The link
between ventricular "late potentials" recorded in the SAECG and re-entrant
ventricular tachycardia in a wide variety of conditions is well established.
(Breithardt, Cain et al. 1991)
Late potentials represent slow or delayed conduction originating from viable cells
within or surrounding myocardial infarct regions, and are believed to represent a
fixed substrate for re-entrant ventricular tachycardia. They are defined as abnormal
signals, which outlast the normal QRS period during normal sinus
rhythm.(Breithardt, Cain et al. 1991)
The noise in conventional ECGs ranges from 8 to 10 pV and is generated primarily
by skeletal muscle, masking the late potentials from myocardial activity which one
would wish to measure. The purpose of signal averaging is to improve the signal-to-
noise ratio to facilitate the detection of these low-amplitude potentials. Temporal
averaging is used in most commercial systems, reducing random or uncorrelated
noise by the square root of the number of waveforms averaged. This process requires
the existence of a repetitive and invariable potential of interest, with a fixed
relationship to an easily detectable reference point such as the peak of the QRS
complex. The signal of interest and the noise must be independent and remain
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independent during averaging. Most signal processing systems use time-domain
analysis to detect late potentials in the terminal QRS complex, requiring high-gain
amplification and appropriate digital filtering to reject low frequencies associated
with the plateau and repolarisation phases of the action potential, ST segment and T
wave. This enhances detection of the high frequency signals that correspond to
ventricular activation.(Cain, Anderson et al. 1996)
Orthogonal bipolar XYZ ECG leads are recorded, averaged, automatically filtered by
software on the recording system, and combined into a vector magnitude called the
filtered QRS complex. Analysis of the filtered QRS complex typically includes:
1. The filtered QRS duration (QRS)
2. The root-mean-square of the terminal 40 milliseconds of the filtered QRS
(RMS)
3. The length of time that the filtered QRS complex remains <40 pV i.e. the
low amplitude signal duration (LAS)
Values of these measurements are dependent on the high pass corner frequency,
which in our case was a 40-Hertz high-pass filter. Characteristics of a late potential
(assuming use of a 40 Hertz high-pass bi-directional filter) include:(Cain, Anderson
et al. 1996)
1. A filtered QRS complex duration >114 milliseconds
2. A signal <20pV in the last 40 milliseconds of the filtered QRS complex
3. Voltage <40pV in the terminal QRS complex for >38 milliseconds
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10.1.1.4 SIGNAL AVERAGED ECG: METHODS
A Megacart ECG machine (Siemens, UK) with signal averaged ECG (SAECG)
recording software installed was used to record all SAECGs. SAECGs were recorded
immediately after the 12 lead ECG recordings as described above.
10.2. RESULTS
Seventeen patients in the carvedilol group and twelve patients in the metoprolol
group had complete QT dispersion and saECG data suitable for analysis.
There was no significant change in QT dispersion (corrected for rate) noted with
either agent (see Table 10-1, Figure 10-1). Turning to SAECG parameters, there was
a slight prolongation of QRS duration with both agents as might be expected with
beta-blocker treatment (see Table 10-2 and Figure 10-2) No significant difference
was noted in the RMS with carvedilol (see Table 10-3 and Figure 10-3). Metoprolol
had a much larger effect in comparison with carvedilol, and this effect was
statistically significant (p=0.011). LAS duration increased in both groups to a very
similar degree (see Table 10-4 and Figure 10-4). The effect on LAS in the metoprolol




Due to the small number of patients involved in this study, it is possible the
apparently statistically significant changes shown are spurious. As with the other
analyses, this study involved a small number of patients, so there was a large
variance for some measures making it impossible to be certain that there is no
difference between the groups in these measures.
Serious ventricular arrhythmia is well recognised as a common mode of death in
CHF. In several of the large-scale beta-blocker studies sudden cardiac death,
believed to be due to ventricular arrhythmia in most cases, was an end-point that was
particularly susceptible to the influence of beta-blockers.(Chadda, Goldstein et al.
1986; Packer, Bristow et al. 1996; 1999; 1999; Hjalmarson and Fagerberg 2000)
In fact, beta blockers have been shown to reduce the risk of sudden cardiac death in
more than 50 randomised trials involving more than 55000 patients.(Hjalmarson
1999) Beta-blockers are well known to raise the threshold for ventricular
fibrillation,(Parker, Michael et al. 1990) and are effective in suppressing ventricular
tachycardia. Our chosen surrogate measures of cardiac electrical stability have both
undergone rigorous examinations. The effect of metoprolol on LAS and RMS
differentiated the two agents under study.
It has been shown that QT dispersion is susceptible to variation, with even time of
day having an influence.(Smetana, Batchvarov et al. 2003) There is no doubt that QT
dispersion is inherantly difficult to measure in a reproducible way, and in particular
the decision as to where the QT interval actually ends has been problematic.(Murray,
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McLaughlin et al. 1994) This is the primary reason for measurement error in QT
dispersion determination.(Somberg and Molnar 2002) Other obsevers, using a
modification of QT dispersion which uses a longer recording (QT variability index)
claim to have been able to identify a difference in the effects of carvedilol and
metoprolol, with carvedilol producing a greater improvement on this parameter than
metoprolol.(Piccirillo, Quaglione et al. 2002) The longer recording method in this
study is likely to result in a more reproducible result.
As metoprolol was seen to be so much more effective at heart rate reduction (see
section 4.4.1), which is usually the most readily assessed method of determining
beta-blocking efficacy, one would have perhaps expected a more marked influence
of this drug on markers of cardiac electrical stability. It is likely that the effect on
LAS and RMS is some reflection of this. This more potent effect of metoprolol is
again, like the effect seen on heart rate in this study, unexpected. The broader anti-
adrenergic properties of carvedilol would be anticipated to suppress ventricular
arrhythmia with greater potency than would metoprolol. Indeed, preious work has
suggested that as far as altering the threshold for ventricular fibrillation is concerned,
it is action on the P2 receptor which matters.(Billman, Castillo et al. 1997)
10.4. CONCLUSION
Data from large clinical studies confirms the effect of beta-blockers to reduce sudden
cardiac death. The surrogate measures used in this study were able to demonstrate a
statistically significant change in some parmeters after 20 weeks of treatment with
metoprolol.
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The techniques themselves have a number of methodological problems. It is likely
that the effect on LAS and RMS seen with metoprolol reflects more the unexpected
greater effect on heart rate reduction seen with metoprolol, rather than any true
influence on electrical stability. Indeed, it is in fact surprising that any significant
difference between the agents was detectable, particularly as an attempt was being
made to discriminate between two inherently rather similar medications.
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Figure 10-1: Effect of treatment on percentage change in corrected QT
dispersion
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.
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Figure 10-2 : Effect of treatment on percentage change of SAECG QRS
duration from baseline
For normally distributed data, the points represent means and bars represent standard
errors. For non-parametric data, the points represent medians and bars represent 95%
confidence intervals.





































Figure 10-3 : Effect of treatment on SAECG RMS percentage change
from baseline
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Figure 10-4 : Effect of treatment on SAECG LAS duration percentage
change from baseline
The points represent medians and bars represent 95% confidence intervals.
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11.1. SUMMARY OF FINDINGS
We found that metoprolol and carvedilol reduced resting heart rate to a similar
degree in the doses used. Metoprolol had a greater effect to suppress the increase in
heart rate in response to beta agonism. Carvedilol had a much more widespread
influence on the peripheral action of beta agonists than did metoprolol. Metoprolol
generally resulted in more improvement in neurohumoral measures than carvedilol,
whilst there was a trend for carvedilol to have an antioxidant action (though this fell
short of reaching clinical significance). Metoprolol had a beneficial effect on some
parameters of cardiac electrical stability. The effect of metoprolol on neurohumoral
measures and on cardiac electrical stability may reflect the marginally greater effect
this drug had on heart rate.
11.2. LIMITATIONS
11.2.1. STUDY DESIGN
In the design of this study, several problems arose. The most important of these was
the timing of systemic infusions and peripheral arterial assessments with respect to
the first dose of study medication. On the first intensive study day, the patients had
already been treated with the first dose of study medication prior to systemic
infusions and peripheral arterial assessments. Thus a true baseline for these
parameters was not recorded. Whilst the first dose of study drug used was very small
indeed (metoprolol 1.25mg, carvedilol 3.125mg), and would be unlikely to have had
any measurable effect, it is scientificially unsatisfactory that this situation arose. This
was unavoidable due to constraints by ethical considerations (see section 2.3). The
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West Ethical Committee of Greater Glasgow Health board felt that it was
unacceptable to involve patients in more than two of the day-long studies, and would
also be unacceptable to involve the patients in more than two forearm
plethysmographic studies which involve arterial cannulation. The committee also
advised an overall reduction in the number of patient visits. We had complete
sympathy with their views, as there is no doubt that involvement in four full days of
stuy would have been a considerable undertaking for any patient, particularly those
with significant CHF.
However, the restriction of the study design to permit a total of nine visits (including
the screening visit) was to have major implications for the overall study. At the time
the study was conceived, clinical practice (based on experience from the US
carvedilol study) was to have up-titration visits at 2-weekly intervals. Thus the
advice form the West Ethics Committee forced the combination of the first day-long
plethysmographic study day with the first day of drug administration and meant that
no true baseline was available for the effects of the drugs on forearm venous
occlusion plethysmography nor for the responses to systemically-administered
adrenergic agonists; this was the only way in which the number of visits necessary
for supervised up-titration could be accommodated. In retrospect, it is deeply
regrettable that this flawed study design was executed, at least without an appeal to
the committee.
Our original study plan had intended the use of a true baseline study day, a study day
just after initiation of medication, a study day after the maintenance dose had been
reached, and a final study day. A table is shown below to illustrate the diffences
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between our 'ideal" study structure and the actual protocol we eventually employed.
We felt that our original study structure had greater scientific validity, but we were
obviously compelled to abide by advice from the West Ethical Committee. The
significant complexity of our study did not lend itself well to the use of two simple
plethysmographic study days; one would speculate that that the West Ethical
Committee decision was based on their experience with other simpler studies where
the effect of a drug could more adaequately be assessed by a simple "before and
after" study design. The known nature of the action of carvedilol, with the
anticipated waning of the a-blocking effect, makes more frequent assessment with
plethysmography and dissection of the different adrenoreceptor actions desirable.
It is also very unfortunate that the intended number of plethysmographic assessments
was not completed, due to problems arising in an unrelated study (see section 2.10.3)
This greatly reduced the numbers of recordings performed.
11.2.2. IDEAL STUDY DESIGN
With the benefit of hind sight, it is now easy to appreciate some of the other flaws
inherent in this study.
Certain of the techniques employed are easy to implement, such as blood analyses or
ECG recording (for saECG or QT dispersion). To achieve more meaningful results
would in the case of many of these parameters have required a much larger sample
size as is obvious from the degree of variance in the results. Thus it would have been
better to have sampled from a larger group of patients for these parameters.
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Other techniques, especially forearm venous occlusion plethysmography, are much
more difficult and time-consuming to employ and would have better been employed
on a small subgroup. The more precise and reproducible nature of these assessments
means less need for a large sample size in any case.
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This was of necessity a small study, and the size of population studied reduces the
certainty with which results can be stated.
The patient population enrolled seems not to have been suffering from the same
severity of CHF as other studies. Whilst the patients had medical histories, ECGs,
echocardiographic data and clinical features (particularly their symptoms) in keeping
with NYHA grade II-III CHF (see section 2.8), the low resting heart rate measured
suggests that their CHF was very well controlled. It is certainly possible that the
patients were clinically better than those enrolled in the large studies.
11.2.4. METHODOLOGY
In some areas, the methodology employed in this now seems inappropriate.
11.2.4.1 HAEMODYNAMICS
Whilst incontovertible data was gleaned on most of the haemodynamic measures
(heart rate, blood pressure), some authors regard non-invasive cardiac output
monitoring as inferior to invasive means of assessing these parameters.(Barry,
Mallick et al. 1997) Thus the data obtained on cardiac output and on stroke volume
may not be robust. It would however have been very difficult, and likely ethically
impossible, to have performed these assessements invasively.
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11.2.4.2 PLETHYSMOGRAPHY
Forearm venous occlusion plethysmography is an elegant technique, and produced
data which, whilst initially surprising to this author (see section 5.5.1), has
corroboration in the literature.(Metra, Nodari et al. 2002)The main issue here is lack
of numbers for the reasons stated above.
11.2.4.3 NEUROHUMORAL, ANTIOXIDANT AND CYTOKINE MEASURES
Most of these measures are well studied and are appropriate. Measurement of plasma
epinephrine concentration was probably unnecessary, as it is notoriously susceptible
to fluctuations.
As discussed in the antioxidant chapter (section 7.2), great doubts remain as to the
validity of these measures, and in particular there are doubts about the validity of
these maesures for assessing response to therapy.(Mak and Newton 2001)
As our study patients all had relatively well-controlled CHF, and none were
cachectic, the utility of cytokine assessments in this population must be questioned.
It is most unlikely that any measurable influence of beta-blockers on cytokines
would have been detectable in this population.
11.2.4.4 LYMHOCYTE BETA RECEPTOR DENSITY
This parameter has been discussed in detail in section 9.4. The best and possibly the
only truly relevant way of assessing myocardial beta-receptor density would have
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been with myocardial biopsies, which would again have presented major ethical
difficulties.
11.2.4.5 CARDIAC ELECTRICAL STABILITY
The main crticism here is use of relatively small numbers, and the attempt to
compare two drugs which are inherently rather similar. This makes the likelihood of
identifying a difference low. There is probably also a criticisim that our patients were
all relatively well, and would not have been expected to have very abnormal baseline
parameters as assessed by these techniques.
11.2.5. p3 ADRENORECEPTOR SUBTYPE
Over the period during which this study was conducted, the p3 adrenoreceptor
subtype was identified. The atypical effect of isoproterenol, a nonselective P-
adrenoceptor agonist, on human ventricular endomyocardial biopsies in the presence
of nadolol, a Pi - and P2-adrenoceptor antagonist, suggested the presence of a
functional third P-adrenoceptor subtype in human ventricular muscle.(Gauthier,
Tavernier et al. 1996) Contrary to p i- and P 2-adrenoceptor pathways, activation of
this receptor by norepinephrine in the presence of a-, Pi- and P2-antagonists, or by
BRL 37344, a selective P3-adrenoceptor agonist, decreases contractile
force.(Gauthier, Tavernier et al. 1996; Gauthier, Leblais et al. 1998) Initially
identified in fat tissue(Krief, Lonnqvist et al. 1993) and subsequently in vascular
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tissue(Gauthier, Langin et al. 2000), this receptor subtype has also been
myocardium.(Gauthier, Tavernier et al. 1996; Gauthier, Leblais et al. 1998;
Kitamura, Onishi et al. 2000; Cheng, Zhang et al. 2001; Moniotte, Kobzik et al.
2001)
In contrast to (3i and P2 adrenoreceptors, (33 adrenoreceptors are linked to inhibitory
Gj proteins, and stimulation of P3 adrenoreceptors inhibits cardiac contraction and
relaxation.(Gauthier, Leblais et al. 1998; Gauthier, Langin et al. 2000; Kitamura,
Onishi et al. 2000; Cheng, Zhang et al. 2001; Moniotte, Kobzik et al. 2001)
Overexpression of human P3 adrenoreceptors in mice reproduces ex vivo the negative
inotropic effects.(Tavernier, Toumaniantz et al. 2003) Although the precise
physiological and pathophysiologic roles of P3 adrenoreceptors remain uncertain,
some work suggests that in the normal heart, P3 adrenoreceptors participate in nitric
oxide (NO)-mediated negative feedback control over contractility.(Gauthier, Leblais
et al. 1998) Data also suggest that following prolonged activation by the sympathetic
nervous system the P3 adrenoceptormediated response is likely to be preserved while
the pi - and P2-adrenoceptor-mediated responses are attenuated. In addition to an
increase in receptor abundance in CHF,(Moniotte, Kobzik et al. 2001) the evidence
supports the view that the p3-adrenoceptor plays a dominant role in regulating
cardiomyocyte function during the high adrenergic tone that is typical of heart
failure.(Moniotte and Balligand 2002) Some recent evidence suggests that
endogenous p3-adrenoceptor activation contributes to cardiomyocyte dysfunction in
heart failure.(Morimoto, Hasegawa et al. 2004)
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The P3 adrenoreceptor is of obvious interest in the context of this study, as it is
certainly possible that the drugs under study have differing effects on this new
receptor. Unfortunately, as the existence and function of this receptor subtype was
still under early investigation it was not possible to assess this potential.
11.3. CLINICAL IMPLICATIONS
The study reported in this thesis is obviously small, but was necessarily so in order
that the mechanism of action of the two agents could be assessed in greater depth.
Whilst mechanism of action of the two drugs is obviously of great interest,
particularly with future therapies in mind, it is in the end the clinical effect of the two
agents is what will determine which one will be used.
11.3.1. THE COMET STUDY
The COMET study was intended as the definitive exploration of differences in
clinical end-point between therapy with carvedilol and metoprolol.(Poole-Wilson,
Cleland et al. 2002) This multi-centre, randomised, double-blind parallel-group trial
compared the effect on mortality and morbidity of carvedilol and metoprolol in
patients with chronic heart failure.(Poole-Wilson, Swedberg et al. 2003) COMET has
one of the longest follow-up periods and greatest number of patient years of exposure
of any heart failure trial. Of the 3029 randomised patients, 1511 on carvedilol were
eventually assessed for primary end-points, while 1518 on metoprolol -were assessed
for primary end-points. The mean study duration was 58 months. There were 512
deaths (438 cardiovascular) in the carvedilol group and 600 (534 cardiovascular) in
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the metoprolol group. There was a 17% reduction in mortality in the carvedilol group
relative to metoprolol (p<0.0017, 95% confidence interval 0.74-0.93). The authors
concluded that carvedilol had a significantly greater effect on survival than
metoprolol.
The COMET study has far from ended the controversy over whether carvedilol or
metoprolol is the superior beta-blocker in CHF. There is dispute over the dose and
formulation of metoprolol used. MERIT-HF study employed a extended-release form
of metoprolol succinate (metoprolol CR/XL), whilst COMET used more
conventional metoprolol tartrate 50 mg BD. A dose of lOOmg metoprolol tartrate per
day was planned in COMET (actual mean dose was 85 mg). The mean dose of
metoprolol in MERIT-E1F was 159 mg of the CR/XL (succinate) formulation,
equivalent to about 106 mg of metoprolol tartrate given the lower bioavailability of
the succinate. In addition, the design of COMET had actually been based on
metoprolol doses used in the MDC trial, where the mean dose achieved was 108mg
metoprolol tartrate per day.(Waagstein, Bristow et al. 1993) Despite basing the
regime doe on MDC, COMET administered metoprolol tartrate only twice a day,
whereas in MDC metoprolol tartrate was administered three times a day. Thus the
dose of metoprolol actually used in COMET was less than that shown to be effective
in MERIT-HF, was less than that used in the MDC trial upon which COMET had
based its dosing target. The fact that the metoprolol, despite being the short-acting
tartrate form, was only given twice a day, compounds the issue.
This problem of equivalent dosing becomes even more obvious when observing the
heart rate reduction in the metoprolol arm of COMET. Reductions in heart rate seen
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in the first few months of COMET were 13.3 bpm in the carvedilol group and 11.7
bpm in the metoprolol group, though after longer treatment the heart rate reduction in
both COMET arms was virtually identical.(Poole-Wilson, Swedberg et al. 2003) This
effect on heart rate during the first few months in COMET leaves open the
possibility that some of the difference in efficacy seen was due to differing degrees
of beta blockade, simply due to an inadequate or at least non-equivalent dose of
metoprolol. In addition, in MERIT-HF, using metoprolol succinate, the heart rate
reduction was greater than in the metoprolol arm of COMET (14.0 bpm). This
produced an annual mortality rate of 7.2% in MERT-HF compared to 10% in the
metoprolol arm of COMET, despite recruitment of potentially a higher risk group of
patients. It is difficult to conclude that in COMET, metoprolol exerted a similar
degree of |3| blockade as carvedilol.
11.3.2. COMPARISON OF COMET WITH THIS STUDY
The relative effects of the two drugs in COMET was the converse of the relative
effect on resting heart rate that was seen in our study, though a statistically
significant level of difference was not reached. In addition, our data suggests a more
potent effect by metoprolol to limit the increase in heart rate with both Pi and P2
agonism. It is gratifying to note that the doses used in COMET were the same as in
our study, where the mean daily dose of metoprolol was 91.7 mg. As with our study,
COMET aimed for comparable reductions in resting heart rate within the two groups.
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The effects of the two agents on heart rate in COMET, given the numbers involved
in the study, make a compelling argument that carvedilol is the more potent at
reducing heart rate when compared to twice daily metoprolol tartrate. Why this was
not seen in our study could be due to:
1. different severity of heart failure in the two groups in this study
2. different sensitivity of the two groups to the actions of the beta blockers in
general.
3. timing of measures of heart rate being more susceptible to a high peak dose
of metoprolol compared to a more even dose of the longer-acting carvedilol.
The first explanation is unlikely, as resting heart rates and other features were very
similar (see Table 2.3 and Table 3.1).
The second explanation is more plausible. There are known polymorphisms of beta-
receptor subtypes, which result in different sensitivities to agonists and indeed may
even influence the development of CHF itself.(Dishy, Sofowora et al. 2001; Small,
Wagoner et al. 2002) One assessment of the MERIT-HF study shows that there is a
clear disparity in the reaction of different individuals to beta-blocker doses: whilst
some patients achieve a significant heart rate response with target doses, others may
achieve a similar heart rate reduction with much smaller doses.(Wikstrand,
Hjalmarson et al. 2002) The benefit in terms of clinical outcome seen was similar in
both groups. Thus the effect of the beta-blocker on heart rate would seem to be more
relevant to outcome than the dose of the beta-blocker used to achieve the heart rate
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reduction. It may be simply that the sample of patients included in our study is not
sufficiently representative of the population as a whole.
Whilst recognising this issue as a major practical difficulty in assessing the effects of
the two drugs on the parameters studied, there are nonetheless differences apparent
between the groups that cannot be readily explained by different beta-receptor
polymorphism distributions. In particular, the finding a greater peripheral action of
carvedilol, and of a difference in the antioxidant effects of metoprolol versus
carvedilol is of interest.
Thus, in favour of the third possibility, it may be that the timing of measurements
may have erroneously indicated a greater effect with metoprolol than with carvedilol.
By measuring resting haemodynamic parameters and haemodynamic parameters
influenced by the beta-agonist infusions a couple of hours after drug administration,
it may be that the effect of metoprolol was actually exaggerated. Presumably the
drug was exerting its peak effect at the measurement times. It is interesting to
speculate that if this is indeed the case, it is likely that the effect of twice-a-day
metoprolol is to produce alternating periods of excess and under-beta blockade. This
would probably not be desirable, and may be another reason for the less favourable
results for patients treated with metoprolol in COMET. What seems clear is that this
formulation and dosing regime of metoprolol is not the equal of carvedilol given
twice daily.
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11.4. DIRECTIONS FOR FURTHER RESEARCH
The last few years have seen an increased understanding of the details of oxidative
stress, and of the serious limitations in our understanding of this phenomenon,
especially with regard to CHF.(Mak and Newton 2001) Future assessment of the
antioxidant properties of carvedilol in CHF should employ more specific markers of
oxidative stress.
Beta-blocker therapy has become a standard of care for patients with CHF. However,
some aspects of therapy remain unclear. The dichotomy in response to metoprolol in
MERIT-HF is one area of interest.(Wikstrand, Hjalmarson et al. 2002) It is also of
note that there were apparent racial (and therefore presumably genetic) differences in
response to bucindolol within the BEST study population.(BEST Trial Investigators
2001) This area is of particular importance if one were to undertake future small-
scale studies of the effects of beta-blockers similar to that presented in this thesis. It
would be important to know that the population under study would be uniform in
distribution of any genetic variation. This may have been a factor causing the
unexpected heart rate effect of metoprolol in this study.
This area of so-called "phamacogenomics" takes as its premise that there are
different degrees of response to pharmacological agents dependent on underlying
genetic polymorphisms. That there are polymorphisms of (3i receptors is well
recognised,(Small, Wagoner et al. 2002) though the clinical relevance of this
knowledge to the application of beta-blockers in CHF is unclear.(Hajjar and MacRae
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